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Abstract 
Chronic Kidney Disease (CKD) is characterised by the expression of alpha smooth muscle 
actin (α-SMA) and Collagen from the aberrant infiltration and proliferation of myofibroblasts. 
This results in renal fibrosis and ultimately end stage renal disease (ESRD). CKD is a 
growing health problem resulting in significant costs to the NHS, making the identification of 
novel therapeutic targets for the treatment of CKD a key clinical priority.  
Transforming growth factor β-1 (TGF -1) plays a critical role in the persistent activation of 
myofibroblasts leading to fibrosis. TGF -1 signals through transmembrane serine-threonine 
kinase type I and II receptors to phosphorylate SMAD3, a downstream intracellular receptor-
regulated SMAD protein (R-SMAD). Upon phosphorylation, activated SMAD3 translocates 
to the nucleus to regulate the transcription of fibrotic genes such as α-SMA and Collagen. 
Studies have shown SMAD3 to have an important role in fibrosis. 
This work sought to identify novel components of TGF β-1 signalling in order to increase our 
understanding of the pathway and identify potential therapeutic targets to treat CKD. This was 
achieved through siRNA and compound screening in renal cells.  
Here, three novel components of the TGF β-1 pathway are described. SET9, a lysine 
methyltransferase and Aurora Kinase A, a serine/threonine kinase were shown to interact with 
SMAD3 to upregulate its transcriptional activity. Inhibitors of SET9 and Aurora Kinase A 
were shown to have anti-fibrotic activities by reducing TGF β-1 signalling. Additionally, 
SETDB1, a different lysine methyltransferase was also shown to interact with SMAD3, acting 
as a brake on TGF β-1 signalling. Identification of novel components of TGF β-1 signalling in 
renal fibrosis will aid our understanding of the mechanisms of fibrosis to develop novel 
therapeutics for the treatment of CKD.  
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Chapter 1. Introduction 
1.1 General Anatomy of the Kidney 
1.1.1 General Structure and Function of the Kidney 
The kidneys are paired bean-shaped organs located on the posterior abdominal wall either side 
of the vertebral column between T12-L3, with the right kidney usually positioned slightly 
lower than the left. They weigh between 135-150g each and are typically 10-12cm in length 
and 5-7cm in width. The kidney is divided into two distinct sections; the cortex and the 
medulla. The medulla is composed of renal pyramids which are separated by renal columns of 
cortical tissue (Preuss, 1993). Figure 1.1 outlines the general anatomy of the kidney. 
The kidneys play a vital homeostatic role within the body including; filtration and excretion 
of circulating metabolic waste products (urea and ammonium), acid-base balance, and fluid 
and electrolyte homeostasis. The by-product of these homeostatic processes is urine. The 
kidneys also have endocrine functions including blood pressure regulation via the renin-
angiotensin-aldosterone system, erythrocyte production via erythropoietin production, and 
bone mineralisation via Vitamin D activation.  
1.1.2 The Nephron 
The nephron is the functional unit of the kidney (Figure 1.2). It is composed of the renal 
corpuscle containing the glomerulus and Bowman’s capsule. The glomerulus is a network of 
capillaries that filters blood supplied by the afferent arteriole, across the Bowman’s capsule, 
into the proximal convoluted tubule (PCT). Together, the glomerular endothelium, the 
glomerular basement membrane and epithelial podocytes selectively filter water and solutes 
depending on their size and charge. The PCT then reabsorbs water, glucose and electrolytes 
from this initial filtrate. The blood which has been filtered by the glomerulus passes through 
the efferent glomerular arteriole where it then descends into the renal pyramids. The tubular 
system is composed of the PCT, loop of Henle, the distal convoluted tubule (DCT) and the 
collecting duct. In the PCT, reabsorption of electrolytes and nutrients from the tubule is 
facilitated by endoluminal microvilli that form a brush border, thereby increasing the surface 
area available for reabsorption. In the downstream loop of Henle, urine is concentrated via an 
intricate counter-current mechanism. Further downstream in the DCT, urine electrolytes are 
again modified prior to arrival of urine at the collecting duct the principle role of which is 
water resorption. Urine then passes to the renal pelvis, then the ureters and finally the urinary 
bladder that controls excretion (Preuss, 1993).  
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Figure 1.1 General Anatomy of the Kidney. Illustration of main anatomical 
structures of the kidney. Image taken from (Drake et al., 2009). 
Figure 1.2 Structure of the Nephron. Illustration of the nephron structure. Image 
taken from (Drake et al., 2009). 
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1.2 Chronic Kidney Disease  
1.2.1 Definition of Fibrosis 
Fibrosis, colloquially termed scarring, is the excessive deposition of extracellular matrix 
(ECM), primarily composed of Collagen proteins, by activated fibroblasts. Activation of these 
fibroblasts to myofibroblasts is characterised by increased Collagen contractility and cell 
motility, facilitated by intracellular cytoskeletal proteins such as alpha-smooth muscle actin 
(α-SMA) which are overexpressed in fibrosis. Fibrosis can occur in numerous organs 
including the heart, lungs, kidney, liver and skin and can be thought of as a “wound healing 
response that has gone out of control” (Wynn, 2007). Tissue injury can result from acute or 
chronic infections, autoimmunity or mechanical trauma. Injured tissues require repair, a 
biological process essential for survival, to restore architecture and regain function. The repair 
process has a regenerative phase in which damaged tissue is replaced by the original cell type 
and a fibrosis phase in which damaged tissue is replaced by connective tissue. In normal 
tissue repair, an inflammatory response results in the appearance of myofibroblasts and 
inflammatory cells to initiate tissue regeneration which then comes to a halt once the damaged 
tissue is repaired. Although initially beneficial, the fibrosis phase can become pathogenic if 
inappropriately sustained, through aberrant myofibroblast activation leading to dysregulated 
ECM deposition and remodelling and the formation of permanent scar tissue. This scar tissue 
replaces normal renal tissue compromising organ function and ultimately leads to organ 
failure (Eddy, 2014).  
A major factor implicated in fibrosis is transforming growth factor β-1 (TGF β-1). The TGF β 
superfamily comprises signalling molecules involved in physiological processes such as 
proliferation, embryogenesis and homeostasis, but also human disease (Massague, 2012). 
TGF β-1, the prototypical member of this superfamily, has long been known to have an 
important role in the pathological response to wound healing and fibrotic diseases (Gordon 
and Blobe, 2008), as discussed further in section 1.5.  
1.2.2 Renal Fibrosis in Chronic Kidney Disease  
Fibrosis is the histological end-point of almost all forms of chronic kidney disease (CKD). 
Excessive accumulation of ECM results in the formation of permanent scar tissue, replacing 
normal renal parenchyma, leading to reduced renal function and, eventually organ failure; 
end-stage renal disease (ESRD) requiring dialysis or transplantation. Renal fibrosis can occur 
in all the major compartments of the kidney including the glomerulus (termed 
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glomerulosclerosis), the tubulointerstitium (termed tubulointerstitial fibrosis) and the 
vasculature (Strutz and Zeisberg, 2006). Once established, renal fibrosis is irreversible. 
The earliest identifiable histological feature of CKD is the aberrant accumulation of 
myofibroblasts, the cells that mediate fibrosis (Meran and Steadman, 2011). TGF β-1 
stimulates fibroblast migration to the site of tissue injury where they become activated and 
differentiate into myofibroblasts. A defining feature of myofibroblasts is their expression of 
α-SMA, a classical fibrotic marker (Bottinger and Bitzer, 2002; Massague, 2012). Upon TGF 
β-1 stimulation, α-SMA is incorporated into stress fibres conferring myofibroblasts with their 
contractile activity (Hinz et al., 2001). Myofibroblasts also produce the fibrillary Collagen-
rich ECM upon TGF β-1 stimulation. The contractile force created by the α-SMA-containing 
stress fibres can be transmitted to the surrounding ECM resulting in ECM reorganisation and 
wound contraction (Tomasek et al., 2002). In fibrotic diseases such as CKD, persistent TGF 
β-1 stimulation and myofibroblast activation results in ongoing fibrosis and progressive organ 
failure.      
1.2.3 Chronic Kidney Disease: Definition and Disease Staging  
The definition of Chronic Kidney Disease (CKD) defined by the global KDIGO organisation 
is glomerular filtration rate (GFR) <60mL/min/1.73m2 for more than 3 months, with or 
without kidney damage or structural or functional abnormalities of the kidney for more than 3 
months, with or without reduced GFR defined by pathological abnormalities or markers of 
kidney damage including blood or urine composition abnormalities or abnormalities in 
imaging tests (Levey et al., 2005).  
As detailed in Table 1.1, CKD can be classified into 5 stages according to kidney function 
defined by GFR. Early detection and treatment of CKD can allow intervention to slow disease 
progression but early detection is challenging due to a paucity of reliable disease markers. 
CKD is often associated with underlying causes such as hypertension, diabetes and 
glomerulonephritis. Secondary complications such as cardiovascular disease, anaemia and 
hypertension make it difficult to estimate the severity of CKD based upon GFR alone.   
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Stage Description 
GFR 
(mL/min/1.73m2) 
1 
Kidney damage with 
normal or increased 
GFR 
>90 
2 
Kidney damage with 
mild reduction in GFR 
60-89 
3 
Moderate reduction in 
GFR 
30-59 
4 
Severe reduction in 
GFR 
15-29 
5 Kidney failure (ESRF) <15 (or dialysis) 
1.2.4 Epidemiology, Risk and Costs of CKD 
CKD is a growing public health issue. In England in 2008/09 there were 1,739,443 people 
aged 18 and over who were registered with CKD (stages 3-5). Prevalence rates continue to 
increase as result of an ageing population and an increasing incidence of Type II diabetes 
mellitus (Arnold et al., 2015). The cost of CKD to the NHS in England alone in 2009–10 was 
estimated at £1.45 billion accounting for around 1.3% of all NHS spending in that year. 
Epidemiological data has revealed that CKD sufferers are far more likely to be need further 
hospital admissions than non CKD sufferers, with associated costs for the NHS (Arnold et al., 
2015). 
More globally, CKD is also a growing health problem with recent reports identifying a 
significant increase in mortality due to CKD from 1990 to 2013 in a survey of 188 countries 
(GBD 2013 Mortality and Causes of Death Collaborators, 2015).   
1.2.5 Aetiology of CKD 
CKD is a multifactorial disease known to have many underlying causes such as hypertension, 
glomerulonephritis and diabetes as well as being associated with complications such as 
cardiovascular diseases, bone disorders and anaemia. The kidney’s role in vital homeostatic 
functions such as regulation of blood pressure and electrolyte balance highlights the 
Table 1.1 Classification of CKD. CKD can be classified into 5 stages based on kidney function GFR. 1 
denoting some kidney damage but with normal GFR to 5 denoting kidney failure requiring dialysis, 
according to the National Kidney Foundation. 
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importance of their role in systemic complications of disease. Significant single-nucleotide 
polymorphism (SNP) associations in UMOD, SHROOM3 and GATM loci have previously 
been associated with an increased risk of CKD (Kottgen et al., 2009; Chambers et al., 2010). 
The findings of these common genetic variants provide insight into mechanisms underlying 
CKD and offer the potential to develop new therapeutic strategies for CKD management, 
although to date this has not been achieved. 
1.2.6 Management of CKD 
Management of ESRF remains limited to either dialysis or transplantation. Measures to 
prevent ESRF include weight control, diet and exercise and blood pressure control. However, 
the evidence for these interventions remains relatively weak. To date, only angiotensin-
converting enzyme inhibitors (ACEi) and angiotensin II receptor blockers (ARBs) have 
proved effective in clinical trials in retarding the progression of CKD (Turner et al., 2012). 
These two agents remain the primary treatment of CKD but at best can only slow the 
progression of the disease.  
The clinical focus is therefore towards early detection and management of risk factors for 
progressive CKD. The pro-fibrotic role of TGF β-1 has been widely described in the literature 
in several species, organs and models of renal injury (Meng et al., 2016; Vega et al., 2016). 
TGF β-1 inhibition has been the focus of much research, with the use of blocking antibodies, 
small molecule inhibitors and gene disruption, but only very few of these approaches have 
proved that TGF β-1 can be successfully targeted (Klinkhammer et al., 2017).  
Inhibition of TGF β-1 by the neutralizing human monoclonal antibody fresolimumab has been 
tested in Phase I and II clinical trials. In Phase II trials in glomerulosclerosis patients, 
fresolimumab showed promising results with improved GFR compared to placebo which 
could be a result of retardation of fibrosis (Klinkhammer et al., 2017; Vincenti et al., 2017).  
Connective tissue growth factor (CTGF) is a pro-fibrotic matricellular protein downstream of 
TGF β. Upregulated CTGF expression is seen in kidneys with renal fibrosis. Reduction of 
CTGF by antisense treatment has proven effective in murine models of kidney disease, 
significantly reducing renal tubulointerstitial fibrosis (Dubey et al., 1997). Phase I and II 
clinical trials using a monoclonal anti-CTGF antibody were found to reduce albuminuria but 
the Phase II trial was prematurely terminated due to poor efficacy of the compound (Adler et 
al., 2010).  
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Because renal fibrosis is partly caused by increased Collagen synthesis and reduced Collagen 
degradation, other research has focussed on a search for therapeutics that increase Collagen 
degradation. Pirfenidone, a synthetic oral compound with anti-fibrotic properties has been 
licensed for the treatment of pulmonary fibrosis. It is thought to disrupt TGF β-1 signalling by 
interfering with gene promotor activity, thereby reducing ECM production and indirectly 
increasing Collagen degradation, although the exact mechanisms are unknown 
(RamachandraRao et al., 2009). Pirfenidone has shown some success in animal models (Vega 
et al., 2016) but in CKD patients it has produced varied results. In diabetic nephropathy Phase 
II trials of low dose Pirfenidone increased GFR compared to placebo but was poorly tolerated 
(Sharma et al., 2011) and was shown to cause a slight but possibly beneficial increase in GFR 
in patients with glomerulosclerosis (Cho et al., 2007). Larger clinical trials are required to 
determine the benefit of Pirfenidone in CKD.  
Endothelin-1 (ET-1) receptor blockers are promising therapeutics for the treatment of renal 
fibrosis. ET-1 is involved in renal fibrosis whereupon it binds to its receptor endothelin 
receptor-A (ETR-A) which promotes renal vasoconstriction resulting in greater glomerular 
pressure and ischemia leading to renal fibrosis and also promotes inflammation and activation 
of the renin angiotensin system (Dhaun et al., 2006). ETR-A blockers were developed and 
used in Phase I and II clinical trials which led to significantly lower proteinuria and blood 
pressure in diabetic and CKD patients (Black et al., 2007). A Phase III clinical trial with over 
4000 patients is now ongoing which will provide further critical data including renal and 
cardiovascular end-points (Egido et al., 2017).  
Although there has been a lot of focus on identifying novel therapeutic targets in renal fibrosis 
and CKD there are still few promising potential candidates that are likely to be used 
clinically. Many treatments show promise in animal models but then produce disappointing 
results in clinical trials. We are still awaiting clinical data concerning some promising 
therapeutics such as Pirfenidone. The discovery of new biomarkers for renal fibrosis and 
CKD would also be very useful in developing more promising treatments in addition to the 
use of GFR and proteinuria which only partially correlate with the progression of CKD.  
There is still an inherent need for the discovery of novel therapeutic targets and markers of 
fibrosis for the detection of CKD and prevention of ESRF and cardiovascular end-points 
resulting from CKD.   
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1.3 Contribution of Cell Types to Renal Fibrosis 
1.3.1 Renal Tubular Epithelial Cells 
In fibrosis, renal tubular epithelial cells are lost due to cell death or undergo epithelial-to-
mesenchymal transition (EMT) resulting in the loss of epithelial cell markers and an increase 
in the expression of mesenchymal markers. Renal tubular epithelial cell dedifferentiation may 
play an important role in fibrosis progression and may also contribute by secreting pro-
fibrotic cytokines and growth factors, in models of CKD (Duffield, 2014). TGF β-1 has a vital 
role in fibrosis, promoting cell death and dedifferentiation of tubular epithelial cells and 
inducing the increased deposition of ECM (Kang et al., 2015). Nevertheless, the role of 
tubular cells in fibrosis remains debated (Liu, 2004). 
1.3.2 Fibroblasts  
Fibroblasts in the kidney are located within the interstitial space where they maintain a steady 
level of ECM to maintain the organs structural integrity. Damage to the kidney results in the 
production of factors such as cytokines, growth factors and mechanical forces that activate 
fibroblasts to become myofibroblasts (Kessler et al., 2001). Myofibroblasts are characterised 
phenotypically by a large nucleolus, cytoplasmic α-SMA stress fibres and prominent rough 
endoplasmic reticulum. They are a non-uniform cell population and display heterogenous 
phenotypes depending on their location, even within single organs (Sorrell and Caplan, 2009). 
Being the principle source of ECM synthesis in fibrosis, makes myofibroblasts a key target in 
research to identify anti-fibrotic therapeutics to inhibit ECM production. Aside from α-SMA, 
other markers used to identify fibroblasts include, Vimentin  and Fibroblast-specific protein 1 
(FSP1) but none of these are specific to fibroblasts alone so identification and analysis of 
fibroblasts is challenging due to the lack of a common specific marker. To further complicate 
matters, ageing fibroblasts are thought to differ in their phenotypes and proliferative capacity. 
The evolving heterogeneity of fibroblasts further hinders the development of fibroblast 
specific-markers (Zeisberg and Kalluri, 2013). Nevertheless, the number of myofibroblasts 
present, as indicated by α-SMA expression correlates with renal disease progression 
(Hewitson and Becker, 1995).  
TGF β-1 induces the differentiation of fibroblasts to activated myofibroblasts leading to 
Collagen matrix remodelling. TGF β-1 increases the ability of fibroblasts to migrate and 
adhere to Collagen fibres and increases their expression of the contractile protein α-SMA. The 
increased expression of α-SMA enhances intracellular tension leading to Collagen contraction 
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and wound healing by myofibroblasts, important mechanisms in ECM remodelling in fibrosis 
(Kondo et al., 2004).   
1.3.3 Origins of Myofibroblasts in Renal Fibrosis 
The origin of myofibroblasts in renal fibrosis is a hot topic of research and has been an intense 
source of debate for many years. Myofibroblasts have been proposed to originate from several 
sources including proliferation from local resident fibroblasts, EMT, Endothelial-
Mesenchymal Transition (EndMT), from bone marrow (BM)-derived cells and from pericytes 
(Figure 1.3) (LeBleu and Kalluri, 2011; Sun et al., 2016).  
A commonly accepted theory of their origin is from the activation of renal interstitial 
fibroblasts (Liu, 2004). Previous research showed that tubular epithelial cells could express 
fibroblastic markers such as FSP1 during fibrogenesis. This lead to the hypothesis that 
fibroblasts could be derived from epithelial-to-mesenchymal transition (EMT) (Strutz et al., 
1995).  
EMT is characterised by the loss of epithelial markers, such as E-cadherin and the acquisition 
of mesenchymal features, such as α-SMA and Vimentin expression, enhanced cell motility 
and invasion and production of Fibronectin and Collagen I (Kalluri and Neilson, 2003). TGF 
β-1 is a potent inducer of EMT in vitro (Fan et al., 1999). In nephrectomised rats the stressed 
tubular epithelial cells become increasingly positive for α-SMA with time after nephrectomy 
with simultaneous disruption of the basement membrane, supporting a model in which 
epithelial cells undergo EMT and migrate to the interstitium (Ng et al., 1998). In the adult 
kidney, mature tubular epithelial cells undergo EMT which has been found to be significant in 
the pathogenesis of renal interstitial fibrosis, as it has been suggested that this is the origin of 
a significant proportion of interstitial fibroblasts in diseased kidneys (Liu, 2004). A study 
using transgenic reporter mice quantitatively determined EMT contribution in unilateral ureter 
obstruction mouse model (UUO), providing evidence that EMT contributed to 36% of 
fibroblast origin. This finding determines that EMT plays a much greater role in renal fibrosis 
than previously thought (Iwano et al., 2002). Furthermore, selective blockade of EMT in a 
whole animal model showed myofibroblast accumulation was actually reversed (Yang et al., 
2002a), suggesting that EMT has an important role in renal fibrosis in the whole animal. On 
the contrary, another study demonstrated the contribution of EMT to myofibroblast 
accumulation was very low and therefore is insignificant in renal fibrosis (LeBleu et al., 
2013). More research is therefore needed to determine the true contribution of EMT in renal 
fibrosis.  
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EndMT is a process similar to EMT with the loss of endothelial cell markers and the 
acquisition of mesenchymal cell markers. This process has been shown to be important in 
several disease models of fibrosis. A study using a transgenic mouse line with traceable 
endothelial lineage in 3 models of renal fibrosis; UUO, streptozotocin (STZ)-induced diabetic 
nephropathy and a model for Alport disease, found myofibroblasts expressed α-SMA and the 
endothelial marker CD31, suggesting an endothelial origin for at least some fibroblasts 
(Zeisberg et al., 2008). Additionally, a similar study using another endothelial lineage-
traceable mouse line and confocal microscopy revealed that 23% and 25% of myofibroblast 
accumulation in the renal interstitium were of endothelial origin in models of STZ-induced 
diabetic nephropathy and UUO, respectively (Li et al., 2010). Blockade of TGF β/SMAD 
signalling to inhibit EndMT demonstrated a decrease in renal fibrosis and reduced disease 
progression in both UUO and STZ-induced diabetic nephropathy (Li et al., 2009). These 
studies indicate a potentially significant contribution for EndMT in the accumulation of 
myofibroblasts in several disease models of renal fibrosis. To confirm this contribution, 
improved endothelial tracing needs to be established. 
Pericytes have recently been suggested as another source of myofibroblasts. Pericytes are 
ECM-producing stromal cells that surround the interstitial capillary endothelium. A study 
used lineage tracking and cell ablation in a mouse model of renal fibrosis to identify a subset 
of mesenchymal-like pericytes as progenitors of myofibroblasts. The pericytes identified 
proliferated within the interstitium and acquired α-SMA expression identifying them as 
myofibroblasts. Pericytes and their involvement in myofibroblast accumulation in renal 
fibrosis is a highly debated subject due to the lack of specific cellular markers. Pericytes 
express some common markers that are also found on fibroblasts such as Platelet-derived 
growth factor receptor 2 (PDGFR2) (Kramann et al., 2015). In contrast, LeBleu et al. 
performed a study to determine the origin of myofibroblasts in renal fibrosis using genetic 
mouse models and cell tracking. They found that the majority of pericytes did not express α-
SMA and considering the cells did express α-SMA, only a small number were positive for 
PDGFR and NG2 expression. Furthermore, when PDGFR and NG2 cells were depleted in the 
UUO model there was no significant reduction in fibrosis, suggesting that the role of pericytes 
in myofibroblast accumulation in renal fibrosis is insignificant. LeBleu et al. discovered 
myofibroblast accumulation originated from 2 major sources; 50% originated from 
proliferation of local resident fibroblasts and 35% from bone marrow-derived cells (BMDC). 
EndMT and EMT contributed to a lesser extent of 10% and 5% respectively. The study 
revealed that BMDC can differentiate into myofibroblasts in the presence of TGF β-1 
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promoting their differentiation and migration. Loss of TGF βR2 prevented the cells from 
differentiating into myofibroblasts, further highlighting a crucial role of TGF β-1 (LeBleu and 
Kalluri, 2011). These results demonstrate that the accumulation of myofibroblasts involves 
several methods and therefore treatments such as anti-proliferative drugs will only partially 
reduce myofibroblast accumulation and fibrosis in the kidney. As TGF β-1 is known to also 
be involved in the proliferation of fibroblasts, studies targeting the TGF β-1 pathway have 
been useful in reducing myofibroblast accumulation in renal fibrosis.  
BMDC, another potential source of myofibroblasts could migrate into the kidney in response 
to injury. A study in a UUO mouse model of renal fibrosis transplanted with bone marrow 
that expressed red fluorescent protein (RFP) under the regulation of an α-SMA promoter 
identified around 35% of myofibroblasts were of bone marrow origin, demonstrating a 
substantial contribution to myofibroblast accumulation in renal fibrosis (LeBleu et al., 2013). 
 
 
Figure 1.3. Source of Fibroblasts in Fibrosis. In fibrosis, fibroblasts are derived from several sources 
including resident fibroblasts, fibrocytes, pericytes, BMDC, EMT and EndMT. Adapted from (Kanasaki et 
al., 2013).  
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1.4 Experimental Models of Renal Fibrosis and CKD 
1.4.1 Cellular Models of CKD 
In order to investigate the mechanisms responsible for renal fibrosis, a number of 
immortalised cell lines are available which represent various models of fibrosis. Each have 
their advantages as well as limitations. These models include, but are not limited to, HK C-8, 
Human Mesangial Cells (THMC) and Mouse Embryonic Fibroblast (MEF) cells. 
HK C-8 cells are proximal tubular epithelial cells derived from humans. A useful cell model 
to study human renal function and the mechanisms renal fibrosis as tubular cell 
dedifferentiation via EMT is thought to be a source of fibroblasts in tubulointerstitial fibrosis.  
THMC are perivascular cells which originate from the glomerulus (Sraer et al., 1996). These 
cells represent an in vitro model of glomerular pathologies and are useful cell line to study the 
effect of fibrosis.  
MEF cells are derived from mouse embryos that present typical features of fibroblasts. Genes 
of interest can be knocked out of these cells to study their function in fibrosis. 
In addition to immortalised cell line models, renal fibrosis can be modelled using Primary 
Renal Fibroblasts (PRFs); fibroblasts isolated directly from human cortical kidney tissue 
providing a primary model of tubulointerstitial fibrosis when treated with TGF β-1. These 
cells are arguably the most suitable cellular model for studying renal fibrosis as they have not 
undergone the process of immortalisation. One limitation of many primary cells studies is that 
there is a limited quantity of tissue and the life-span of primary cultures can be relatively 
short..  
1.4.2 Whole Organism Models of CKD 
The development of in vivo animal models to mimic renal disease is important to provide a 
better understanding of the pathways and mechanisms involved in renal fibrosis and for 
testing potential drug candidates.  
UUO is the best characterised experimental model of chronic renal disease. Surgically-
induced UUO in rodents produces progressive renal fibrosis similar to that seen in most 
human disease. The duration and severity can be manipulated in this model and obstruction 
can be reversed by release of ligature. UUO is induced by a single surgical ligation of one 
ureter (Klahr and Pukerson, 1994) and results in the gradual development of tubular injury 
and cell death, macrophage and T cell infiltration and the accumulation of myofibroblasts 
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leading to ECM deposition and subsequently renal tubulointerstitial fibrosis (Chevalier et al., 
2009). This model most closely resembles obstructive nephropathy in humans, which is the 
commonest cause of ESRD in the paediatric population.  
1.4.3 Limitations of CKD Models to Human Disease 
Cell and animal models provide us with an opportunity to increase our understanding of the 
mechanisms of disease and to develop and test novel therapeutics. Whilst they exhibit 
similarities to human disease, they do not precisely replicate human disease and so there will 
always be limitations to these models. For example, working with primary and immortalised 
cell lines that are far removed from their normal environment limits the cross-talk between 
cells and signalling pathways that occur in their normal conditions, potentially limiting their 
natural response.  
Genetic engineering allows us to manipulate animal models to present a particular 
genotype/phenotype to mimic human disease for the development of new therapeutics but the 
limitations to these animal models include the disease developing artificially (surgically, 
genetically engineered) therefore not representing all the disease features or not closely 
resembling the human disease. Cellular and animal models should therefore be used with 
caution and ideally not in isolation. Using more than one model might overcome some of 
these limitations.  
1.5 TGF β Signalling 
1.5.1 The TGF β Superfamily 
The Transforming growth factor β (TGF β) superfamily are well characterised and 
multifunctional secreted growth factors. The superfamily includes TGF βs (1-3), inhibins (A 
and B), bone morphogenetic proteins (BMPs 1-20) and activins (A and B) (Gordon and 
Blobe, 2008). The TGF β superfamily are ubiquitously expressed and almost every cell in the 
human body expresses and responds to at least one member of this superfamily (Siegel and 
Massague, 2003). They therefore play a role in a diverse range of biological activities, 
including cell proliferation and differentiation, wound healing and tissue homeostasis, 
apoptosis and angiogenesis. Alterations in the TGF β superfamily pathways can result in 
human disease such as connective tissue disorders, fibrosis, and cancer (Schmierer and Hill, 
2007).  
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It was clear from when TGF β was first discovered that it had diverse and even opposing 
effects depending on the cell type and context. A fairly simple pathway was discovered 
consisting of TGF β receptors (TGF βRs) and SMAD proteins which function as signal 
transducers and substrates for the TGF βRs. However this simple pathway was found to lead 
to a vast range of effects in many biological processes (Massague, 2012). Many other 
regulators and related pathways have since been identified, indicating the complexity of this 
signalling pathway.  
A family of TGF β receptors are positioned at the cell membrane. In response to TGF β 
ligands, cellular responses are transduced via these transmembrane serine/threonine kinase 
type I and type II receptors, together with a group of intracellular modulators (SMAD 
proteins) which constitute the cellular machinery responsible for detecting and responding to 
TGF β. There are three types of contextual determinants that can regulate the transcriptional 
response of TGF β signalling; 1. Many signal transduction factors can control TGF β ligand 
binding to the receptors and subsequently the receptors to SMAD proteins. 2. Transcription 
factors that bind to activated SMADs can determine which genes are targeted and whether 
transcription of those genes are negatively or positively regulated. 3. The epigenetic state of 
the cell can provide either an active ‘open chromatin’ (accessible to binding of SMAD 
complexes) or repressive ‘closed chromatin’ (silenced state and closed to SMAD complex 
binding) (Massague, 2012). 
Ligands of the TGF β superfamily initiate cell signalling by binding to cell surface 
serine/threonine receptors, type I (activin like kinase (ALK) 1-7) receptors and type II TGF β 
receptors. Increasing numbers of co-receptors have been identified that are thought to regulate 
ligand binding to the type I and II receptors. Type II receptors are constitutively active 
serine/threonine kinases and upon ligand binding adopt conformational changes to recruit and 
interact with a type I receptor to form an active receptor complex (Shi and Massague, 2003). 
The type II receptor phosphorylates the glycine serine (GS) rich domain of the type I receptor 
activating its serine/threonine kinase activity. The Type I receptor transduces its cellular 
effects by directly phosphorylating a conserved family of transcriptional mediators, known as 
SMADs. Phosphorylation of 2 receptor-activated SMAD (R-SMADs) results in formation of 
an active complex with SMAD4, a common SMAD, this complex is then translocated to the 
nucleus where it can interact with transcription factors, co-activators and co-repressors to 
regulate the transcription of target genes (Heldin et al., 1997; Shi and Massague, 2003). 
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TGF β signalling occurs predominantly through SMAD-mediated pathways, but other 
signalling molecules are also involved, including extracellular-signal-regulated kinase (ERK), 
p38 and JUN N-terminal Kinase (JNK), all of which are mitogen activated protein kinase 
(MAPK) pathways (Derynck and Zhang, 2003; Miyazono et al., 2005). This cross-talk with 
other signalling pathways highlights the complexity of TGF β superfamily signalling and the 
diverse cellular effects the TGF β superfamily can mediate.  
1.5.2 The TGF β-1 Signalling Pathway  
Cells synthesise and secrete TGF β-1 into the ECM in an inactive form containing mature 
TGF β-1 and a signal peptide, the latency-associated peptide (LAP). Cleavage of LAP 
induced by environmental conditions and proteases (plasmin, cathepsin D, furin convertase 
and MMP2 and 9) or mechanical disruption of the complex results in TGF β-1 release and 
binding to its receptor (Lyons et al., 1988).  
Phosphorylation of type I receptor allows the recruitment of intracellular SMAD3. The 
activated receptor I phosphorylates a conserved Ser-X-Ser motif (x = any amino acid) within 
the C-terminal domain of SMAD3, generating an acidic tail, thereby allowing for binding of 
SMAD4. Phosphorylated SMAD3 oligomerises with SMAD4 and the complex translocates to 
the nucleus to regulate transcription of pro-fibrotic SMAD3 target genes, such as ACTA2 
which encodes α-SMA (Hu et al., 2003). Within the nucleus, SMAD4 can enhance SMAD3 
transcriptional activity by acting as a co-factor. The final result is an increase in expression of 
SMAD3 target genes, in response to TGF β-1 (Liu et al., 2012) (Figure 1.4). SMAD7 is an 
inhibitory SMAD which acts to negatively regulate TGF β-1 signalling by complexing with 
TGFβ RI to inhibit phosphorylation of R-SMADs (Nakao et al., 1997). Smad ubiquitination 
regulatory factor 1 (Smurf 1) and Smurf 2 are E3 ubiquitin ligases which degrade SMADs 
and can complex with SMAD7 to degrade TGFβ R1, acting to regulate the signalling pathway 
(Ebisawa et al., 2001; Ma et al., 2018).   
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1.5.3 The Role of TGF β-1 in Human Disease 
TGF β-1 signalling is a critical regulator of essential cellular processes and many human 
diseases arise from disruption of this signalling pathway resulting in its aberrant activation or 
inhibition (Gordon and Blobe, 2008).  
Cardiovascular disease (CVD) 
TGF β-1 is a predominant ligand expressed in CVD, demonstrated in TGFβ1-/- mice which 
die early through excessive systemic inflammatory response resulting in the infiltration of 
lymphocytes and macrophages into the heart (Kulkarni and Karlsson, 1993).  
Connective tissue diseases 
Marfan syndrome (MS) is a multisystem connective tissue disease, clinically characterised by 
cardiac, skeletal and vision abnormalities. Mutations have been identified in TGFβ RI and II 
in MS patients affecting the kinase domains of the receptors resulting in loss of function 
(LeMaire et al., 2007).    
Cancer 
Figure 1.4. TGF β-1/SMAD Signalling Pathway. TGF β-1 signalling pathway mediated via cell surface membrane 
receptors and downstream SMAD mediators to allow transcription of target genes.  
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TGF β’s role in cancer is diverse, acting as a tumour suppressor early on in carcinogenesis but 
later switching to a tumour promoter. TGF β signalling and its role in human cancer is evident 
as demonstrated by the mutations in the TGF β signalling components, identified in hereditary 
and sporadic cancers (Elliott and Blobe, 2005).   
Breast Cancer 
Several alterations in the TGF β signalling pathway has been discovered in breast cancer and 
TGF β is well known to regulate normal mammary growth and development. A thymine to 
cytosine polymorphism in the coding sequence of the TGF β1 gene resulting in a leucine to 
proline amino acid substitution has been shown to lead to higher TGF β-1 levels resulting in 
an increased risk of breast cancer (Ziv et al., 2001).  
Fibrosis 
TGF β-1 is known to have an important role in the pathological response to tissue wounding, 
resulting in the development and progression of fibrosis. The aberrant deposition of ECM in 
organs such as the skin, liver, lungs and kidneys leads to loss of organ function and eventually 
organ failure. TGF β-1 is a major regulator of ECM formation and remodelling and its 
excessive signalling has been well defined in the pathogenesis of many fibrotic diseases 
(Verrecchia and Mauviel, 2007a).  
1.5.4 The Role of TGF β-1 in Renal Fibrosis 
TGF β-1 plays a central role in wound healing and tissue remodelling but also in the 
development of tissue fibrosis, including renal fibrosis. Overexpression of TGF β-1 from the 
albumin promoter is enough to directly cause renal fibrosis, indicating the critical role of TGF 
β-1 (Liu et al., 2006).    
Injury to tissue initiates a repair process in which TGF β-1 expression is upregulated by 
parenchymal cells and infiltrating cells such as lymphoid cells and macrophages. Further 
production of TGF β-1 is caused by extracellular signalling molecules angiotensin II and 
thromboxane and within injured tissue plasmin, thrombospondin and reactive oxygen species 
activate latent TGF β-1 production. Furthermore, TGF β-1 feedback loops via the autocrine 
and paracrine signalling also increase TGF β-1 production. The aberrant upregulation and 
accumulation of TGF β-1 acts to increase ECM synthesis and reduce ECM degradation 
consequently resulting in tissue fibrosis.  
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The ECM serves important cellular functions such as structural support, cellular adhesion and 
barriers against fluids. The ECM provides specialised tissue functions within each tissue type 
and these specialised functions are accomplished by TGF β-1 regulated expression of specific 
matrix proteins. For example, within the kidney the interstitial matrix consists of Collagen I 
and III, Fibronectin and Tenascin.  
Under normal tissue repair, TGF β-1 controls enzymes that regulate ECM synthesis including 
matrix metalloproteinases (MMP) and plasmin. Under pathological conditions SMAD3 is 
highly activated whereas SMAD7 is degraded by Smurf 1 and 2 via ubiquitin-dependent 
degradation (Ebisawa et al., 2001). This results in reduced TGF βI receptor degradation, 
amplified TGF β-1 signalling and increased transcription of SMAD3 target genes and 
activation of myofibroblasts leading to excessive expression of ECM proteins such as α-SMA, 
Collagen I and Fibronectin (Ebisawa et al., 2001; Verrecchia and Mauviel, 2007b; Lan, 2011; 
Meng et al., 2015b). 
1.6 SMAD Signalling 
1.6.1 The SMAD Signalling Protein Family 
The SMAD are a family of proteins similar to the gene products of the Drosophila gene 
'mothers against decapentaplegic' (Mad) and the C. elegans gene Sma. SMADs are signal 
transducers and transcription factors that mediate multiple signalling pathways. There are 8 
known human SMAD proteins that can be divided into 3 subgroups based on structure and 
function (Figure 1.5). The first subgroup, receptor-activated SMADs (R-SMADs) are direct 
substrates of the TGF β kinase receptors. The second subgroup interact with R-SMADs and 
contribute to signalling co-regulatory SMADs (co-SMADs). The third subgroup are inhibitory 
SMADs (I-SMADs) which act as negative regulators by inhibiting SMAD activation. R-
SMAD 1, 5 and 8 are mediators of the BMP receptor signalling, whereas R-SMAD 2 and 3 
are mediators of TGF β and activin receptor signalling. SMAD4 is a shared co-SMAD which 
participates in both TGF β/activin and BMP signalling pathways by associating with R-
SMADs after receptor activation. SMAD4 is required for R-SMAD signalling function 
(Watanabe et al., 1997; Kretzschmar and Massague, 1998; Massague et al., 2005). SMAD 6 
and 7 are inhibitory SMADs; SMAD7 negatively regulates SMAD3 and TGFβ Rs via 
degradation (Kavsak et al., 2000).  
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1.6.2 The SMAD3 Transcription Factor 
SMAD3 is a 48kDa protein with two globular domains coupled by a linker domain (Figure 
1.6). The amino terminal Mad Homology 1 (MH1) domain of SMAD3 contains a β-hairpin 
structure that mediates direct DNA binding, this structure is conserved in all R-SMADs and 
SMAD4.  
The linker domain is a proline rich, flexible and unstructured region with phosphorylation 
sites for kinases such as MAPKs and cyclin-dependent kinases (CDKs) suggesting a function 
in integrating cross-talk from other signalling pathways. The carboxy terminal Mad 
Homology 2 (MH2) domain is highly conserved and facilitates protein-protein interaction. 
The MH2 domain also contains a region of hydrophobic patches, referred to as the 
“hydrophobic corridor”, a location for various interactions such as with DNA-binding co-
factors (Kretzschmar and Massague, 1998; Schmierer and Hill, 2007; Massague, 2012).  
 
Figure 1.5. Classification of the SMAD Family of Proteins. The SMAD family of proteins are classified 
into 3 subgroups; receptor-activated SMADs (R-SMADs), co-SMADs and inhibitors SMADs (I-
SMADs).They each have distinct roles within the TGFβ signalling pathway. 
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1.6.3 The Role of SMAD3 in Renal Fibrosis 
SMAD3 has an important role in renal fibrosis; SMAD3 knockout mice are resistant to 
tubulointerstitial renal fibrosis in the UUO model of obstructive nephropathy (Sato et al., 
2003; Inazaki et al., 2004) and resistant to glomerular sclerosis caused by induction of type 1 
diabetes with streptozotocin (Fujimoto et al., 2003). 
Additionally, SMAD3 knockout mice are resistant to fibrosis in other organs including 
bleomycin-induced pulmonary fibrosis (Zhao et al., 2002), radiation-induced skin fibrosis 
(Flanders et al., 2002), angiotensin II-induced cardiac fibrosis (Chung et al., 2010) and carbon 
tetrachloride-induced liver fibrosis (Schnabl et al., 2001). 
Furthermore, overexpression of SMAD7, a negative regulatory protein of TGF β-1/SMAD3 
pathway inhibits SMAD3, consequently protecting against renal fibrosis in various animal 
models (Dooley et al., 2003; Lan et al., 2003; Wang et al., 2005).  
Treatment with halofuginone, a SMAD3 inhibitor reduces renal fibrosis in rats (Benchetrit et 
al., 2007) and reduces fibrosis in other organs (Pines, 2008). Collectively, all of these data 
Figure 1.6. Structure of SMAD3. SMAD3 consists of MH1 and MH2 domains that are joined by a linker 
region. The TGF βRI phosphorylates SMAD3 at the C terminal sequence Ser-X-Ser (where X can be any 
amino acid). The linker can be phosphorylated by CDKs, MAPKs (green) and glycogen synthase kinase 3 
(GSK3) (red). The phosphorylated linker creates docking sites for regulators of SMAD3. The N terminal 
domain binds DNA (Massague, 2012).  
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show that inhibition of SMAD3 would have clinical utility in the treatment of fibrosis. 
However, no SMAD3 inhibitory compounds have been developed for clinical application to-
date.   
This necessitates a more thorough evaluation of SMAD3 signalling in response to pro-fibrotic 
signals in the kidney and other organs, to determine whether SMAD3 can be inhibited in an 
alternative and possibly indirect manner. This will involve identification of factors that are 
needed for the regulation of SMAD3, and an evaluation of such factors as targets in fibrosis. 
1.7 Lysine Methyltransferases 
1.7.1 The SET-domain Lysine Methyltransferase Family 
DNA is stored in the form of chromatin in the nucleus of eukaryotic cells. Chromatin consists 
of nucleosomes composed of 146bp of DNA wrapped around 2 of each of the core histones 
H2A, H2B, H3 and H4 (Luger et al., 1997). The unstructured N-terminal tails of the core 
histones protrude from the nucleosomes and play a critical role in organising the structure and 
accessibility of the nucleosomal DNA (Angelov et al., 2001). Two types of chromatin have 
been defined: heterochromatin, a compressed and transcriptionally silent structure and 
euchromatin, a more open, transcriptionally active arrangement (Grunstein et al., 1995). 
Histone tails undergo post-translational modifications including methylation, acetylation, 
phosphorylation and ubiquitination that modulate the structure and ‘openess’ of chromatin to 
allow access for transcription factors and regulate the expression of genes (Strahl and Allis, 
2000). Acetylation of histone tails has been well studied and is generally known to convert 
chromatin to an open, transcriptionally active form. More recently, the focus of epigenetic 
research has been to determine the effects of other types of covalent modifications of 
chromatin, including methylation, particularly of histones H3 and H4. Histones are well 
known to be substrates of methylation (Murray, 1964), lysines 4, 9, 27 and 36 of H3 and 
lysine 20 of H4 have been identified as preferential sites of methylation (Strahl et al., 2001; 
Xu et al., 2001).  
Histone methylation by the SET-domain lysine methyltransferase family of proteins transfers 
a methyl group from S-adenosyl-L-methionine (AdoMet) to the amino group of a lysine 
residue on histones or other proteins, leaving a methylated lysine residue and the co-factor 
byproduct S-adenosyl-L-homocysteine (AdoHcy) (Nishioka et al., 2002; Dillon et al., 2005). 
A major focus of research has been the study of lysine methylation in histones, which 
identified SUV39H1 as the first histone lysine methyltransferase (HKMT) which targets 
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lysine 9 of H3 (H3K9), correlating with transcriptional repression. Subsequently, many other 
lysine methyltransferases have been identified, the majority of which target lysines within 
histone tails. Furthermore, the HKMTs that methylate histone tail lysines all contain a SET 
domain, a conserved catalytic domain of 130 amino acids. The SET domain was found to be 
conserved in the PEV modifier SU(VAR)3-9, the Polycomb-group protein E(Z), and the 
trithorax-group protein TRX (Jenuwein et al., 1998). Crystal structures reveal the structure of 
the SET domain is folded in such a way that the two most conserved motifs within the domain 
(RFINHXCXPN and ELXFDY) are brought together forming an active site which is 
conveniently located next to the peptide-binding cleft and where the methyl donor will bind 
(Dillon et al., 2005). Studies have demonstrated that the cysteine-rich N- and C- terminal 
flanking regions (pre- and post-) to the SET domain are also required for enzymatic activity 
(Rea et al., 2000). Lysine histone methylation can also result in transcriptional activation, 
such as the methylation of H3K4 which correlates with acetylation, also known to regulate the 
transcriptional activation of chromatin. SET9 has been identified as a lysine methyltransferase 
specific for the methylation of K4 of H3 causing transcriptional activation (Nishioka et al., 
2002).  
1.7.3 SET9 
SET9, originally isolated from human cells, specifically mono-methylates lysine 4 of histone 
H3 (H3-K4) in a SET-domain-dependent manner to up-regulate transcriptional activation. 
This methylation of H3K4 inhibits acetylation of K4 and causes displacement of the histone 
deacetylase NuRD and also prevents H3-K9 methylation by SUV39h1 (Nishioka et al., 2002).  
Monomethylation of H3K9 by SET9 has been shown to mediate ECM gene expression and 
silencing SET9 attenuates TGF β-1 mediated ECM gene expression (Sun et al., 2010), 
indicating a potential role in renal fibrosis.  
Further studies have shown that SET9 not only methylates histones but also non-histone 
proteins including p53 (Chuikov et al., 2004), TAF10 (Kouskouti et al., 2004), and androgen 
receptor (AR) (Gaughan et al., 2011) regulating their transcriptional activity. Furthermore, 
SET9 has been shown to have some involvement in the TGF β-1/SMAD signalling pathway; 
SET9 methylates the inhibitory SMAD7, targeting it for proteasomal degradation, resulting in 
upregulation of TGF β-1/SMAD signalling (Elkouris et al., 2016).  
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1.7.4 SETDB1 
ESET (SETDB1) was originally identified as a functional partner of the transcription factor 
ERG (Yang et al., 2002b). Identification of conserved SET, pre- and post-SET domains 
suggested histone methyltransferase activity of ESET (Rea et al., 2000). The human homolog 
of ESET was identified as SETDB1 (SET domain, bifurcated 1) and was shown to 
specifically methylate lysine 9 of histone 3 (H3K9). SETDB1 has been shown to co-localise 
with HP1, a heterochromatin protein to play an important role in euchromatic gene silencing 
and transcriptional repression (Schultz et al., 2002).  
SETDB1 has been associated with SMAD3; in response to TGF β-1, SMAD3 recruits 
SETDB1 to the Snai1 promoter where it initiates H3K9 methylation which in turn represses 
H3K9 acetylation. SETDB1 therefore regulates SMAD3 activity by alterations to methylation 
and acetylation at the SNAI1 gene, attenuating Snai1 expression, the driver of EMT. In 
response to TGF β-1, cells downregulate SETDB1 expression during EMT. (Du et al., 2018).   
1.7.5 SET9 and SETDB1 in Human Disease 
Epigenetic alterations resulting in altered chromatin could play a key role in the pathogenesis 
of Huntington’s disease (HD). Chromatin remodeling and neuronal gene transcriptional 
dysfunction have been strongly correlated to HD pathogenesis (Ryu et al., 2006). Expression 
of SETDB1 and levels of trimethylated H3K9 have been shown to be elevated in HD patients 
therefore identifying SETDB1 as a target for treatment in HD (Ryu et al., 2006).  
Recent reports show that SETDB1 has also been associated with gene silencing in cancer. 
Increased SETDB1 expression has been shown to play a role in tumorigenesis, promoting 
tumour cell proliferation and tumour growth (Sun et al., 2015). Mammary epithelial cells 
downregulate SETDB1 expression allowing the cells to progress through EMT by attenuating 
the SMAD3-SETDB1 complex-mediated repression of Snai1. Breast cancer cells that are able 
to invade surrounding tissue exhibit decreased expression of SETDB1, evidence that SETDB1 
suppresses metastasis.  
Similarly, a SET9 feedback loop has been identified where SET9 regulates the stability of 
DNA methyltransferase-1 protein which in turn represses SET9 promoter transcriptional 
activity with Snai1 has been shown to play a role in modulating breast cancer metastasis; 
silencing of SET9 allowed cells to progress through EMT, favouring the generation of cancer 
stem cells. SET9 levels were lower in samples from patients with cancer recurrence compared 
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to samples from patients in remission, indicating a role for SET9 as a tumour suppressor in 
breast cancer (Montenegro et al., 2016).  
These studies demonstrate the involvement of both SET9 and SETDB1 in EMT and 
subsequently in diseases such as breast cancer. They also raise the possibility that both of 
these methyltransferases and their epigenetic modulation be involved in other pathways and 
diseases.  
SET9 expression is upregulated in prostate cancer cells, where it has a pro-proliferative and 
anti-apoptotic role. SET9 has been found to interact with and methylate the androgen receptor 
(AR) enhancing its transcriptional activity by facilitating its recruitment to target genes 
(Gaughan et al., 2011). SET9 has also been shown to methylate the estrogen receptor (ER) to 
stabilise the protein and enhance its transcriptional activity. An ER mutation strongly 
associated with breast cancer at K303 demonstrated an increase in SET9 methylation at K302 
in vitro. Similarly, SETDB1 has been shown to form a complex with and methylate p53 in 
cancer cell lines (Fei et al., 2015). These studies demonstrate an alternative but equally 
important role for SET9 and SETDB1 interacting with non-histone proteins to regulate their 
transcriptional activity. This led us to examine what roles these methyltransferases could play 
in TGF β-1/SMAD signalling in renal fibrosis.  
1.8 Aurora Kinase Signalling 
1.8.1 The Aurora Kinase Protein Family 
The Aurora Kinase (AURK) family, consisting of Aurora A, B and C in humans are closely 
related serine-threonine protein kinases, involved in the regulation of the mitotic phase of the 
cell cycle (Vader and Lens, 2008). The function of each AURK is related to their localisation 
at particular points during the cell cycle. Aurora A (AURKA) is important for cell cycle 
progression, particularly entry into mitosis and is localised at the centrosome during 
interphase and at the spindle during mitosis (Stenoien et al., 2003; Seki et al., 2008). AURKA 
is also involved in centrosome assembly and maturation as well as spindle formation (Sardon 
et al., 2008). Aurora Kinase B (AURKB) is localised to the chromosomes where it is 
responsible for chromosome condensation and chromosome attachment to the mitotic spindle, 
as well as cytokinesis (Welburn et al., 2010). Much less is known about AURKC; it is thought 
to be involved in meiosis.  
The AURKs role in the cell cycle is well characterised but their mechanism of action still 
remains poorly understood. Their small number of known substrates give little indication of 
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their role and therefore identification of other AURK substrates is important in determining 
their functions.  
1.8.2 The Role Aurora Kinases in Human Disease 
AURKA is located on chromosome 20q13.2 known to be frequently amplified in tumours and 
cancer cell lines (Katayama et al., 2003). AURKA overexpression results in centrosome 
amplification, colony formation and tumour growth due to dysregulation in mitosis (Bischoff 
et al., 1998). AURKB overexpression leads to failed cytokinesis and is thought to also be 
involved in tumourigenesis as it has been shown to be overexpressed in some tumour types 
but its role is less clear as AURKB is located on chromosome 17p12.1, a region that has not 
yet been associated with amplification in tumours (Katayama et al., 2003). Both AURKA and 
AURKB being implicated in tumourigenesis has enabled the exploration of AURK inhibitors 
as targets for anticancer treatments (Damodaran et al., 2017). 
1.9 Aims 
The aims of this research were to: 
1. Validate a previously identified potential therapeutic target in CKD, SET9 and 
determine its role in TGF β-1/SMAD3 in renal fibrosis.  
2. Screen a library of methyltransferase siRNAs to identify additional enzymes which 
may play an important role in the regulation of TGF β-1 signalling in renal 
fibrosis.  
3. Establish an effective technique for isolating Primary Renal Fibroblasts to provide 
a more relevant primary cell model.  
4. Use the primary cell model to screen a library small molecule inhibitors to 
determine their effect on cell proliferation and validate any attractive compounds.  
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Chapter 2: Materials and Methods 
2.1 Risk Assessment  
All experiments were performed in compliance with Biological Control of Substances 
Hazardous to Health (BIOCOSH) and Control of Substances Hazardous to Health (COSHH) 
regulations. All laboratory work was conducted in accordance with Institutional rules and 
regulations. 
2.2 Mammalian Cell Culture and Compounds 
2.2.1 Mammalian Cell Culture 
HK C-8 cells are an immortalised human renal proximal tubular epithelial cell line purchased 
from ATCC. THMC cells are an immortalised human renal mesangial cell line contributed by 
Prof. Jill Norman, University College London. Skin Fibroblast cells are an immortalised cell 
line acquired from Dermatology Department at Newcastle University. SET9 MEFs were 
obtained from Guiseppe Testa (IFOM IEO, Milan) whereas SMAD3 MEFs were obtained 
from Prof. Erwin Bottinger (Mt. Sinai School of Medicine, New York City). Primary Renal 
Fibroblast cell lines were purchased from DV Biologics (Palo Alto, CA) or isolated in-house 
(section 2.5).  
HK C-8 and THMC cells were maintained in DMEM F12 (LZBE12-719F, Lonza) 
supplemented with 10% (v/v) foetal bovine serum (FBS) (Lonza) and 1% (v/v) 10,000 units 
penicillin and 10 mg streptomycin/ml (Sigma Aldrich). pCAGA12-luc reporter stably 
transfected HKC8 cells were maintained in DMEM F12 supplemented with 10% (v/v) FBS, 
1% (v/v) penicillin streptomycin and 300μM hygromycin B from Streptomyces hygroscopicus 
(Sigma). All MEF cells and skin fibroblast cells were maintained in DMEM (LZBE12-604F 
Lonza) supplemented with 10% (v/v) FBS and 1% (v/v) penicillin streptomycin (Sigma 
Aldrich). Primary renal fibroblasts (isolated in-house or purchased) were maintained in I Gro 
Fibroblast Cellutions Medium (DV Biologics) supplemented with 10% (v/v) FBS (Lonza) and 
1% (v/v) penicillin streptomycin (Sigma Aldrich). 
DMEM F12 fully supplemented with 10% (v/v) foetal bovine serum (Lonza) and 1% (v/v) 
penicillin streptomycin (Sigma), hereby referred to as full media (FM). DMEM F12 
supplemented with only penicillin streptomycin (Sigma), hereby referred to as basal media 
(BM). DMEM F12 supplemented with 0.5% (v/v) foetal bovine serum (Lonza) and 1% (v/v) 
penicillin streptomycin (Sigma), hereby referred to as full media (0.5% serum starved). 
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2.2.2 Cell Subculturing  
Cell culture was carried out in a BioMat class II microbiological safety cabinet. To passage 
cells, culture media was removed from the culture flask and cells gently washed two times 
with phosphate buffered saline (PBS) (Sigma Aldrich) and incubated with 1 x Trypsin-EDTA 
(Sigma Aldrich) solution at 37°C for 2-3 minutes until cell detachment. Trypsin was 
neutralised by the addition of an equal volume of FM to the flask and the cell suspension was 
transferred to a sterile universal tube (Star Lab) and centrifuged at 400 x g for 5 minutes. The 
supernantant was removed and cell pellet was resuspended in FM and seeded into new flasks 
at a 1:3 dilution. In-house mycoplasma tests were carried out every 2 months using a 
Mycoplasma Detection Kit (R&D Systems). 
2.2.3 Cell Storage 
Cells were resuspended to 1x106 per ml of freezing media (FBS containing 10% dimethyl 
sulfoxide (DMSO) (Sigma Aldrich)) and divided into 1ml aliquots in cryogenic tubes 
(Thermo Scientific) before being stored in a Mr FrostyTM Container (Thermo Scientific) at -
80°C. For long-term storage (>2months) cells were transferred to liquid nitrogen after 24 
hours at -80°C. To animate cells, the cryogenic tubes of cells were taken from liquid nitrogen 
and thawed in a 37ºC water bath then added to pre-warmed FM in a culture flasks. Once cells 
had adhered, the culture medium was changed to fresh FM.  
2.2.4 Compounds 
Transforming Growth Factor beta 1 (TGF -1)  
Transforming Growth Factor beta 1 (TGF -1), a potent growth factor, was purchased in 
lyophilised form from R & D Systems, reconstituted in 20 μg/ml in sterile 4 mM HCl 
containing 1 mg/ml human or bovine serum albumin at 20 μg/ml and stored in aliquots at -
80ºC.  
(R)-PFI hydrochloride 
(R)-PFI hydrochloride (Chemical Name: (1R)-1-[[3-(Trifluoromethyl)phenyl]methyl]-2-oxo-
2-(1-pyrrolidinyl)ethyl]1,2,3,4-tetrahydro-6-isoquinolinesulfonamide hydrochloride) (R-PFI-
2), a potent and selective SET9 histone lysine methyltransfersase inhibitor, was purchased 
from R & D Systems in powder form, reconstituted in DMSO (Sigma Aldrich) at 100mM and 
stored at -20ºC. 
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Cycloheximide (CHX) 
Cycloheximide (CHX) (Chemical Name: 3-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2-
hydroxyethyl]glutarimide), is an antibiotic produced by S. griseus. Its main biological activity 
is translation inhibition in eukaryotes resulting in cell growth arrest (Schneider-Poetsch et al., 
2010). CHX was purchased from Sigma Aldrich in powder form and resuspended in DMSO 
at 100μg/ml.  
MG-132  
MG-132 (chemical name: benzyl (S)-4-methyl-1-1((S)-4-methyl-1-((S)-4-methyl-1-
oxopentan-2-ylamino)-1-oxopentan-2-ylamino)-1-oxopentan-2-ylcarbarmate), a membrane 
permeable proteasome inhibitor, was purchased as a ready-made solution in DMSO at a 
concentration of 10 mM (Sigma Aldrich) and stored at -20°C. 
MK-5108 
MK-5108 is a potent Aurora Kinase A inhibitor and was purchased from Selleck Chem and 
resuspended in DMSO then used at a concentration of 30-50μM in HK C-8 cells and in UUO 
mice at 45mg/kg body weight in 1% methylcellulose, administered by daily oral gavage.  
SB505124 
SB505124 is an ALK5 inhibitor, a potent selective inhibitor of TGF βRI kinase, was 
purchased from Tocris. SB505124 was used at 5μM in PRF cells.  
2.3 Plasmids 
pCAGA12-luc plasmid was acquired from Caroline Hill (The Francis Crick Institute, 
London). The FLAG-tagged SET9 wild-type (FLAG-SET9WT) and mutant (FLAG-
SET9H297A) plasmids were contributed by Dr Danny Reinberg (Howard Hughes Medical 
Institute, New York). SMAD3 C (1-211) and SMAD3 NL (199-425) plasmid vectors were 
purchased from Addgene.  
2.4 siRNA and DNA Plasmid Transfection 
2.4.1 siRNA Transfection 
Cells were transfected using Lipofectamine® RNAiMAX transfection reagent (Life 
Technologies) according to the manufacturer’s guidelines. siRNA sequences used are shown 
in  Table 2.1. Transfection mixtures were prepared by adding the required volume of siRNA 
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at a final concentration of 25-50nM and transfection reagent in a 1:3 volume ratio, 
respectively, to basal medium (without antibiotics). The transfection mixture was incubated at 
room temperature for 20 minutes then added directly to seeded cells (forward transfection) or 
to a dish or well with cells subsequently seeded on top of the transfection mix (reverse 
transfection). Transfections were incubated for 24-96 hours at 37ºC to obtain optimal gene 
knockdown. Efficient gene knockdown was then determined by Western Blotting.  
 
 
siRNA Target siRNA Sense Sequence 
Scrambled (non-targeting siRNA) UUCUCCGAACGUGUCACGU 
SET9 GTAATCCGTCATCGTCCAGGTGC 
SETDB1 Dharmacon M-020070-00 
Aurora Kinase A Sigma SIHK0140 
Aurora Kinase B Sigma SIHK0145 
 
Table 2.1 siRNA Sequences and their Gene Target 
2.4.2 Plasmid DNA transfection 
Mammalian expression plasmids were transfected using Lipofectamine LTX reagent (Life 
Technologies), by forward transfection. Transfection mixtures were prepared by adding 3μl of 
LTX reagent to every 1μg of plasmid in basal media (200 μl/well of 6-well plate, 0.5 
ml/90mm plate, 1 ml/150mm plate). The LTX reagent and plasmid mixture was incubated at 
room temperature for 20 minutes then added dropwise to 60-70% confluent cells in culture 
medium. Transfected cells were incubated for 48-72 hours before harvesting.  
2.4.3 Stable cell cloning  
HKC8 cells were used to create a stable cell line expressing pCAGA12-luc due to their ease 
of transfection and their intact TGF β-1 signalling pathway. The cells were transfected with 
1μg of pDR2 carrier plasmid containing Hygromycin B (Sigma Aldrich) selection marker and 
10μg of pCAGA12-luc plasmid using Lipofectamine transfection reagent (Life 
Technologies). 48 hours post-transfection, cells were cultured in FM containing hygromycin 
B selection at concentrations of 400μg/ml with subsequent media changes every 4-5 days. 
After two weeks, colonies arose from cells maintained in 400μg/ml selection. Colonies were 
selected and maintained in FM containing 300μg/ml hygromycin B. They were then tested for 
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luciferase induction in the presence of TGF β-1. A single clone with absent luciferase 
expression in the absence of TGF β-1, exhibiting a high luciferase count in the presence of 
exogenous TGF β-1 was selected for further experimentation. 
2.4.4 Methyltransferase siRNA Screen 
HK C-8 cells were stably transfected with the TGF β-1 responsive CAGA-luc reporter 
plasmid then reverse transfected with either control SCR siRNA or a library of 50 
methyltransferase siRNAs at a final concentration of 25 nM. The siRNA library contained 
three pooled specific siRNAs to each of the 50 methyltransferases selected to be investigated, 
contributed by Dr. Luke Gaughan (Northern Institute for Cancer Research, Newcastle). An 
untransfected control -/+ TGF β-1 was also included. Each pool of siRNA was performed in 
quadruplicate. The cells were treated with 1ng/ml TGF β-1 for 24 hours, a luciferase assay 
was subsequently performed, correcting for protein quantity using a BCA assay.  
2.5 Isolation of Primary Renal Fibroblast (PRF) Cells 
Human PRFs were isolated from human nephrectomy kidney specimens. Tissues were 
derived from human nephectomised kidney segments or sections from kidneys deemed 
unsuitable for transplantation (rejected due to donor reasons). Ethical approval was obtained 
from the National Research Ethics Committee, East Midland, UK for work on gene and 
protein expression in the kidney. 
An outgrowth method as described by (Tan and Hewitson, 2016) was used to isolate the PRFs 
from dissected cortical tissue which was plated directed onto a scratched cell culture dish. The 
tissue was then maintained in high glucose enriched media RMPI 1640 (Sigma Aldrich), 
supplemented with 10% (v/v) FBS and 1% (v/v) penicillin streptomycin (Sigma), for 14 days, 
with media changes every 3-4 days. Once cells started to grow out, the tissue was gently 
removed. The cells were trypsinised once they reached a monolayer of 75% confluency and 
transferred to culture flasks until confluent. To characterise cell morphology by scanning 
electron microscopy, cells were fixed in 2% glutaraldehyde for 2 hours and before addition of 
mounting medium and imaging of the cells to look for spindle-shaped cell morphology. The 
cells were also characterised by immunofluorescence to identify the expression of fibroblast 
markers alpha-smooth muscle actin (α-SMA), fibronectin and Collagen I, Collagen III and 
S100 and the absence of an epithelial cell markers, E-cadherin and K-cadherin. Once 
characterised, the cells were used to study their response in proliferation assays, siRNA 
knockdowns, wound healing and collagen contractility assays. Cell proliferation arrested after 
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passage 4 and the cells changed phenotype, consequently, isolated PRF cells were not used 
beyond passage 3. 
2.6 SDS-poly acrylamide gel electrophoresis (SDS-PAGE) and Western blotting (WB)  
2.6.1 SDS-PAGE 
Cell lysates were prepared by adding SDS sample buffer (125 mM Tris-HCl, pH 6.8, 5% 
SDS, 10% glycerol, 10% β-mercaptoethanol and 0.01% bromophenol blue) directly to cells 
washed with PBS. The cell lysates were then boiled for 10 minutes at 100ºC before being 
loaded on to a precast NuPAGE Novex® 4-12% Bis-Tris Protein Gel (Life Technologies). 
SeeBlue® Plus2 Pre-stained Protein Standard (Life Technologies) was loaded alongside the 
samples to determine the molecular weight of the proteins. Proteins were separated by XCell 
SureLock® Mini-Cell (ThermoFisher) filled with 1x MOPS running buffer (10 x buffer: 
52.3g MOPS, 30.3g Tris Base, 5g SDS, 1.5g EDTA made up to 500 ml ddH20) at a constant 
voltage of 160V.  
2.6.2 Western Blotting (WB) 
Following protein separation by gel electrophoresis, proteins were electrotransferred to PDVF 
membrane (Hybond, Amersham) using the XCell IITM Blot Module, with the inner chamber 
filled with 1x transfer buffer (10x buffer: 30.3g Tris base, 144g Glycine, made up to 1l 
ddH20) and the outer chamber filled with water, at a constant voltage of 30V for 90 minutes. 
For  molecular weight proteins >150 the Fisherbrand™ TV100-EBK Electroblotter was filled 
with transfer buffer and set at a constant voltage of 25V overnight at room temperature (RT).  
The blots were blocked in 1x Tris-Buffered Saline (TBS) (10x stock containing 87.6g NaCl, 
12.1g Tris, made up to 1l ddH2O pH8.0) containing 5% bovine serum albumin (BSA) (Sigma 
Aldrich) for 1h at RT. Primary antibodies were diluted between 1:500 to 1:2000 in 1 x TBS 
containing 1% BSA overnight at 4°C. Blots were washed for 3 x 5 minutes in 0.1% tween-
TBS with gentle rocking then incubated in secondary antibodies (rabbit anti-mouse,  mouse 
anti-rabbit, mouse anti-goat horseradish peroxidase-conjugated, Dako) diluted 1:1000 in 1x 
TBS containing 1% BSA for 1h at RT. After 2x 5 minute washes in 1x 0.1% Tween-TBS and 
1x 5 minute wash in 1x TBS with gentle rocking, the blots were developed with ECL reagents 
(Pierce) and were exposed on X-ray film (Agfa). Protein bands were then quantified using 
Image J.  
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Antibody Species Supplier Applications 
SMAD3 Rabbit Abcam IP, IF, WB, IHC, CHIP 
SMAD3  Mouse Sigma IP, IF, WB 
SMAD2/3 Rabbit Cell Signaling IF, WB 
SMAD2 S20 Goat Santa Cruz IF, WB 
P-SMAD2/3 Rabbit Cell Signaling IF, WB, IP 
P-SMAD32/3 ser423/425 Rabbit Santa Cruz WB, IP 
SET9  Mouse Millipore IP, IF, WB 
SET9 (S4E5) Mouse Santa Cruz  WB 
SET9 Rabbit Cell signaling IP, WB, CHIP 
FLAG M2 Mouse Sigma IP, IF, WB 
GAPDH Mouse Sigma WB 
GAPDH Rabbit Sigma WB 
PARP 1 Mouse Sigma WB 
HDAC1 Goat Sigma WB 
Collagen I Rabbit Abcam IF, WB, IHC 
Collagen I Mouse  Sigma IF, WB 
Collagen I Rabbit Novis IF, WB 
Collagen III Rabbit Abcam IF, WB, IHC 
α-SMA Rabbit Abcam IF, WB, IHC, CHIP 
α-SMA  Mouse Sigma IF, WB 
Fibronectin Rabbit Sigma IF, WB 
PAI-1 Rabbit Abcam IF, WB 
S100 Rabbit Abcam IF, WB 
Vimentin V9 Rabbit Abcam IF, WB 
E-cadherin Mouse Sigma IF, WB 
ESET G4 Mouse Santa Cruz IP, IF, WB 
ESET H300 Rabbit Santa Cruz IP, IF, WB 
ESET Mouse Abcam IP, IF, WB 
SMYD2 C20 Goat Santa Cruz IP, IF, WB 
MLL C20 Goat Santa Cruz IP, IF, WB 
Aurora Kinase A Rabbit Abcam IP, IF, WB 
Aurora Kinase B Rabbit Abcam IP, IF, WB 
P-Aurora Kinase A/B Rabbit Abcam WB, IHC 
α-Tubulin Mouse Sigma WB 
α-Actin Mouse Santa Cruz WB 
β-Actin Mouse Sigma WB 
IgG  Rabbit Abcam IP 
IgG  Mouse Sigma IP 
HA tag (agarose) Goat Abcam IF, WB 
HA tag (agarose) Mouse Abcam IF, WB 
GST Goat Abcam IP, WB 
SMAD7  Rabbit Thermo Fisher WB 
Histone H3 Rabbit Abcam WB 
P53 Rabbit Abcam WB 
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Table 2.2 Antibodies used for Western Blotting (WB), Immunoprecipitation (IP), Immunofluorescence 
(IF), Immunohistochemistry (IHC) and Chromatin Immunoprecipitation (ChIP). 
2.7 Bacterial Transformation, Plasmid DNA Isolation and Gel Electrophoresis 
2.7.1 Bacterial transformation of plasmid DNA 
Plasmid DNA was transformed using NEB® 5-alpha Competent E.coli chemically competent 
cells (New England Biolabs). Approximately 500ng of plasmid DNA was added to the 
competent cells, mixed by gently flicking and incubated on ice for 30 minutes before heat 
shock at 42ºC for 30 seconds. The cells were placed back on ice for 2 minutes before the 
addition of 500μl SOC outgrowth medium (2% Peptone, 0.5% Yeast Extract, 10mM NaCl, 
2.5mM KCl, 10mM MgCl2, 10mM MgSO4, 20mM Glucose) and incubation at 37ºC with 
agitation for 45 minutes. The cell culture was mixed by gently flicking of the tube then 200μl 
culture was spread on to pre-warmed LB agar plates (1% (w/v) tryptone, 1% (w/v) NaCl, 
0.5% (w/v) Yeast Extract, 1.5% (w/v) agar) containing the antibiotic selection 100 μg/ml 
ampicillin and incubated at 37°C overnight. 
2.7.2 Amplification of transformed DNA 
For DNA maxi prep culture, single colonies were picked from the LB plates and incubated in 
4ml LB medium (1% (w/v) NaCl, 1% (w/v) tryptone, 0.5% (w/v) yeast extract) containing the 
antibiotic selection 100ug/ml ampicillin with 200 rpm agitation at 37ºC. After 4 hours the 
culture was transferred to a conical flask containing 200ml LB medium with antibiotic 
selection and incubated overnight with 200rpm agitation at 37ºC.   
2.7.3 Plasmid DNA Extraction 
For maxiprep cultures the ChargeSwitch®-Pro Filter Plasmid Maxiprep Kit (Invitrogen) was 
used according to the manufacturer’s protocol. The kit involved resuspension of the bacterial 
pellets, cell lysis, filtration of cellular debris, precipitation, washing and elution of plasmid 
DNA. Resultant purified DNA was resuspended in 500μl Nuclease-free water (Severn 
Biotech) and DNA concentration measure using the Nanodrop spectrophotometer (Thermo 
Scientific).  
2.7.4 Agarose Gel Electrophoresis 
To ensure successful cloning, purified plasmid DNA were subjected to gel electrophoresis to 
determine DNA size. Plasmid DNA (500ng) was mixed with 4μl 5x DNA loading buffer 
(Bioline). Samples were loaded into a 1% Agarose/TAE buffer (40mM Tris, 20mM acetic 
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acid, 1mM EDTA) gel and run at 100V using Mini-Sub Cell GT Cell system (Bio-Rad) until 
satisfactory separation was achieved. 1kb ladder (Promega) was loaded alongside the samples 
as a molecular weight marker. DNA size was visualised on a GBOX Chemi gel doc system 
(Syngene).  
2.8 Protein Purification  
GST resin columns were used for GST-tagged protein purification (GE Healthcare). Bacterial 
cell pellets expressing recombinant proteins were resuspended in 600μl of lysis buffer (PBS 
containing 1% Triton-X-100) on ice, sonicated and cleared by centrifugation at 1000 x g. 
Clarified lysates were then transferred to GST spin columns and incubated on ice for 5 
minutes. Columns were centrifuged at 1000 x g for 30s and flow-through discarded. 600μl 
chilled PBS was added to the column and centrifuged again at 1000 x g for 30 seconds, this 
wash step was repeated. The column was then placed into a fresh tube and 120μl chilled 
elution buffer (20mM L-glutathione (reduced) in 50mM Tris pH8.0) added to the column and 
centrifuged at 1000 x g for 30s. The flow-through contained the purified protein. 
2.9 Nuclear and Cytoplasmic Extractions 
Nuclear and cytoplasmic fractions were isolated using sequential centrifugation steps, in 
Hypotonic Buffer Solution (20mM Tris-HCl pH7.4, 10mM NaCl and 3mM MgCl2) and Cell 
Extraction Buffer (100mM Tris pH7.4, 2mM NaVO4, 100mM NaCl, 1% Triton-X-100, 1mM 
EDTA, 10% glycerol, 1mM EGTA, 0.1% SDS, 1mM NaF, 0.5% deoxycholate and 20mM 
Na4P2O7, 1mM PMSF, Protease Inhibitor). Cells seeded onto 100mm culture dishes were 
gently washed with PBS then scraped and centrifuged at 3000 x g at 4ºC to collect the cell 
pellet. The supernatant was discarded and the cell pellet resuspended in 500μl hypotonic 
buffer and incubated on ice for 15 minutes. 25μl of 10% IGEPAL (Sigma Aldrich) was added 
to each sample and vortexed for 10 seconds. The samples were centrifuged at 3000 x g for 10 
minutes at 4ºC. The supernatant contained the cytoplasmic fraction. The nuclear pellet was 
then resuspended in 50μl Cell Extraction Buffer and incubated on ice for 30 minutes, 
vortexing at 10 minute intervals. The sample was then centrifuged at 10 000 x g for 30 
minutes at 4ºC. The supernatant contained the nuclear fraction. SDS sample buffer was added 
to both fractions and subjected to Western blotting analysis.  
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2.10 Immunoprecipitation: Cell Lysates, Purified Proteins and Nuclear Cell Fractions 
2.10.1 Immunoprecipitation from Cell Lysates 
To analyse protein-protein interactions, immunoprecipitations (IP) were carried using cell 
lysates. 1ml IP lysis buffer (50mM Tris pH7.4, 150mM NaCl, 1mM EDTA, 1% Triton-X-
100, 1x protease inhibitor tablet (Roche), phosphatase inhibitor (100μl in 10ml Sigma)) was 
added directly to cells grown on 100mm culture dishes and incubated on ice for 5 minutes. 
Cells were then scraped, transferred into Eppendorf tubes and sonicated. Cells were 
centrifuged at 4ºC for 25 minutes at 20,000 x g to remove insoluble cell debris. 50μl was 
taken from each sample as an input sample. 20μl (per sample) of protein G dynabeads (Life 
Technologies) were washed in PBS and incubated with 1μg of primary antibody overnight at 
4ºC with rotation. An isotype immunogloblin antibody was included to serve as a negative 
control. The following day, the samples were washed 3 times with 1ml FLAG wash buffer 
(50mM Tris pH7.4, 150mM NaCl, 1mM EDTA, 1% Triton-X-100, 1x protease inhibitor 
tablet (Roche) and phosphatase inhibitor (Sigma Aldrich)). After the final wash, samples were 
centrifuged to remove any excess wash buffer and re-suspended in 50ul SDS-sample buffer 
(10ml 3x stock: 2.4ml 1M Tris pH 6.8, 3ml 20% SDS, 3ml glycerol, 1.6ml β-merceptoethanol 
and few grains of bromophenol blue) and subjected to SDS-PAGE and Western blotting 
analysis. 
2.10.2 Immunoprecipitation with Nuclear Cell fractions 
Immunoprecipitations were also carried out on nuclear cell fractions, in which case nuclear 
fractions were extracted from cells (section 2.9) before being incubated with protein G 
dynabeads.  
2.10.3 Immunoprecipitation with Purified Proteins  
Recombinant human SET9 (Millipore) and either purified GST-SMAD3 C or GST-SMAD3 
NL were mixed together and incubated on ice for 30mins before 500μl PBS containing 
protease inhibitors (Sigma) was added. Protein G sepharose beads (Life Technologies) were 
washed in PBS and blocked with 1ml 0.2% BSA in PBS for 1 hour on rotation. 25μl of 
blocked sepharose beads were added to 1ug SET9 primary antibody and 1ug control IgG 
antibody (Sigma). Samples of recombinant SET9 and GST-SMAD3 C and SET9 and GST-
SMAD3 NL were then added to tubes of SET9 coupled sepharose beads and IgG control-
coupled sepharose beads and incubated on rotation at 4°C overnight. After 3-5 washes in PBS 
buffer B (10ml containing 100mM Tris pH8.0, 500mM NaCl, 0.5% Tween 20, and 1x 
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protease inhibitor tablet) and elution in 50μl SDS sample buffer, samples were subjected to 
SDS-PAGE and Western blotting analysis.  
2.11 Proliferation Assay 
Approximately 5000 cells/well were seeded into a 96-well plate, starved in BM and treated as 
required. 5μl WST-1 reagent (Roche) was then added directly to the medium in each well and 
incubated at 37ºC for 30 minutes. The plate was then read at 450nm on MultiskanTM FC 
Microplate Reader (Thermo Scientific).  
2.12 Protein Half-Life Assay 
10 000 cells/well were seeded onto a 96-well plate and left overnight to adhere. The following 
day cells were treated with 5ng/ml TGF β-1 for 24 hours. Subsequently, medium was 
replenished with fresh FM containing 5ng/ml TGF β-1 and 60μg/ml cycloheximide (CXH) 
was added to wells for set time-points 0-6 hours. At each time-point, the medium was 
removed and cells gently washed with PBS. SDS-sample buffer was added to the wells and 
the cells subjected to Western blotting analysis. 
2.13 Ubiquitylation  
To examine ubiquitylation, cells were transfected overnight with the indicated plasmids, then 
treated with 10ng/ml TGF β-1 and a low-dose 1μM MG-132 then subjected to Ni-NTA 
chromatography. For immunoprecipitation of ubiquitylated proteins, 50 μl equilibrated 
nickel–agarose (Ni-NTA Qiagen) was added to each sample and incubated at 4°C for 8 h, 
followed by subsequent washes of the pelleted agarose in wash solutions 1 (8M urea, 0.1M 
Na2HPO4/NaH2PO4, 0.01M Tris–HCl, pH8, 10mM β-mercaptoethanol) and 2 (8M urea, 0.1M 
Na2HPO4/NaH2PO4, 0.01M Tris–HCl, pH 6.3, 10mM β-,ercaptoethanol and 0.1% Triton-X-
100). The proteins were then eluted from the agarose using 70 ul elution buffer (200 mM 
imidazole, 0.15M Tris–HCl, pH6.7, 30% glycerol, 0.72M β-mercaptoethanol and 5% SDS). 
The samples were mixed with SDS sample buffer then subject to Western blotting analysis 
probing with an anti-SMAD3 antibody. 
2.14 Immunofluorescence  
Cells were seeded on 8-chamber tissue culture slides (Falcon). After treatment with TGF β-1 
and/or SET9 inhibitor R-PFI, the cells in each chamber of the culture slide were washed with 
200μl PBS (Sigma), fixed with 200μl ice-cold 100% methanol and blocked in 200μl PBS 
containing 5% goat serum (Sigma) for 1 hour at room temperature. Primary antibodies were 
37 
 
applied at a dilution of 1:100 in PBS overnight at 4ºC. Secondary Alexa Fluor antibodies were 
then applied at 1:200 in PBS for 2 hours in the dark at RT. Lastly, DAPI nuclear stain (Sigma) 
was applied at 0.5μg/ml in PBS for 10 minutes in the dark at room temperature. The chambers 
were washed 3 times in PBS, chamber wells removed and a coverslip mounted with 
Fluorescent mounting medium (Dako). Control slides were treated with secondary only 
antibodies. The slides were imaged using a Zeiss Axioimager microscope and analysis 
completed with Image J software to determine fluorescence intensity.  
2.15 Luciferase Reporter Assay 
2.15.1 Cell Transfection 
pCAGA12-luc reporter stably-transfected HKC8 cells were seeded in 48-well plates, reverse 
transfected with either control or a library of pooled methyltransferase siRNAs, acquired from 
Dr. Luke Gaughan (Northern Institute of Cancer Research, Newcastle University) at a final 
concentration of 25nM. After 24 hours, cells were treated with 1ng/ml TGF β-1. Each siRNA 
was transfected in quadruplicate. After 24h, cells were washed in PBS and harvested in 55μl 
per well 1x Reporter Lysis Buffer (Promega) and one freeze-thaw cycle (-80ºC for 10 minutes 
then 37ºC for 10 minutes) was performed. 
2.15.2 Luciferase Assay 
Cells were scraped into microcentrifuge tubes and 30μl of each sample transferred into a 96-
well white opaque microplate (Greiner Bio-one). 50μl of luciferase Assay Reagent (Promega) 
was then added to the samples in each well of the plate. The plate was inserted into a 
FilterMax plate-reader (Molecular Devices), shaken for 30 seconds and luminescence 
measured.  
2.15.3 BCA Assay 
A bicinchoninic acid assay (BCA) assay (Thermo Scientific) was performed on the remaining 
25μl of each sample following the manufacturer’s protocol, to correct for protein quantity. 
25μl of each sample was transferred to a clear 96-well culture microplate (Greiner Bio-one), 
alongside a standard prepared from 0-2000μg/ml BSA. 200μl of working reagent (WR) – 1:50 
Reagent A (sodium carbonate, sodium bicarbonate, bicinchroninic acid and sodium tartrate in 
0.1M sodium hydroxide) and Reagent B (4% cupric sulfate), respectively, was added to each 
sample and standard and incubated for 30 minutes at 37ºC and absorbance measured by a 
FilterMax plate-reader (Molecular Devices) at 450nm.  
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The luciferase readouts were corrected for BCA readouts and the data represented by bar 
graphs of the fold change in luciferase activity with error bars of standard deviation. 
2.16 Wound Healing Assay  
Cells were seeded into a 2-well silicone cell culture insert (Ibidi) to create reproducible 
500μm cell-free wounds in 12-well plates. The following day the cells were treated with or 
without 10ng/ml TGF β-1 and in subsequent experiments with or without SET9 inhibitor 
(Tocris) 5-30μM or transfected with SCR or SETDB1 siRNA. 24h after treatment, the inserts 
were carefully removed and the cells imaged at 4h intervals over 0-48h using a Zeiss 
Axiomager II microscope. Wound closure was measured by % cell surface coverage using 
NIS-Elements and Image J microscope imaging software. 
2.17 Collagen Contractility Assay  
Adapted from (Grinnell et al., 1999), 10ml of collagen gel solution was prepared (2ml 5X 
DMEM, 0.81ml rat tail Collagen I, 37μl NaOH and 7.15ml ddH2O). 6x105 cells treated with 
or without SET9 inhibitor for 24 hours were pelleted then re-suspended in the 5ml Collagen 
gel solution and aliquoted into a 24-well plate. Collagen gels were left to set for 30 minutes at 
37°C before the addition of FM with or without 10ng/ml TGF β-1 to the top of the gel 
matrices. A stress period of 24 hours was allowed for the cells to develop α-SMA stress 
fibers, after which the Collagen matrices were released with a needle to detach the matrices 
from the sides of the wells. The diameter of the Collagen matrices were measured 24-48 hours 
after release. In subsequent experiments the cells were transfected with siRNAs before being 
pelleted.  
2.18 Chromatin Immunoprecipitation (ChIP)  
Chromatin from PRFs was prepared, after cross-linking cells in 1% formaldehyde for 10min 
at room temperature, using ChromaFlash High-Sensitivity ChIP Kit (Epigentek). 20µg of 
chromatin was used, with 1µg of respective antibody. Oligonucleotide sequences 
TTTCAGCTTCCCTGAACACC and CGGGTAATTAAAAGAGCCACTG were used to 
amplify the human sequence corresponding to the Rat SBE2 SMAD binding element, 
identified by sequence alignment 55, with 19 cycles of PCR. GAPDH oligonucleotides were 
used as recommended. 
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2.19 In Vitro kinase reactions 
Recombinant SMAD3 (Sino 50991-M20B) and recombinant AURKA (Abcam ab42595) 
were incubated at 30°C in kinase buffer containing 50mM Hepes pH 7.4, 3mM MgCl2, 3mM 
MnCl2, 1mM DTT, 3μM Na orthovanadate and 0.5mM ATP. One unit of calf intestinal 
phosphatase (CIP) (Promega) was added where shown. Reactions were stopped by the 
addition of Laemmli buffer prior to either NuPAGE 4-12 % gradient gel electrophoresis 
(Thermofisher) in MOPS buffer (Thermofisher) to resolve band shifted proteins, or standard 
discontinuous NuPAGE 10 % polyacrylamide gel electrophoresis (Thermofisher) in MOPS 
buffer, followed by immunoblotting. 
2.20 Flow Cytometry 
To measure apoptosis, FITC annexin V staining was used as per manufacturer’s instructions 
(BD, 556547), on cells exposed to 10μM drug compounds or 1μM Staurosporine for the 
indicated times. For cell cycle analysis cells were treated overnight with 1μM drug 
compounds then fixed in 70% ethanol for 30 minutes prior to washing twice in PBS, 
treatment with 5μg/ml RNase then staining with 1μg/ml propidium iodide before analysis of 
cells gated to remove sub-G1 populations. 
2.21 Unilateral Ureteral Obstruction (UUO) Model of Renal Fibrosis 
UUO surgery was performed on 14 female mice under isoflurane general anaesthesia in 
accordance with aseptic protocols approved by Comparative Biology Centre (CBC) and 
Animal Scientific guidelines implemented by the Home Office. The lower abdominal area 
was shaved and a subcutaneous injection of buprenorphine diluted in injectable saline was 
given as pain relief. A laparotomy was performed, cutting through the skin and muscle via the 
linea alba. A retractor was used to allow access to the internal viscera. The intestines were 
moved up and out of the abdominal incision and rested on gauze soaked in sterile saline. The 
intestines were then covered with more gauze and soaked in saline to prevent them drying out. 
The left ureter was then isolated and double ligated using non-degradable 5/0 mersilk suture. 
The ureter was then cut between the two sutures. The intestines were then replaced and the 
muscle layer sutured using normal interrupted sutures of round bodied 5/0 vicryl. The skin 
was sown shut using inverted interrupted sutures of cutting 5/0 vicryl in order to bury the knot 
to prevent the mice scratching them. The incision site was finally glued shut. Mice were then 
allowed to develop fibrosis. The contralateral, uninjured kidney served as an intraindividual 
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control. Animals were culled at days 10-post surgery. A minimum of 7 mice were used in 
each group. UUO surgery was performed by Dr Ana Moles. 
2.22 Immunohistochemistry 
2.22.1 Immunohistochemistry: α-SMA, Phospho-SMAD3, Phospho-Aurora A, Collagen I 
and III 
Immunohistochemistry (IHC) as performed on 5μm paraffin-embedded tissue sections that 
were cut by Newcastle Molecular Pathology Node Proximity Lab, Cellular Pathology, 
Newcastle upon Tyne Hospitals NHS Foundation Trust. Slides of tissue were placed into a 
glass rack and placed in glass jars of xylene (Cell Path), xylene, 100% ethanol (Fisher 
Chemicals), 70% ethanol, respectively, for 5 minutes each to de-wax and hydrate the sections. 
The sections were then quenched in 2% hydrogen peroxide (Sigma Aldrich) for 15 minutes to 
block endogenous peroxidase activity. The slides were washed in PBS before performing 
antigen retrieval, following the primary antibody manufacturer’s recommendation. Antigen 
retrieval for α-SMA, phospho-SMAD3, phospho-aurora A was heat-mediated using 40mM 
sodium citrate buffer boiled for 1 minute in a pressure cooker. Antigen retrieval for Collagen I 
and Collagen III was enzymatic using Collagenase (Sigma Aldrich) 8mg/ml in TBS preheated 
to 37ºC and incubated on slides for 1 hour at 37ºC. The slides were then blocked with ready-
to-use (2.5%) normal horse blocking serum (ImmPRESS HRP Reagent Kit, Vector 
Laboratories) for 30 minutes at RT. Primary antibodies were applied overnight at 4ºC at 
dilutions of 1:100-1:500. The following day, the slides were washed in PBS for 5 minutes 
before the application of secondary ImPRESSTM Reagent for 30 minutes at room temperature. 
The slides were washed again in PBS then incubated with DAB substrate solution (Buffer 
Stock solution, DAB stock solution, Hydrogen Peroxide solution, Vector Laboratories) for 1-
2 minutes until the tissue just started to turn brown, then washed immediately with PBS for 5 
minutes. The slides were then counterstained with haematoxylin (Weigert’s Haematoxylin 
Solution Set, Sigma Aldrich) for 4 minutes and rinsed with water for 5 minutes to wash off 
excess stain. Finally, the sections underwent dehydration in 50% ethanol, 70% ethanol, 100% 
ethanol, 100% ethanol, xylene, xylene, respectively, for 5 minutes each then coverslips were 
mounted over the stained tissue using DPX mounting medium (Sigma Aldrich) and left to dry 
for 30 minutes.  
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2.22.2 Picro-Sirius Red 
For Picro-Sirius red staining, slides were de-waxed and hydrated as described above then 
stained with haematoxylin for 8 minutes and washed in running tap water for 5 minutes. The 
slides were stained in Picro-Sirius Red for 1 hour (0.5g Sirius Red in 500ml (1.3% in water) 
saturated aqueous solution of picric acid, both from Sigma Aldrich). The slides then 
underwent 2 rapid (0.5 seconds) washes in acidified water (5ml glacial acetic acid (Sigma 
Aldrich) in 1lml distilled water) followed by dehydration in three rapid changes of ethanol 
70%, 100%, 100%, respectively. The slides were finally cleared in xylene and mounted in 
DPX/pertex and left to dry for 30 minutes.  
2.22.3 Masson’s Trichrome 
Masson’s Trichrome staining was performed by Newcastle Molecular Pathology Node 
Proximity Lab, Cellular Pathology, Newcastle upon Tyne Hospitals NHS Foundation Trust.  
Masson’s Trichrome staining is used for the detection of collagen fibres in tissues. The 
collagen fibres are stained blue, the nuclei are stained black and the cytoplasm and muscle 
fibres are stained red. The slides were deparaffinised and rehydrated using 100% ethanol, 
95% ethanol then 70% ethanol, respectively, then washed in distilled water. The slides were 
then placed in Weigert's iron hematoxylin working solution for 10 minutes to stain the nuclei 
then rinsed in running warm tap-water for 10 minutes to remove excess stain. The slides were 
then stained in Biebrich scarlet-acid fuchsin solution for 10-15 minutes, washed in distilled 
water then stained in phosphomolybdic-phosphotungstic acid solution for 10-15 minutes. 
Without rinsing, the slides were transferred to aniline blue solution and stained for 5-10 
minutes, rinsed in distilled water and differentiated in 1% acetic acid solution for 2-5 minutes.  
The slides were washed in distilled water and dehydrated very quickly through 95% ethanol, 
100% ethanol (to remove Biebrich scarlet-acid fuchsin staining) and then cleared in xylene. 
Lastly, the slides were mounted with resinous mounting medium (Vector Laboratories). 
2.22.4 Imaging and analysis  
Tissues were imaged on a Nikon Eclipse Upright Microscope at x20 and x40 magnifications. 
A threshold was set to determine positive staining. 10-15 images per slide were taken and 
scored for % positive staining. Outliers were removed and median % positive staining was 
plotted per slide with error bars of standard deviation.  
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2.22.5 Acute CCl4 Liver Injury Model 
6 mice were used per group. Mice received carbon tetrachloride at a dose of 2.0ml/kg of body 
weight (1:1 v/v in olive oil), as a single intraperitoneal injection. Control mice received a 
single intraperitoneal injection of olive oil at a dose of 2.0ml/kg of body weight. Mice were 
harvested 48 hours post-injection. 
2.22.6 α-SMA Immunohistochemistry  
IHC was performed on paraffin-embedded tissue sections of mouse liver. The sections were 
deparaffinised and hydrated in xylene and graded ethanol washes then endogenous peroxidase 
activity was blocked with 0.6% hydrogen peroxide solution for 10 minutes. Antigen retrieval 
was achieved using unmasking solution at 1:1000 dilution (F3777 Sigma Aldrich). 
Avidin/Biotin Blocking Kit (Vector Laboratories) was used for 20 minutes to block 
endogenous avidin and biotin. Non-specific binding was blocked using 20% swine serum for 
30 minutes followed by α-SMA primary antibody applied at 1:100 overnight at 4°C. The 
following day, the slides were washed with PBS and incubated with biotinylated goat anti-
fluorescein at 1:300 (BA-0601 Vector Laboratories) for 30 minutes at room temperature. The 
slides were then washed with PBS followed by a 30 minute incubation with Vectastain Elite 
ABC Reagent (Vector Laboratories). DAB peroxide substrate kit (Vector Laboratories) was 
used to visualise the staining, counterstaining with Mayer’s haematoxylin (Sigma Aldrich) 
and then the slides were mounted. Stained slides were analysed at 10x magnification using a 
Nikon Eclipse Upright microscope and NIS-Elements BR analysis software. Ten random 
fields were analysed per mouse liver tissue section. 
2.23 Isolation of Stellate Cells  
2.23.1 Obtaining the Liver from the Mouse  
To harvest the liver from the mouse, the abdomen was cut open, the intestines were moved to 
the right hand side to expose the portal vein. The portal vein was then injected with Hanks 
Balanced Salt Solution + (HBSS+, Gibco) to blanche the liver. The vena cava was then cut 
and the liver removed and placed into a specimen tube with HBSS +.  
2.23.2 Processing the Liver to Isolate Hepatic Stellate Cells (HSC) 
Pronase 1 and Collagenase were added to the specimen tubes of 8 livers, the livers were cut 
into small pieces to aid digestion and placed into an incubated specimen shaker at 37°C at 180 
rpm for 15-25 minutes. The liver mixture was then pushed through fine mesh into a beaker 
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containing DNase (Sigma Aldrich) in HBSS + and centrifuged for 7 minutes at 1800 x g. The 
supernatant was carefully removed and the cells resuspended in DNase and HBSS +. The 
resuspended cell mixture was then carefully added to a new falcon tube containing Optiprep 
(Sigma Aldrich) to create 2 layers then HBSS + was added on top, creating a tri-layered 
solution. The layered solution was centrifuged at 1500 x g for 23 minutes. After 
centrifugation, there should be a visible layer of stellate cells present just below the top layer 
of solution. The stellate cells were removed and added to a new falcon tube of DNase and 
HBSS + and centrifuged at 1800 x g for 7 minutes. The supernatant was removed and the 
resultant cell pellet was stellate cells which were then placed in culture flasks containing 
DMEM (Sigma Aldrich) supplemented with 10% FBS and 1% penicillin streptomycin. 
2.24 Statistical Analyses  
T-test and ANOVA were performed using Statistical Software Prism 7.0 (Graph Pad). No 
normalisation test was performed due to the limited number of samples in each experiment. 
Unpaired t-test was performed to compare the means of two unmatched groups. One-way 
ANOVA was performed to determine statistically significant differences between means of 
more than two groups affected by one factor. Data are represented as the mean +/- standard 
deviation (SD). p Value <0.05 was considered statistically significant, the following 
classifications were used to represent significance: * = p <0.05; ** = p<0.01; *** = p<0.001.  
Z-score, a screening window coefficient was performed to identify hits from the 
methyltransferase high-throughput siRNA screen (Zhang et al., 1999). Hits from the screens 
were identified as having a Z-score of above 3 or below -3.  
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Chapter 3. SMAD3:SET9 Interaction in the TGF β-1 Signalling Pathway 
 
3.1 Introduction and Objectives 
SET9 belongs to the evolutionarily conserved suppressor of variegation (Su(var)), enhancer of 
zeste (E(z)) and Trithorax (Trz); SET-domain family of lysine methyltransferases that are 
known to be involved in transcriptional regulation. SET9 is known to monomethylate lysine 4 
of histone 3 (H3K4) to activate gene transcription (Wang et al., 2001).   
SET9 has also been shown to methylate several transcription factors including p53, estrogen 
receptor (ER), androgen receptor (AR) and Transcription initiation factor TFIID subunit 10 
(TAF10) (Kouskouti et al., 2004; Subramanian et al., 2008; Gaughan et al., 2011; Lehnertz et 
al., 2011) as well as non-transcriptional proteins, such as p300/CBP-associated factor (PCAF) 
(Oudhoff et al., 2016), (Masatsugu and Yamamoto, 2009) which demonstrates alternative, 
non-transcriptional roles for SET9.  
With reference to fibrosis, it has been demonstrated that histone H3 monomethylation on 
lysine 9 is involved in the regulation of ECM gene expression and that silencing SET9 
attenuates TGF β-1 mediated ECM gene expression (Sun et al., 2010). Furthermore, RNAi-
mediated SET9 knockdown significantly attenuated renal fibrosis in UUO mice (Sasaki et al., 
2016). In pulmonary fibrosis, studies show that SET9 is involved in the regulation of the TGF 
β-1 signalling pathway and subsequent ECM production through lysine methylation of an 
inhibitory downstream effector SMAD7. SET9 methylation of SMAD7 targets this inhibitory 
SMAD for ubiquitin-dependent degradation. Silencing or inhibiting SET9 therefore causes an 
increase in SMAD7 levels, resulting in reduced TGF β-1-mediated ECM protein expression 
(Elkouris et al., 2016).  
Together, these studies demonstrate an important role of SET9 in ECM production but the 
potential role of SET9 in key processes leading to myofibroblast differentiation, migration 
and contractility has yet to be explored. Additionally, the role of SET9 in the regulation of 
other SMADs has yet to be determined.  
SMAD3 activation and translocation into the nucleus is a process that could be manipulated to 
reduce TGF β-1 signalling and therefore renal fibrosis. Identification of factors involved in 
SMAD3 nuclear import could be crucial in identifying novel therapeutic targets to down-
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regulate TGF β-1 signalling in renal fibrosis and other diseases in which TGF β-1 is 
implicated.  
Interestingly, a lysine-rich KKLKK (K denotes lysine) nuclear import signal between residues 
40-44 has been identified in human SMAD3 (Xiao et al., 2000). Mutation of lysine residues 
40 and 41 or 43 and 44 eradicates TGF β-1-induced SMAD3 nuclear import. Although, 
KKLKK motif alone does not function as a classical nuclear localization sequence (NLS) as 
fusion to a heterologous protein is not sufficient to allow nuclear import (Yao et al., 2008). 
Interestingly, this suggests that although KKLKK is required for SMAD3 nuclear import, 
there are additional unidentified factors that interact with this motif to facilitate SMAD3 
nuclear import. 
Similarity between the KKLKK nuclear import motif of SMAD3 and the lysine-rich 
sequences targeted by the lysine methyltransferase, SET9 in other SET9 substrates suggests a 
potential role for SET9 in the regulation of SMAD3 nuclear import via this KKLKK motif. 
Should this be true, SET9 would be an attractive, novel target in renal fibrosis. Figure 3.1 
highlights SET9 methylation targets including possible methylation targets of SMAD3. 
 
 
Figure 3.1. Methylation Targets for SET9. Sequence alignment of published methylation targets for SET9 and 
putative SMAD3 methylation sites (below). Conserved basic residues are highlighted including lysine (K) and 
arginine (R).  
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Here I present a novel interaction between SET9 and SMAD3, the most important 
downstream mediator of TGF β-1 signalling. SET9 regulates SMAD3 transcriptional activity 
and influences the subsequent expression of TGF β-1-regulated fibrotic genes such as α-SMA, 
Collagen I and Collagen III in renal cell lines and human PRFs, isolated as part of this project. 
I go on to suggest that pharmacological inhibition of SET9 would be an attractive therapeutic 
target in the treatment of renal fibrosis and CKD.  
3.2 Results 
3.2.1 SMAD3 Interacts with SET9 
SET9 has previously been shown to interact with proteins by recognising ‘KKLKK’ motifs 
within partner proteins. Analysis of SMAD3 protein identifies a ‘KKLKK’ motif at amino 
acids 41-44, therefore the ability for SET9 to regulate the TGF β-1 signalling pathway 
through interacting with SMAD3 was examined. 
Immunoprecipitation of endogenous SET9 from HK C-8 whole cell lysates resulted in co-
immunoprecipitation of SMAD3, whereas immunoprecipitation with control 
immunoglobulins did not recover SMAD3. Upon treatment with exogenous TGF β-1, an 
enrichment of the SET9-SMAD3 interaction was observed (Figure 3.2A).  
A reciprocal experiment was performed in which immunoprecipitation of endogenous 
SMAD3 from HK C-8 whole cell lysates resulted in co-immunoprecipitation of SET9 (Figure 
3.2A). In order to test the strength of the SMAD3-SET9 interaction, this immunoprecipitation 
was also performed after adjustment of cell lysates by the addition of sodium chloride. Co-
immunoprecipitation of SMAD3-SET9 was still observed in 600mM sodium chloride, 
demonstrating a strong interaction between SET9 and SMAD3. The inclusion of control 
immunoglobulins and lack of GAPDH immunoprecipitation demonstrate specificity in the 
SMAD3-SET9 interaction (Figure 3.2B). 
Finally, to exclude antisera cross-reactivity, a third immunoprecipitation was performed. 
FLAG-tagged SET9 was overexpressed by transient transfection into HK C-8 cells and 
immunoprecipitated via the FLAG epitope. Co–immunoprecipitation of endogenous SMAD3 
was observed, again with enrichment upon TGF β-1 treatment (Figure 3.2C). There was no 
detectable SMAD3 in immunoprecipitation from control cells transfected with an empty 
vector. Overall, the data suggested that SET9 interacts with SMAD3 and this interaction is 
enhanced in response to TGF β-1. 
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3.2.2 SMAD3 Interacts with SET9 Through its NL Domain 
The SMAD3 protein contains two globular domains; one at either terminus. The SMAD3 C 
terminus contains the MH2 domain, responsible for protein-protein interactions with co-
SMADs such as SMAD2 and SMAD4. The N terminus contains the DNA binding domain 
(DBD) and the cryptic nuclear localisation signal (NLS) (Xiao et al., 2000). In order to 
identify the region of SMAD3 that interacts with SET9, vectors encoding GST-tagged 
SMAD3 residues 1-211 (NL domain) or residues 199-425 (C-terminal domain) were used to 
generate truncated, recombinant SMAD3 proteins from BL21 E.coli bacterial cells (Figure 
3.2D). These proteins were purified over GST-sepharose columns, as described in Materials 
and Methods section 2.8 and individually tested for interaction with commercially sourced 
recombinant human SET9 protein, by immunoprecipitation. Following immunoprecipitation 
with SET9 antibody, Western blotting demonstrated that only the SMAD3 NL fragment 
protein was co-immunoprecipitated with SET9. The IgG control immunoglobulins showed 
only minor recovery of the SMAD3 NL protein, most likely due to low level, non-specific 
binding but not sufficient to account for the levels of SMAD3 NL co-immunoprecipitated by 
SET9 antibody (Figure 3.2E). These data suggest that SET9 interacts with N-terminus of 
SMAD3, but not the C-terminus of SMAD3.  
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Figure 3.2. SET9 Interacts with SMAD3. (A) HK C-8 cells were cultured for 24 hours in basal medium (BM) 
or full medium (FM) then treated with DMSO vehicle (-) or 5ng/ml TGF β-1 (+) overnight. 
Immunoprecipitations (IPs) with either SET9 or control antibody (Ctrl IgG) were followed by immunoblotting as 
indicated. Representative experiments of 3 are shown. (B) HK C-8 cells treated as in (A) were used for 
immunoprecipitation with either SMAD3 or isotype control antisera (Ctrl IgG) as indicated. Cell lysates were 
adjusted by addition of sodium chloride (NaCl) in the case of 300mM and 600mM NaCl, prior to 
immunoprecipitation and immunoblotting as shown. IP washes contained the same NaCl concentration as that of 
the adjusted lysates. Representative experiment of 3 is shown. (C) HK C-8 cells were transfected with FLAG-
SET9 or empty control vector overnight, starved for 24 hours in BM prior to treatment with DMSO vehicle or 
5ng/ml TGF β-1 overnight. Immunoprecipitation was then performed using FLAG antibody prior to 
immunoblotting as indicated. (D) Vector maps of GST tagged SMAD3 residues used to generate SMAD3 
A 
B 
B 
C 
C 
D 
Full length SMAD3 
SMAD3 N terminus 
SMAD3 C terminus 
1 211 
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recombinant proteins. (E) Purified recombinant full-length SET9 and SMAD3 C terminus or NL terminus 
proteins were mixed in PBS prior to immunoprecipitation with a SMAD3 antibody, then immunoblotting as 
shown. 
 
3.2.3 SET9 Regulates SMAD3 Nuclear Import and Protein Turnover 
To further delineate the role of SET9 in the TGF β-1/SMAD3 signalling pathway, the effect 
of SET9 on known key regulatory steps in the pathway was examined, including SMAD3 
nuclear import and proteasomal turnover.  
Firstly, to examine SMAD3 nuclear translocation, immunofluorescence was performed in HK 
C-8 cells transfected with SET9 siRNA or a control SCR siRNA. Upon SET9 knockdown, a 
marked redistribution of SMAD3 to the cytoplasm was observed, compared to cells 
transfected with control SCR siRNA that exhibited primarily nuclear staining (Figure 3.3A).  
To support the immunofluorescence data, subcellular fractionation was performed in the 
presence of SET9 siRNA or a control SCR siRNA in HK C-8 cells. Upon transfection of the 
control SCR siRNA, SMAD3 was progressively translocated from the cytoplasm to the 
nucleus with increasing concentrations of exogenous TGF β-1. At 5ng/ml TGF β-1 SMAD3 
was almost undetectable in the cytoplasmic fraction. However, transfection of SET9 siRNA 
resulted in two effects; firstly, the overall levels of SMAD3 protein were reduced compared to 
control transfectants. Secondly, SET9 knockdown resulted in a redistribution of SMAD3 
between the nuclear and cytoplasmic compartments; SMAD3 exhibited persistent cytoplasmic 
presence despite the treatment of exogenous TGF β-1. Overall, the data suggest that SET9 is 
required for TGF β-1-driven SMAD3 nuclear translocation in addition to the ability for SET9 
to modulate SMAD3 protein levels (Figure 3.3B).  
Given that SET9 silencing resulted in a reduction in SMAD3 levels, this was examined 
further by studying the half-life of SMAD3. Cycloheximide (CXH) was applied to HK C-8 
cells to block de novo protein synthesis, then SMAD3 levels were examined by Western 
blotting, in the presence of exogenous TGF β-1 (Figure 3.3C). Densitometric analysis (not 
shown) demonstrated that the half-life of SMAD3 was approximately 118 minutes in cells 
transfected with a control siRNA (Figure 3.3). However, transfection of SET9 siRNA 
produced not only a lower steady-state level of SMAD3 but also an increase in SMAD3 
turnover, reducing SMAD3 half-life to approximately 48 minutes (Figure 3.3D).  
The half-life of SMAD3 was also examined in SET9 +/+ and SET9 -/- MEF cells to exclude 
any confounding effects of siRNA transfection. Western blotting showed similar steady state 
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levels of SMAD3 in both cell types, but SMAD3 exhibited a shorter half-life in the SET9 -/-
MEF cells compared to the wild type SET9 +/+ MEF cells upon CXH treatment (Figure 3.3), 
suggesting that SMAD3 is destabilised upon loss of SET9. 
Finally, to determine whether the methyltransferase activity of SET9 is involved in the 
regulation of SMAD3 protein turnover, the half-life of SMAD3 was examined in stably 
transfected cells expressing either wild type FLAG-SET9WT or the methyltransferase-deficient 
mutant SET9, FLAG-SET9H297A (Figure 3.3E). SMAD3 levels exhibited increased stability in 
the FLAG-SET9WT overexpressing cells compared to those cells expressing FLAG-
SET9H297A, upon CXH treatment. This demonstrated that SET9 stabilises SMAD3 in a 
methyltransferase-dependent manner.  
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Figure 3.3. SET9 Regulates SMAD3 Nuclear Import and Protein Turnover. (A) HK C-8 cells were 
transfected with either control siRNA or SET9 siRNA for 12 hours, starved in BM for 24 hours prior to 
overnight treatment with 5ng/ml TGF β-1. Fixed cells were stained with the indicated antibodies and appropriate 
Alexa Fluor-labelled secondary antibodies. Control slides with secondary antibodies only did not exhibit 
fluorescence (Appendix). (B) HK C-8 cells were transfected and starved as in (A) then treated with vehicle (0) or 
TGF β-1 (1–5ng/ml) overnight. Nuclear (n) and cytoplasmic (c) fractions were subject to immunoblotting as 
indicated, using HDAC1 as a nuclear marker. (C) HK C-8 cells were transfected and starved as in (A) then 
treated with TGF β-1 (5ng/ml) overnight. 50µg/ml cycloheximide (CHX) was then applied for the indicated 
times prior to Western blotting as indicated. (D) SET9 +/+ and -/- MEFs were treated as in (C) and subject to 
Western Blotting. (E) HK C-8 cells stably expressing FLAG-SET9WT or methyltransferase-deficient FLAG-
SET9H297A were treated and a half-life assay performed as in (C).  
 
Ubiquitylation is known to target SMAD3 for proteasomal destruction, as a means of 
downregulating TGF β-1 signalling (Fukuchi et al., 2001). Given the effects of SET9 
methyltransferase activity upon SMAD3 protein turnover, SMAD3 ubiquitylation was 
examined in the presence of a selective SET9 inhibitor, R-PFI-2 (Figure 3.4), or upon 
overexpression of the FLAG-SET9H297A mutant (Figure 3.4). The proteasomal inhibitor MG-
132 was also used to enrich for the presence of ubiquitylated SMAD3, which would otherwise 
be destroyed by the proteasome. 
His-tagged ubiquitin was transfected into HK C-8 cells prior to nickel agarose (Ni-NTA) pull 
down to retrieve ubiquitylated SMAD3 species. Treatment with MG-132, produced an 
abundance of ubiquitylated SMAD3 (high molecular weight SMAD3). Addition of the SET9 
inhibitor R-PFI-2 resulted in an increase in the levels of ubiquitylated SMAD3 compared to 
control cells treated with MG-132 only (Figure 3.4A). Finally, the ubiquitylation of SMAD3 
was examined in the HK C-8 cells stably expressing FLAG-SET9WT or methyltransferase-
deficient FLAG-SET9H297A mutant. Enrichment of ubiquitylated SMAD3 was observed in the 
cells expressing the FLAG-SET9H297A mutant compared to the cells expressing FLAG-
SET9WT (Figure 3.4B). In conclusion, these data suggest that SET9 methyltransferase activity 
plays a role in the stabilising SMAD3 protein levels, through influencing SMAD3 
ubiquitylation and subsequent proteasomal destruction.  
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Figure 3.4. SET9 Regulates SMAD3 Ubiquitylation. (A) HK C-8 cells were transfected with His-tagged 
ubiquitin (His-Ub) and either empty vector or FLAG-SMAD3 prior to treatment with 5ng/ml TGF β-1 for 24 
hours. Either DMSO vehicle or 30uM R-PFI-2 was then applied overnight along with 1µM MG-132 prior to Ni-
NTA pulldowns followed by immunoblotting. All cells received MG-132 and TGF β-1. Ubiquitylated SMAD3 
species are indicated (Ub-SMAD3). (B) HK C-8 cells stably expressing wild-type FLAG-SET9WT (wt) or 
methyltransferase-deficient FLAG-SET9H297A (mt) were transfected and treated with TGF β-1 and MG-132 as in 
(A), then subjected to Ni-NTA pulldowns and immunoblotting as indicated. Ubiquitylated SMAD3 species 
detected with SMAD3 antibody are indicated (Ub-SMAD3). All results are representative of n=3 experiments. 
 
3.2.4 Characterisation of Mouse Embryonic Cell Lines (MEFs) 
Given the observed effects of SET9 on TGF β-1 signalling, cells from the SET9 knockout 
mouse were obtained for further characterisation. SET9 knockout MEFs are a useful model 
because fibroblastic cells respond to TGF β-1 and the permanent absence of SET9 expression 
provides a system which does not rely upon transient overexpression of SET9 or transient 
siRNA knockdown of SET9. To determine whether loss of SET9 might phenotypically mimic 
loss of SMAD3, cells from the SMAD3 knockout mouse were also studied. Wild-type (+/+) 
and matched knockout (-/-) SMAD3 mouse embryonic fibroblasts (MEFs) were obtained 
from Erwin Bottinger, Mount Sinai Hospital, New York and wild-type (+/+) and matched 
knock-out (-/-) SET9 MEFs from Giuseppi Testa, European Institute of Oncology, Milan. 
Initially, the MEFs of different genotypes were treated with TGF β-1 for 24-72h and then 
imaged to examine cell phenotype (Figure 3.5). SMAD3 +/+ and -/- cells maintained in FM 
have a similar phenotype of an ordered monolayer of largely rounded cells. When treated with 
TGF β-1 the differences between +/+ and -/- emerge. Upon treatment with TGF β-1, the 
SMAD3 +/+ cells exhibit a spindle shaped morphology, typical of activated myofibroblasts, 
whereas SMAD3 -/- cells show a more unstructured morphology with gaps between cells. The 
A B 
54 
 
SET9 +/+ and -/- MEF cells treated in parallel showed the same phenotypic changes in 
response to TGF β-1 as the SMAD3 MEFs, respectively (Figure 3.5). This demonstrates that 
loss of SET9 results in the same phenotype as loss of SMAD3, evident upon treatment with 
exogenous TGF β-1 and might suggest that SET9 is required for the activation of fibroblasts 
to the myofibroblast phenotype. 
 
Figure 3.5. Phenotypes of SMAD3 and SET9 +/+ and -/- MEF cells. (A) SMAD3 +/+ and -/- MEFs and (B) 
SET9 +/+ and -/- MEFs were seeded into 24-well plates in FM and treated with or without 10ng/ml TGF β-1 for 
24-72 hours then imaged in brightfield to observe differences in phenotypes between the cell lines. 
 
To further characterise the transition to myofibroblasts, SET9-/- MEFs were subject to 
immunofluorescence for accepted pro-fibrotic markers Collagen I (COLI), Collagen III 
(COLIII), Fibronectin (FN1), Plasminogen Activator Inhibitor-1 (PAI-1) and Alpha-Smooth 
Muscle Actin (α-SMA). Cells seeded in 6 well plates on glass coverslips were treated with or 
without 10ng/ml TGF β-1 for 120h before immunofluorescence staining as described in 
Materials and Methods section 2.14. The pro-fibrotic markers showed a reduction in 
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expression in the SET9 -/- cells compared to SET9 +/+ cells, with both cell types showing a 
slight of induction of expression when treated with TGF β-1 (Figure 3.6).  
 
Figure 3.6. Expression of Pro-Fibrotic Markers in SET9 +/+ and -/- MEF Cells.  SET9 +/+ and -/- MEFs 
were treated with or without TGF β-1 and subjected to immunofluorescence for expression of the pro-fibrotic 
markers COLI, COLIII, FN1, PAI-1 and α-SMA. Images of cells treated with 10ng/ml TGF β-1 shown. Top row 
images display the expression of the pro-fibrotic markers in SET9 +/+ cells with TGF β-1 treatment, bottom row 
of images shows expression of pro-fibrotic markers in SET9 -/- cells with TGF β-1 treatment (untreated images 
not shown). Control slides with secondary antibodies only did not exhibit fluorescence (Appendix). The images 
were quantitatively analysed using Image J and are represented as bar graphs of fold change in mean 
fluorescence per cell. All results are representative of n=3 experiments; values are mean±s.d. P values: ** 
denotes P<0.01 (t-test). 
 
3.2.5 SET9 is Required for Fibroblast Migration in Wound Healing Assays 
Fibrosis has been described as an aberrant wound healing response (Wynn, 2007), involving 
migration of activated myofibroblasts to the site of tissue inury, fibroblast migration was 
therefore studied, by performing wound healing assays on the SMAD3 and SET9 MEF cells. 
SMAD3 and SET9 +/+ and -/- MEFs were seeded into wound forming chambers as described 
in Materials and Methods section 2.16, treated with or without TGF β-1 and imaged at 4 hour 
intervals until the wound was completely closed (Figure 3.7A). Both SMAD3 and SET9 +/+ 
MEFs in FM closed the wound in less than 20 hours whereas both SMAD3 and SET9 -/- 
MEFs only achieved 80% closure of the wound, even after 24 hours. This effect was further 
enhanced with the treatment of TGF β-1 (Figure 3.7B). The results from these assays 
demonstrate that the SET9 and SMAD3 -/- MEF cell lines have reduced capacity to migrate to 
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close the wound compared to their respective WTs. The finding that SET9 -/- MEFs and 
SMAD3 -/- 
MEFs have similar phenotypes implies that SET9 could have an important role in the wound 
healing response to tissue injury and might therefore be involved in fibrosis. 
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Figure 3.7. SET9 Regulates TGF β-1-driven Transformation and Wound Healing. (A) MEFs with the 
indicated genotypes were grown in cell culture inserts, in triplicate, overnight prior to wound formation by 
chamber removal. Wounds were photographed every 4 hours, then surface coverage was calculated. (B) 
Performed as in (A) with the addition of 5ng/ml TGF β-1 overnight. Representative data from one patient of 
three are shown. Values are mean±s.d. (C) Representative images of the indicated genotypes at 0, 4, 12 and 24 
hours during wound healing assay (A).  
 
Further wound healing assays were performed with SET9 +/+ MEFs treated with a 
commercially available specific SET9 inhibitor, R-PFI-2. Initially, SET9 +/+ MEFs were 
seeded into chamber inserts and treated with a range of R-PFI-2 concentrations of 10-30μM 
or a DMSO vehicle control. Whilst DMSO had no effect on wound closure compared to no 
treatment control, a reduction in wound healing in response to R-PFI-2 treatment was 
observed (Figure 3.8A). To exclude off-target effects of the inhibitor, the effect of R-PFI-2 on 
both SET9 +/+ and -/- MEFs was examined (Figure 3.8B). The inhibitor had minimal effect 
on wound healing in the SET9 -/- cells, suggesting that the inhibition in wound closure seen 
in the SET9 +/+ cells in response to R-PFI-2 is indeed mediated through SET9. Taken 
together, the data demonstrate that SET9 is involved in fibroblast migration into the site of the 
wound.  
A cell line derived from human renal mesangial cells isolated from the glomerulus of normal 
kidneys (THMC) acts as an additional model of fibrosis as mesangial cell proliferation and 
matrix overproduction are predominant pathological features of glomerular sclerosis, for 
example in diabetic nephropathy (Sraer et al., 1996). Therefore, wound healing assays were 
performed in THMC cells and demonstrated comparable results with the R-PFI-2 SET9 
inhibitor reducing the cells capability to migrate (Figure 3.8).  
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Figure 3.8. The Effect of SMAD3 and SET9 on Wound Healing in MEFs and THMCs. (A) SET9 +/+ MEF 
cells were seeded into chamber inserts and treated with a range of concentrations of R-PFI-2 as indicated, a 
DMSO vehicle control and untreated cells as a further control prior to wound healing assays. (B) SET9 +/+ and -
/- MEF cells set up as in (A) with or without 30μM R-PFI-2 treatment. (C) THMCs set up as in (B). All graphs 
representative of n=3 experiments.  
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3.2.6 SET9 is Required for Collagen Contractility Mediated by Fibroblasts 
A hallmark of renal fibrosis is the ability of activated fibroblasts to increase tissue 
contractility, which involves increased expression of intracellular α-SMA and subsequent 
extracellular Collagen contraction. Fibroblasts migrate to the site of injury and attach to 
Collagen fibrils where they exert mechanical tension to cause contraction of the Collagen 
lattice. In the presence of TGF β-1, fibroblasts differentiate into myofibroblasts and exert 
greater contractile forces on the ECM, resulting in reorganisation of the actin cytoskeleton 
and wound contraction (Li and Wang, 2011). A Collagen gel contractility assay can assess 
wound contraction by cells. A polymerized Collagen matrix containing fibroblasts remains 
attached to the culture dish during contraction. Mechanical tension develops during 
contraction, and cellular stress fibers assemble. This leads to mechanical loading, followed by 
release of the matrices, resulting in mechanical unloading and further contraction as 
mechanical stress dissipates. 
To analyse the effect of SET9 on the MEF cells’ ability to contract Collagen gels were 
prepared in 24-well plates containing purified rat tail Collagen I into which SMAD3 or SET9 
MEF cells were added. The Collagen matrices were treated with or without 5ng/ml TGF β-1 
in FM for 24 hours, then released from the bottom and the edges of the wells with a needle 
and allowed to contract over 24 hours. The Collagen disc diameter was measured at 0, 6, 12 
and 24 hour time-points after being released from the wells to give a measure of contraction 
of the gels. . Figure 3.9A represents the amount of contraction (mm) of the Collagen discs 
over a 24 hour period after being released. The graphs demonstrate that the Collagen discs 
embedded with SMAD3 and SET9 +/+ cells contracted up to 10mm in diameter over 24 hours 
compared to the discs embedded with SMAD3 and SET9 -/- cells which only showed 
contraction of 4mm and 3mm, respectively. SMAD3 and SET9 -/- cells have significantly 
reduced ability to contract the Collagen gels compared to the SMAD3 and SET9 +/+ cells in 
the presence of TGF β-1. 
THMC mesangial cells were also examined using Collagen contractility assays to determine 
the effect of R-PFI-2 on contractility. The THMCs were treated with and without R-PFI-2 and 
with and without 5ng/ml TGF β-1. R-PFI-2 significantly reduced the ability of the THMC 
cells to contract Collagen gels compared to DMSO treated cells. TGF -1 treatment enhanced 
contractility of the THMCs Collagen gels but R-PFI-2 maintained its suppressive effect on the 
contractility (Figure 3.9B).    
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Figure 3.9. SET9 Regulates TGF β-1-driven Collagen Contractility. (A) MEFs with the indicated genotypes 
were used in Collagen contractility assays in triplicate, after treatment with 5ng/ml TGF β-1. The Collagen disc 
diameters were measured over the indicated time-points, representing the amount of contraction of the Collagen 
discs. Images show single representative Collagen discs overlying ruler measure. (B) THMCs were treated with 
either DMSO vehicle or 5µM R-PFI-2, with and without 5ng/ml TGF β-1 and examined in Collagen contractility 
assays, in triplicate. All graphs representative of n=3 experiments. 
 
3.2.7 Isolation and Characterisation of Primary Human Renal Fibroblasts (PRFs) 
As renal fibroblasts are responsible for ECM deposition in CKD, isolation of primary human 
renal fibroblasts was undertaken. These cells should mimic the behaviour of activated 
myofibroblasts upon exposure to TGF β-1 and serve as a more representative model of CKD 
than other cell types, such as immortalised cell lines. An outgrowth method was established, 
to isolate primary renal fibroblasts from human nephrectomised kidney segments or kidney 
sections from organs deemed unsuitable for transplantation (rejected due to donor reasons). 
This method involved finely dissecting renal cortical tissue then attaching this onto a pre-
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scratched cell culture petri dish. The tissue was then maintained in high glucose enriched 
medium, for 14 days, during which time cells began to outgrow from the tissue (Figure 
3.10A,B). The cells were trypsinised once they reached a monolayer of 75% confluency and 
sub-cultured in cell culture flasks until confluent. The resultant populations of cells were 
characterised to ensure fibroblasts had been isolated, as described in more detail below. 
The primary cells were treated with or without 5ng/ml TGF β-1, then brightfield microscopy 
images obtained to examine their morphology. The primary cells took on an elongated, 
spindle morphology, typical of the appearance of fibroblasts when treated with TGF β-1 
(Figure 3.10C). Electron microscopy images were also taken of the cells treated with TGF β-
1. Elongated, spindle-shaped cells with rough membranes were observed, in keeping with 
fibroblastic appearance (Figure 3.10C).  
The isolated cells were next characterised by immunofluorescence to examine the expression 
of characteristic fibroblast markers. Cells stained positively for the fibroblast markers α-SMA, 
Collagen I, and Collagen III, all of which were more highly expressed upon TGF β-1 
treatment. The mesenchymal marker Vimentin, and Zonula occludens-1 (ZO-1) were also 
expressed in the isolated cells. Importantly, the expression of E-cadherin and K-cadherin, 
known epithelial cell markers were completely absent in the cells (Figure 3.10D). This pattern 
of expression suggests that the isolated cells were fibroblasts. 
Next, proliferation assays were performed to determine whether the cells would respond to 
growth factors that are known to stimulate fibroblast growth. Stimulation of the cells with 
TGF β-1 produced a significant increase in the proliferation of the isolated cells. Additionally, 
the cells showed significantly increased proliferation in response to PDGF, a known mitogen 
for fibroblasts (Figure 3.10F).  
Finally, the cells were transiently transfected with siRNAs targeting either SMAD3 or SET9. 
Western blotting demonstrated effective knockdown of the respective targets, thereby 
allowing analysis of cells depleted of our proteins of interest, SMAD3 and SET9 (Figure 
3.10G). 
Altogether, the data suggest that the outgrowth method described can be used to isolate rather 
pure populations of primary renal fibroblasts. These cells were subsequently used to study 
profibrotic markers, wound healing and Collagen contractility assays upon treatment with the 
SET9 inhibitor.   
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Figure 3.10. Isolation and Characterisation Primary Renal Fibroblasts. (A) Cortical kidney sections were 
dissected and inserted onto 90mm tissue culture dishes for the outgrowth method of renal fibroblasts. (B) 
Brightfield image of fibroblast cells outgrowing from cortical kidney section. (C) Brightfield images of isolated 
PRF cells in the absence (i) or presence (ii) of 10ng/ml TGF β-1 treatment. Scanning electron microscope images 
of isolated PRF cells (iii and iv). (D) Immunofluorescence images showing the expression of fibroblastic 
markers in PRF cells; α-SMA, Collagen I, Collagen III treated with or without TGF β-1 as indicated. (E) 
Vimentin and ZO1 were also present, whereas E-cadherin and K-cadherin, both epithelial cell markers were 
absent in the PRFs. Control slides with secondary antibodies only did not exhibit fluorescence (Appendix). (F) 
WST-1 proliferation assay showing fold response to treatment with 10ng/ml TGF β-1 and 25-50ng/ml in 0.5% 
serum-starved PRF cells. (G) Knock downs in PRF cells using SMAD3 and SET9 specific siRNAs compared to 
a scrambled (SCR) control siRNA.  
 
3.2.8 Treatment of PRFs with SET9 Inhibitor Reduces Expression of Pro-Fibrotic Markers 
To determine whether PRFs respond in the same manner as the MEFs, PRF cells were 
subjected to SET9 inhibition with R-PFI-2 hydrochloride at a dose of 30μM. Upon SET9 
inhibition, expression of pro-fibrotic markers Collagen I and III, Fibronectin and α-SMA were 
all reduced in the absence and in the presence of TGF β-1 (Figure 3.11). This suggests that 
treatment of TGF β-1-activated fibroblasts with SET9 inhibitor might reduce the deposition of 
ECM in the context of CKD, if the PRFs treated with TGF β-1 are representative of the 
diseased state. 
3.2.9 Treatment with SET9 Inhibitor Reduced Wound Healing and Collagen Contractility 
of PRFs 
It is established that fibroblast migration to the site of tissue injury is critical for tissue 
contraction and ECM deposition in normal wound healing and fibrosis. In order to examine 
the role that SET9 might have in these processes, wound healing assays were performed to 
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examine fibroblast migration in the presence or absence of the SET9 inhibitor R-PFI-2 
(Figure 3.11B). In the presence of TGF β-1, PRF cells treated with R-PFI-2 showed reduced 
wound healing compared with cells maintained in full medium (FM). Figure 3.11B shows 
brightfield images of PRFs at 0h, 12h and 24h with and without 30uM R-PFI-2 treatment (in 
the absence of TGF β-1) and quantitative analysis represented by line graphs as % of cell 
surface coverage (Figure 3.11C).  
A key feature of activated fibroblasts (myofibroblasts) is their ability to contract extracellular 
Collagen. This is achieved through intracellular expression, and incorporation, of α-SMA into 
the cell cytoskeleton which can communicate to the extracellular compartment, to facilitate 
matrix tension and traction against extracellular Collagen. The role of SET9 in Collagen 
contractility was examined using the contractility assay previously described. Treatment of 
PRFs with R-PFI-2 significantly reduced the PRF cells ability to contract Collagen discs 
(Figure 3.11C). Cells treated with 30μM R-PFI-2 and suspended in Collagen gel matrices 
presented a larger diameter than cells without treatment. The addition of 10ng/ml TGF β-1 
resulted in significantly increased contractility of the gel matrices in the presence and absence 
of the inhibitor. Cells treated with the inhibitor and TGF β-1 still presented with larger 
diameters than TGF β-1 treatment only (Figure 3.11C). 
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Figure 3.11. Treatment of PRFs with a SET9 Inhibitor Significantly Reduces Expression of Pro-Fibrotic 
Markers. (A) PRFs treated with or without 5ng/ml TGF β-1 and with and without 5uM R-PFI-2 then subjected 
to immunofluorescence for fibrotic markers Collagen III, Collagen I, Fibronectin and α-SMA. All results are 
representative of n=3 experiments; values are mean±s.d. ** denotes P<0.01 *** denotes P<0.001 **** denotes 
P<0.0001 (t-test). The images were analysed using Image J and represented as bar graphs. (B) PRFs treated with 
or without R-PFI-2 and imaged at 12 hour time-points during wound healing. Graph represents 3 images per 
time point plotted as a line graph. (C) PRFs were subject to Collagen contractility assays simultaneously treated 
with either DMSO vehicle or 5µM R-PFI-2, -/+ TGF β-1.  
 
3.2.10 SET9 Regulates TGF β-1-driven α-SMA Expression 
The expression of α-SMA in response to TGF β-1 is considered a hallmark of myofibroblast 
transdifferentiation to the active, diseased state. Expression of α-SMA not only marks these 
cells as active but plays a role in cytoskeletal reorganisation to produce the spindle-shaped 
morphology that was absent in the SET9 -/- MEFs studied earlier. Additionally, α-SMA 
expression facilitates Collagen contractility, critical to tissue retraction that occurs in normal 
wound healing and fibrosis, and that was shown to be reduced upon SET9 inhibition in the 
previous section. 
Given that SET9 is known to be a transcriptional regulator, and SMAD3 interacts with SET9 
in response to TGF β-1, I hypothesised that the mechanism by which SET9 can regulate α-
SMA expression and myofibroblast transdifferentiation is through the modulation of SMAD3 
recruitment to cis-regulatory regions of the human α-SMA gene. This was examined using 
chromatin immunoprecipitation assays. 
The putative SMAD3 binding site within the human ACTA2 gene was identified by sequence 
homology to the rat α-SMA gene, which has previously shown to be directly regulated by 
SMAD3 (Hu et al., 2003). Oligonucleotides were designed to flank this SMAD3 binding site 
and used in polymerase chain reaction. 
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Chromatin immunoprecipitation assays using antibodies to either SMAD3 or SET9 were 
performed to study their recruitment to the aforementioned putative SMAD3 binding site 
within the ACTA2 gene in PRF cells. In response to TGF β-1, recruitment of SMAD3 to the α-
SMA gene was increased compared to vehicle treated cells indicating that in PRF cells 
SMAD3 is indeed recruited to the SMAD3 binding site of α-SMA. No SMAD3 binding to the 
GAPDH control gene could be detected, demonstrating specificity of SMAD3 recruitment to 
the ACTA2 gene (Figure 3.12A).  
Treatment with TGF β-1 also resulted in recruitment of SET9 to the ACTA2 gene, indicating 
that SET9 may regulate α-SMA at the transcriptional level. The recruitment of SMAD3 and 
SET9 to the same cis-regulatory region is in keeping with a model whereby an interaction 
between SET9-SMAD3 may be required for regulation of α-SMA. To test this hypothesis 
further, the effect of SET9 knockdown was also examined. Transfection of SET9 siRNA 
produced a significant reduction in SMAD3 recruitment (Figure 3.12B), an effect that could 
be partly rescued by the addition of the proteasomal inhibitor MG-132. These data argue 
against the model in which SET9 is passively recruited to the ACTA2 gene but fit with the 
previously presented data in which SET9 facilitates SMAD3 nuclear import, in response to 
TGF β-1, to allow SMAD3 binding to the ACTA2 gene regulatory sequence. 
Upon R-PFI-2 treatment of PRFs, approximately a 60% reduction in α-SMA protein 
expression is seen, suggesting that the inhibition of SET9 reduces the further activation and 
differentiation of myofibroblasts in response to TGF β-1 (Figure 3.12C).  
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Figure 3.12. SET9 Regulates TGF β-1-driven α-SMA Expression. (A) PRFs were treated with either vehicle 
or 5ng/ml TGF β-1 for 24 hours prior to chromatin immunoprecipitation with either SMAD3 (left) or SET9 
(right) antibodies. Control slides with secondary antibodies only did not exhibit fluorescence (Appendix). ChIP 
material was subject to PCR for either α-SMA or GAPDH to demonstrate selective recruitment. Purified human 
genomic DNA was used as a positive control in PCR (PCR control); NTC, no template control reaction. (B) 
PRFs were transfected with siRNA targeting either SET9, SMAD3 or control siRNA (Ctrl siRNA). 24 hours 
later, all cells were treated with 5ng/ml TGF β-1 and 5µM MG-132 where indicated. A further 24 hours later, 
cells were used in chromatin immunoprecipitation assays with SMAD3 Ab28379, as described in (A). (C) PRFs 
were treated simultaneously with either DMSO vehicle or 5µM R-PFI-2 along with 5ng/ml TGF β-1 as in (B) 
and immunostained to detect α-SMA; nuclei are stained blue with DAPI. All results are representative of n=3 
experiments. 
 
3.3 Discussion 
Fibrosis is the main characteristic of almost all forms of CKD. Recent studies in animal 
models of kidney disease have suggested that fibrosis and fibrogenesis are major contributors 
to CKD progression (Duffield, 2014) and fibrosis predicts a poorer clinical outcome in CKD 
(Menn-Josephy et al., 2016). With the increasing prevalence of ESRD, research has been 
A 
B C 
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focused on identifying anti-fibrotic therapies however to-date no specific treatments have 
been developed to reduce fibrosis (Tampe and Zeisberg, 2014).  
With TGF β-1/SMAD3 signalling cascade being a key signalling pathway in the pathogenesis 
of renal fibrosis, there has been focus on using blocking antibodies and inhibitors of TGF β-1 
as a treatment in fibrotic diseases. Although there has been success in animal models (Sharma 
et al., 1996; Ziyadeh et al., 2000), in clinical trials metelimumab, a TGF β-1 neutralizing 
antibody, did not demonstrate efficacy in patients and resulted in serious adverse effects 
(Denton et al., 2007). These studies indicate that targeting downstream signalling mediators 
of the TGF β-1 pathway such as SMADs may be more effective than targeting upstream 
signalling.  
SMAD3 in particular has been a focus of research as the literature has shown SMAD3 has an 
important role in renal fibrosis, demonstrated by SMAD3 knockout mice that are resistant to 
renal fibrosis (Sato et al., 2003; Inazaki et al., 2004). Similarly, SMAD3 inhibitors have been 
developed but none are used clinically therefore an alternative approach to interfere with TGF 
β-1 signalling is required. A lysine methyltransferase SET9 has already been shown to be 
involved in TGF β-1 signalling and ECM production in fibrosis (Elkouris et al., 2016) and 
siRNA knockdown of SET9 significantly reduced renal fibrosis in mice. SET9 has been 
shown to already have a role in the TGF β-1/SMAD pathway; SET9 inhibition increased the 
expression of SMAD7, an inhibitory downstream effector of the TGF β-1 pathway (Elkouris 
et al., 2016). This further supports the suggestion that SMAD3 and SET9 could provide 
desirable therapeutic targets in the treatment of CKD and other fibrotic diseases. SET9’s role 
and interaction with other transcription factors to regulate TGF β-1 signalling is still to be 
explored.  
SMAD proteins are known to be subject to phosphorylation and ubiquitylation to regulate 
TGF β-1 signalling (Ebisawa et al., 2001; Massague, 2012) but can also be regulated by other 
modifications such as acetylation and methylation. For example, SMAD6, a BMP-signalling 
effector protein, has been found to interact and be methylated by arginine methyltransferase 
PRMT, facilitating the BMP-signalling pathway (Elkouris et al., 2016). Methylation can 
regulate transcription factor function by several mechanisms including regulating protein 
stability, interaction with other proteins and genomic targets (Sarris et al., 2014).  
SET9 has been shown to methylate non-histone proteins such as TAF10 (Kouskouti et al., 
2004), p53 (Chuikov et al., 2004) and the ER (Subramanian et al., 2008) to regulate their 
transcription. The methylation of p53 and ER by SET9 results in their stabilisation and 
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subsequent transcriptional activation, supporting the theory that SET9 can also control non-
histone transcriptional regulators.  
A nuclear localisation signal (NLS)-like motif KKLKK has been identified in SMAD3 and is 
thought to be conserved across all TGF β pathway-specific SMADs. This motif is located 
within the N terminus of SMAD3 and has been shown to be responsible for its nuclear import 
(Xiao et al., 2000). Given the presence of the KKLKK motif in SMAD3 and previous 
findings that have shown SET9 to interact with similar motifs in other non-histone proteins 
such as TAF10 (Kouskouti et al., 2004), p53 (Chuikov et al., 2004) and AR (Gaughan et al., 
2011), I sought to interrogate the role of SET9 on SMAD3 function. Immunoprecipitation 
experiments demonstrated an interaction between the two proteins. Interestingly, this 
interaction is shown to be mediated through the N-terminal domain of SMAD3 which 
harbours the KKLKK motif indicating that like other non-histone proteins the interaction 
between SET9 and SMAD3 may be mediated through this motif. 
In response to TGF β-1, the type I and type II receptors positioned at the cell membrane form 
an active heterotetrameric complex which then phosphorylates an intracellular modulator, 
SMAD3. The phosphorylated SMAD3 then forms a heterodimer with SMAD4 and the active 
complex is translocated to the nucleus where it binds to cis-regulatory elements of target 
genes promoting the recruitment of additional transcriptional co-factors to mediate target gene 
transcription (Kretzschmar and Massague, 1998). I hypothesised that SET9 could also have a 
role in this signalling pathway by interacting with and regulating SMAD3 to modulate the 
expression of fibrotic genes and therefore could present as a novel therapeutic target for the 
treatment of renal fibrosis. 
Immunofluorescence and cellular fractionation of HK C-8 cells demonstrated that following 
siRNA-mediated depletion of SET9, SMAD3 nuclear import was markedly reduced following 
addition of TGF β-1. The failure of SMAD3 to translocate to the nucleus following SET9 
depletion may indicate that the interaction with SET9 occurs in the cytoplasm and is required 
for activation and translocation of SMAD3. SET9 is known to methylate histone 3 lysine 4 
which is a marker of transcriptional activity but the data presented here shows that SET9 
interacts with the SMAD3 protein rather than mediating activation of SMAD3 genes, 
illustrating a new role for SET9.  
SET9 depletion negatively impacts the stability of SMAD3, reducing its half-life upon 
knockdown compared to control. SET9 has been shown to positively regulate the stability of 
another transcription factor, p53 by methylating one residue within the carboxyl-terminus 
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regulatory region (Chuikov et al., 2004). When the methyltransferase activity of SET9 is 
disrupted, this reduces the stability of SMAD3 suggesting the methyltransferase activity of 
SET9 could play a role in the stability of SMAD3, perhaps by regulating SMAD3 
ubiquitylation and subsequent proteosomal destruction. Conversely, SET9 interacts with and 
methylates SMAD7 promoting interaction with the E3 ligase Arkadia and subsequent 
ubiquitylation-dependent degradation (Elkouris et al., 2016). However, SMAD7 is an 
inhibitory SMAD, the inhibition of SET9 results in elevated SMAD7 levels and inhibition of 
TGF β-1/SMAD signalling and subsequent expression of fibrotic genes. This demonstrates 
that SET9 can dictate different outcomes depending on the substrate and type of interaction. 
We were unable to determine whether SET9’s interaction with SMAD3 was enough to 
regulate its transcriptional activity or whether SET9 directly methylated SMAD3, as it has 
been shown to do with other non-histone substrates. The data we have collected strongly 
indicates that SET9 methylates SMAD3 but this must be further explored to determine the 
exact mechanism of SET9.  
It has been demonstrated that SET9 H3 monomethylation is involved in the regulation of 
ECM gene expression and silencing of SET9 attenuates TGF β-1 ECM gene expression (Sun 
et al., 2010). Furthermore, knockdown of SET9 expression significantly attenuated renal 
fibrosis in UUO mice (Sasaki et al., 2016). Additionally, we found that SET9 -/- MEFs 
exhibited significantly reduced expression of fibrotic markers Collagen I, Collagen III, 
Fibronectin, PAI-1 and α-SMA in the presence of TGF β-1 compared to SET9 +/+ MEFs, this 
mimics the phenotype of SMAD3 -/- MEFs suggesting that SET9 could also have an 
important role in TGF β-1 signalling and the development of renal fibrosis. 
For the first time, the data presented here shows that SET9 regulates several TGF β-1-driven 
myofibroblast functions and that SET9 is required for SMAD3 to be recruited to the ACTA2 
gene. α-SMA is known to be a marker of myofibroblasts in the kidney, in a transgenic 
reporter mouse model under the regulation of the Collagen Type I, Alpha 1 (ColIα1) 
promoter, all cells in UUO mouse kidney interstitium that produce Collagen I also express α-
SMA, whereas very few cells expressed α-SMA that did not produce Collagen (Lin et al., 
2008), therefore α-SMA can be used as an imperfect marker of myofibroblasts in the kidney. 
The results demonstrated that SET9 is required for SMAD3 recruitment to the ACTA2 gene in 
PRFs. Taken together, the data show that SET9 is required for and regulates SMAD3 
stabilisation, nuclear import and then recruitment to the ACTA2 gene. These activities lead on 
to myofibroblast differentiation, increased α-SMA expression and Collagen contractility. 
With myofibroblast differentiation, the increased expression of α-SMA and consequent 
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Collagen contractility being the main characteristics of fibrosis, inhibition of SET9 could be 
exploited as a therapeutic target in the treatment of CKD (Liu et al., 2003; Duscher et al., 
2014).  
A key feature of fibrosis is the increased migration and contractility of activated fibroblasts. 
SMAD3 knockdown has been shown to significantly reduce migration of fibroblasts and their 
ability to contract Collagen (Flanders, 2004; Dobaczewski et al., 2010; Branski et al., 2016) I 
have also replicated these findings in SMAD3 -/- MEFs. However, the role of SET9 in 
regulating fibroblast migration and contractility has not been examined until now. SET9 -/- 
MEFs exhibited significantly retarded migration and reduced ability to contract Collagen gels 
in response to TGF β-1 compared to SET9 +/+ MEFs. These results are also in keeping with 
studies in SMAD3-null mouse models. SMAD3-null mice have been reported to exhibit 
reduced migratory ability of myofibroblasts and reduced Collagen gel contraction 
(Dobaczewski et al., 2010), suggesting that SET9 could have an equally important role in 
regulating these key mechanisms.  
In fibrosis, myofibroblast migration results in their accumulation at the site of injury and 
subsequent ECM deposition. Previous work has shown SET9 to be required for ECM 
deposition (Sun et al., 2010), therefore, targeting and inhibiting SET9 to retard the migration 
and accumulation of myofibroblasts at the site of injury will further reduce ECM deposition 
and provide an additional option to treat CKD. Additionally, a study showed SET9-null mice 
exhibited a strong protective effect against the development of pulmonary fibrosis but showed 
no major phenotypic changes (Elkouris et al., 2016). This suggested that SET9 inhibitors 
could be potential therapeutics for fibrosis.  
Furthermore, a potent and selective SET9 inhibitor, R-PFI-2 applied to human primary renal 
fibroblasts in the presence of TGF β-1 also retarded the cells’ ability to migrate and contract 
collagen. The SET9 inhibitor also reduced expression of fibrotic markers in PRFs in the 
presence of TGF β-1, mimicking the effects we demonstrated in the SET9 -/- MEFs. This 
further supports the hypothesis that SET9 has an important role in the development of renal 
fibrosis and can be targeted as a therapeutic with the use of selective inhibitors. 
R-PFI-2 occupies part of the peptide-binding groove that is usually occupied by the target 
lysine residue and the peptide backbone of the preceding two residues of the substrate peptide. 
These two residues have been shown to be the most important residues for substrate binding 
by SET9 (Dhayalan et al., 2011), suggesting that R-PFI-2 will be effective at inhibiting the 
wide variety of SET9 substrates. R-PFI-2, has been shown to exhibit over 1000-fold 
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selectivity to SET9 over other methyltransferases. Although very selective, negligible activity 
of the inhibitor can be seen on other methyltransferases G9a, EZH2, EHMT1 which could 
possibly result in some off-target effects on biological processes these methyltransferases are 
involved in such as embryogenesis and regulation of the cell cycle. This inhibitor would need 
to be tested further to exclude any off-target effects.  
In summary, SET9 inhibition significantly reduces the activity of SMAD3 by impeding its 
nuclear import, protein turnover and recruitment to the ACTA2 gene consequently reducing 
expression of fibrotic genes. SET9 knockdown also reduces myofibroblast migration and 
Collagen contraction; key mechanisms of fibrosis. Our findings present SET9 as a novel 
target for the treatment of renal fibrosis. The use of R-PFI-2 could provide an effective 
treatment for renal fibrosis but more research will need to be carried out to determine any off-
target effects of the drug and its clinical relevance in the treatment of renal fibrosis.  
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Chapter 4. The Role of Methyltransferase SETDB1 in TGF β-1/SMAD3 
Signalling in Renal Fibroblasts 
 
4.1 Introduction and Objectives 
Epigenetic post-translational modifications have been a hot topic in human disease research in 
recent years. Chromatin consists of tighly packed double-stranded DNA, wrapped around core 
histones proteins. Histones have long tails that undergo post-translational modifications to 
alter the structure of chromatin, thereby regulating the ability of transcription factors to access 
DNA binding sites in order to modulate gene expression. Acetylation, deacetylation and 
methylation of DNA and histones are examples of these modifications that regulate gene 
expression. Methylation of lysine residues within histones has received particular interest 
because of its crticial role in the transcriptional regulation of gene expression in disease (Sun 
et al., 2010). 
Histone modifications cause transcriptional activation or repression depending upon the 
precise nature of the modifiction. For example, mono-methylation of histone 3 lysine 4 
(H3K4) generally results in upregulation of gene expression whereas di- and tri- methylation 
of histone 3 lysine 9 (H3K9) often results in gene repression. Trimethylated H3K9 is 
frequently found in constitutive regions of transcriptionally silent heterochromatin, where it 
seems to prevent inappropriate transcription (Ruthenburg et al., 2007). SETDB1 is a histone 
lysine methyltransferase (HKMT) known to methylate H3K9, causing transcriptional 
repression. SETDB1–mediated transcriptional repression is important in the context of 
embryogenesis and postnatal development (Matsui et al., 2010), X-chromosome inactivation 
(Minkovsky et al., 2014) and myogenesis (Song et al., 2015).  
On a molecular level, SETDB1 is involved in several signalling pathways such as Wnt and 
non-canonical Wnt signalling and TGF β signalling (Takada et al., 2007; Sun et al., 2015; Du 
et al., 2018). In the non-canoncial WNT signalling pathway, SETDB1 forms a co-repressor 
complex with NLK, a kinase and CHD7, a transcription factor resulting in H3K9 methylation. 
In turn, this attenuates recruitment of co-activators to the peroxisome proliferator-activated 
receptor-gamma (PPAR-gamma) gene, supressing transcription from the PPAR-gamma locus. 
As a consequence, this event drives differentation of mesenchymal stem cells to an 
osteoblastic cell lineage (Takada et al., 2007).  
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SETDB1 is upregulated in Huntington’s Disease and several cancer types in which  SETDB1-
mediated transcriptional repression is likely to contribute to disease pathogenesis (Ryu et al., 
2006). These cancers include breast cancer, ovarian cancer, lung cancer, hepatocellular cancer 
and melanoma (Ceol et al., 2011; Rodriguez-Paredes et al., 2014; Liu et al., 2015; Wong et 
al., 2016). In this context, SETDB1 overexpression is thought to cause transcriptional 
repression of tumour supressor genes, leading to both tumourgenesis and metastasis.  
Aside from histones, methyltransferases have been shown to methylate non-histone proteins. 
SETDB1 has been found to regulate non-histone proteins involved in transcription. For 
example, SETDB1 can directly methylate p53, resulting in increased p53 stability in cancer 
cells (Fei et al., 2015). Additionally, SMAD3 can recruit SETDB1 to the IL-2 promoter in 
response to TGF β-1 to induce trimetylation of H3K9, resulting in transcriptional repression 
of the IL-2 gene in immunoregulatory T cells (Wakabayashi et al., 2011).  
This opens up the possiblity that SETDB1 could also regulate other genes downstream in 
TGF β-1/SMAD3 signalling. Together with our findings that SET9 directly interacts with 
SMAD3 to regulate its transcriptional activity, protein turnover and nuclear translocation, I 
sought to identify other methyltransferases that could be involved in the TGF β-1 signalling 
pathway in renal fibrosis.  
4.2 Results 
4.2.1 Methyltransferase siRNA Library Screen  
In order to identify methyltransferase enzymes that could be involved in the TGF β-1/SMAD3 
signalling pathway, a library containing siRNA designed to target 50 methyltransferases was 
screened. The commercially available siRNA library contained three pooled specific siRNAs 
to each of the 50 methlytransferases. This library was introduced into HK C-8 cells that were 
stably transfected with a TGF β-1 responsive luciferase reporter construct termed pCAGA12-
luc that contains multiple copies of the CAGA box. The stably transfected HK C-8 cells were 
reverse transfected with the siRNA library or SCR negative control siRNA and some cells 
were left untransfected as an additional control. The cells were then treated with 1ng/ml TGF 
β-1 for 24 hours and a luciferase assay was subsequently performed on cell lysates. The 
screen was performed twice with the siRNA added into different wells in each screen, in case 
the processing order within the luciferase assay introduced any bias into the results (Figure 
4.1A,B). Z-scores were calculated from Screen 1 and 2 and potential hits were identified as 
having a Z-score of above 3 or below -3 (Figure 4.1C,D) (Zhang et al., 1999). 
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Methyltransferases identified as potential hits in both Screen 1 and Screen 2 were then 
retested on an independent third assay for verification (Figure 4.1E). T-test analysis was 
applied and confirmed SETDB1 as a significant hit; SETDB1 siRNA knock-down resulted in 
a significant increase in SMAD3 luciferase activity confirming an inhibitory role for SETDB1 
in TGF β-1/SMAD3 signalling.  
 
 
Number Methyltransferase  
 
Number Methyltransferase  
1 ASH1L  
 
26 PRMT5  
2 ASH2L 
 
27 PRMT6  
3 CARM1  
 
28 PRMT7  
4 DOT1L  
 
29 PRMT8  
5 EHMT1  
 
30 SET7/9 
6 EHMT2  
 
31 SET8 
7 EZH1 
 
32 SETD1A  
8 EZH2 
 
33 SETD2  
9 LCMT1  
 
34 SETD3  
10 LCMT2  
 
35 SETD4 
11 METT10D  
 
36 SETD5  
12 METT11D1  
 
37 SETD6  
13 METT5D1  
 
38 SETDB1  
14 MLL  
 
39 SETDB2  
15 MLL2 
 
40 SETMAR  
16 MLL3 
 
41 SMYD2 
17 MLL4 
 
42 SMYD3 
18 MLL5 
 
43 SMYD5 
19 NSD1 
 
44 SUV39H1  
20 PRDM1  
 
45 SUV39H2  
21 PRDM2  
 
46 SUV420H1  
22 PRDM5  
 
47 SUV420H2  
23 PRMT1  
 
48 SUZ12  
24 PRMT2  
 
49 WHSC1  
25 PRMT3  
 
50 WHSC1L1  
 
Table 4.1 Methyltransferase siRNA Library. Library of methyltransferase siRNAs with their designated 
number used in proliferation screens to identify potential targets of the TGF β-1/SMAD3 pathway in renal 
fibrosis. 
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Figure 4.1. Methyltransferase siRNA Library Screen. (A) HK C-8 cells were stably transfected with the TGF 
β-1 responsive CAGA-luc reporter plasmid then reverse transfected with either control SCR siRNA or a library 
of 50 pools of methyltransferase siRNAs at a final concentration of 25nM. An untransfected control -/+ TGF β-1 
was also included. Each pool of siRNA was performed in quadruplicate. The cells were treated with 1ng/ml TGF 
β-1 for 24 hours, a luciferase assay was subsequently performed, correcting for protein quantity using a BCA 
assay. Luciferase readouts are presented as fold change in luciferase activity over SCR control siRNA 
transfectants. (B) The screen was repeated as in (A) but with the siRNAs transfected in the plates in a different 
order to avoid bias. (C) Z-scores were calculated from the results of Screen 1 and 2 (A and B) and plotted in 
ascending order. Potential hits were identified as having a Z-score above 3 or below -3. (D) A validation siRNA 
test was performed on methyltransferases which identified as top hits in screen 1 and 2 and presented with the 
greatest Z-scores. Values are mean±s.d. P values: ** denotes P<0.01 *** denotes P<0.001 **** denotes 
P<0.0001 (t-test). 
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Table 4.2. Methyltransferase siRNA Screen Z-Score hits. Positive and negative Z-score ‘hits’ from Screen 1 
and 2. * denotes methyltransferases containing a SET domain.  
 
 
 
 
 
 
 
 
 
 
Gene Name Z-Score Effect Gene N0 Function 
SMYD2 -8.5 Negative 41 Lysine Methyltransferase * 
     
LCMT1  -8.2 Negative 9 Leucine Carboxyl 
Methyltransferase 
MLL  -7.6 Negative 14 Lysine Methyltransferase 
EZH2 -7.6 Negative 8 Lysine Methyltransferase 
SUZ12  -6.8 Negative 48 Component of Lysine 
Methyltransferase complex 
PRC2/EED-EZH2 
PRMT2  -5.5 Negative 24 Protein Arginine 
Methlytransferase 
METT5D1  -5.3 Negative 13 Probable Methltransferase-Like 
Protein 
SUV420H2  -5 Negative 47 Lysine Methyltransferase 
PRDM5  -4.8 Negative 22 Sequence-specific DNA-binding 
Transcription Factor * 
SUV420H1  -4.6 Negative 46 Lysine Methyltransferase * 
MLL3 -4.3 Negative 16 Lysine Methyltransferase * 
SETD2  -3.8 Negative 33 Lysine Methyltransferase * 
WHSC1L1  -3.7 Negative 50 Lysine Methyltransferase 
SETD5  -3.6 Negative 36 Function yet to be determined 
but like to function as a Lysine 
Methyltransferase * 
SETMAR  -3.6 Negative 40 Lysine Methyltransferase * 
SETD4 6.2 Positive 35 Lysine Methyltransferase * 
ASH1L  6.2 Positive 1 Lysine Methyltransferase * 
SETD3  6.7 Positive 34 Lysine Methyltransferase * 
NSD1 8.9 Positive 19 Lysine Methyltransferase * 
LCMT2  11 Positive 10 Probable S-adenosyl-L-
methionine-dependent 
Methyltransferase 
EHMT1  12 Positive 5 Lysine Methyltransferase 
PRDM1  15.9 Positive 20 Repressor of beta-interferon gene 
expression 
SETDB1  19 Positive 38 Lysine Methyltransferase * 
80 
 
4.2.2 SETDB1 Co-localises and Interacts with SMAD3 
Although the luciferase assay used to identify SETDB1 is useful for a medium throughput 
screen, the non-physiological nature of the system may lead to false positive results. 
Therefore, the role of SETDB1 in TGF β-1/SMAD3 signalling was examined in more detail 
to determine whether SETDB1 is a bona fide regulator of this pathway.  
Firstly, to establish where SETDB1 was expressed in renal tubular epithelial cells with respect 
to SMAD3, dual-immunofluorescence was performed in HK C-8 cells treated with or without 
10ng/ml TGF β-1 and stained for SMAD3 (red) and SETDB1 (green) (Figure 4.2A). 
Quantative anaylsis demonstrated that under basal conditions SMAD3 and SETDB1 were 
primarily localised to the cytoplasm (94% and 93% of total protein, respectively). Upon 
stimulation with TGF β-1, 83%  of SMAD3 translocated from the cytoplasm to the nucleus. 
Interestingly, 30% of total SETDB1 also translocated to the nucleus upon TGF β-1 
stimulation, demonstrating that SMAD3 and SETDB1 co-localised under basal conditions and 
translocate in a similar manner, in the presence of TGF β-1 (Figure 4.2B).  
SETDB1 has previously been shown to interact with SMAD3 in human embryonic kidney 
cells, in response to TGF β-1 (Du et al., 2018). To confirm this finding in the system used 
here, immunoprecipiation of endogenous SETDB1 from HK C-8 cell lysates was performed. 
Co-immunoprecipitation of SMAD3 could not be identified, even in the presence of TGF β-1 
treatment. This could be a result of very low levels of endogenous SETDB1 within the cells, 
or that the interaction may take place in the nucleus which could therefore be difficult to 
detect from whole cell lysates. Immunoprecipitation of SETDB1 was therefore performed on 
nuclear fractions from HK C-8 cells which resulted in co-immunoprecipitation of SMAD3 in 
the presence of TGF β-1 (Figure 4.2C). Interestingly, no co-immunoprecipitation of SMAD3 
was detected in the absence of exogenous TGF β-1 treatment. Additionally,  SMAD3 could 
not be detected upon immnoprecipitation with control immunoglobulins, demonstrating 
specificity. The reason why the SETDB1-SMAD3 interaction could be detected only in 
nuclear lysates presumably reflects SMAD3 being present at higher levels in the nucleus upon 
TGF β-1 stimulation. Other studies have confirmed these findings, identifying a strong 
association of SETDB1 and SMAD3 in the nucleus compared with only very weak interaction 
in the cytoplasm, suggesting an enhanced affinity for the interaction with TGF β-1 activated 
SMAD3 (Du et al., 2018).  
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Figure 4.2. SETDB1 Co-localises and Interacts with SMAD3. (A) PRF cells were starved in BM for 24 hours 
prior to -/+ 10ng/ml TGF β-1 treatment for 48 hours. Fixed cells were stained with the indicated antibodies for 
dual immunofluorescence with the appropriate Alexa Fluor-labelled secondary antibodies. Control slides with 
secondary antibodies only did not exhibit fluorescence (Appendix). (B) The immunofluorescence images were 
quantitatively analysed using Image J and are represented as bar graphs of % of total protein. (C) 
Immunoprecipitation was performed on HK C-8 nuclear fractions -/+ 10ng/ml TGF β-1 with either SETDB1 
antibody or control (IgG) antibody, followed by immunoblotting as indicated. All results are representative 
of n=3 experiments; values are mean±s.d. P values: ** denotes P<0.01 *** denotes P<0.001 **** denotes 
P<0.0001 (t-test). 
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4.2.3 SETDB1 Silencing Results in Increased Expression of SMAD3 and Pro-Fibrotic 
Markers 
To investigate the role of SETDB1 in the TGF β-1/SMAD3 signalling pathway, the effect of 
SETDB1 knockdown was examined. HK C-8 cells were transfected with SETDB1 siRNA or 
SCR control siRNA. Immunoblotting, performed on nuclear fractions, demonstrated a 52% 
reduction in expression of SETDB1 by densitometric analysis compared to SCR control 
(Figure 4.3A). Silencing SETDB1 in HK C-8 cells resulted in increased SMAD3 expression 
under basal conditions or upon exogenous TGF β-1 treatment, indicating that SETDB1 can 
regulate the expression of SMAD3 (Figure 4.3B). This result was subsequently confirmed by 
immunofluorescence of PRF cells transfected with SETDB1 siRNA or SCR siRNA control, 
treated with or without TGF β-1, then dual-stained with SMAD3 (green) and SETDB1 (red) 
antibodies (Figure 4.3). Analysis of immunofluorescence images demonstrated a 45% 
decrease in SETDB1 expression upon knockdown, which resulted in a 70% increase in 
SMAD3 expression under basal conditions. Comparable results were also seen with TGF β-1 
treatment (Figure 4.3).  
Because SMAD3 is a key regulator of TGF β-1 signalling in fibrosis, the effect of SETDB1 
knock-down on the expression of the pro-fibrotic markers was then examined. Upon SETDB1 
siRNA knock-down in PRF cells, the expression of α-SMA, Collagen I and Collagen III 
proteins were all increased compared to SCR control siRNA transfectants, with or without 
TGF β-1 treatment, particularly α-SMA which was significantly increased upon SETDB1 
knock-down (Figure 4.3). This suggests that SETDB1 inhibits pro-fibrotic gene expression 
possibly through the regulation of SMAD3 protein levels.  
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Figure 4.3. SETDB1 Silencing Results in Increased Expression of SMAD3 and Pro-Fibrotic Markers. (A) 
HK C-8 cells were transfected with SETDB1 siRNA or a control siRNA at a final concentration of 40nM, 
followed by 10ng/ml TGF β-1 treatment for 24 hours. Immunoblotting was then performed on nuclear fractions 
with antibodies as indicated. (B) HK C-8 cells were transfected as in (A) -/+ 10ng/ml TGF β-1 with subsequent 
immunoblotting performed on whole cell lysates with antibodies indicated. (C) PRF cells were transfected with 
SETDB1 siRNA or control SCR siRNA at a final concentration of 40nM and treated -/+ 10ng/ml TGF β-1 for 48 
hours. Fixed cells were stained with the indicated antibodies and appropriate Alexa Fluor-labelled secondary 
antibodies. Control slides with secondary antibodies only did not exhibit fluorescence (Appendix). The images 
were quantitatively analysed using Image J and are represented as bar graphs of fold change in fluorescence per 
cell. (D) Immunofluorescence in PRFs was performed as in (C) but stained with antibodies as indicated. Images 
were quantitatively analysed as in (C). (TGF β-1 images not shown in D). All results are representative of n=3 
experiments; values are mean±s.d. P values: * denotes P<0.05 ** denotes P<0.01 *** denotes P<0.001 **** 
denotes P<0.0001 (t-test). 
 
4.2.4 SETDB1 Silencing Enhances Wound Healing and Collagen Contractility of PRFs 
As previously described, fibroblast migration to the site of tissue injury results in ECM 
deposition and extracellular Collagen contractility, which are essential processes in both 
normal wound healing and fibrosis. Because these are known to be regulated by TGF β-1, we 
examined the role of SETDB1 in these processes.  
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Firstly, wound healing assays were performed in PRFs transfected with either SETDB1 
siRNA or SCR control siRNA. The assays were performed on glass coverslips which were 
then subjected to immunofluorescence for SETDB1, to ensure effective SETDB1 knock-
down. SETDB1 knock-down increased the rate of migration of the cells which demonstrated 
95% surface coverage at 12 hours compared to 83% cell surface coverage by SCR control 
(Figure 4.4A). This represents an approximate 50% increase in migration upon SETDB1 
knock-down. This effect was also observed upon TGF β-1 treatment, albeit to a lesser extent 
(93% and 88% cell surface coverage at 12 hours, respectively, representing an approximately 
a 25% increase in migration) (Figure 4.4B). Immunofluorescence images confirmed knock-
down of SETDB1 upon siRNA transfection compared to SCR control (Figure 4.4C).   
Collagen contractility assays were next performed with PRFs transfected with SETDB1 or 
SCR control siRNA and resuspended in Collagen gel matrices. SETDB1 knock-down lead to 
an increase in the ability of the PRF cells to contract the Collagen matrices, resulting in 
appearance of smaller diameter Collagen gels compared to SCR control siRNA transfectants. 
This effect was seen under basal conditions or in the presence of exogenous TGF β-1 
treatment (Figure 4.4D). The migration and Collagen contractilty results in PRF cells suggest 
a role for SETDB1 in the regulation of renal fibrolasts, the cell type responsible for renal 
fibrosis.     
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Figure 4.4. SETDB1 Silencing Enhanced Wound Healing and Collagen Contractility of PRFs. (A) PRF 
cells were transfected with SETDB1 siRNA or control SCR siRNA at a final concentration of 40nM on glass 
coverslips then subject to wound healing assays over a 24 hour period followed by immunofluorescence (C) 
stained with the indicated antibodies and appropriate Alexa Fluor-labelled secondary antibodies. (B) Performed 
as in (A) with the addition of 10ng/ml TGF β-1 treatment after transfection which was maintained throughout the 
24 hours wound healing assay. Brightfield images of the wound healing assays were taken at 4 hour intervals, 
quantitatively analysed using Image J and represented as line graphs of % cell surface coverage over time. (D) 
PRF cells were transfected as in (A) for 24 hours followed by resuspension in Collagen matrix gels that were 
seeded into 24-well plates and allowed to set for 24 hours in FM -/+ 10ng/ml TGF β-1. The Collagen matrices 
were then released from the edges of the wells and their diameters measured after a further 24 hours and 
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represented as a bar graph of contraction (mm). All results are representative of n=3 experiments, each point/bar 
is representative of a triplicate. 
 
4.3 Discussion  
Methyltransferase enzymes have been shown to modulate the activity of numerous 
transcription factors through multiple mechanisms including methylation of histone proteins 
that alter the chromatin landscape and by modifying non-histone proteins, thereby directly 
effecting their function.  
As previously discussed, this work identified the lysine methyltransferase SET9 as having an 
important role in TGF β-1/SMAD3 signalling in renal fibrosis. This led to a screen for other 
methyltransferases involved in TGF β-1/SMAD3 signalling. From 2 screens of 50 human 
methyltransferase target genes in HK C-8 cells, 23 enzymes were identified as potential 
regulators of TGF β-1/SMAD3 signalling. Calculation of statistical Z-score analysis identified 
15 enzymes with a Z-score cut-off of below -3 and 8 enzymes with a Z-score of above 3. A 
further validation screen was performed which identified the methyltransferase SETDB1 as 
having the greatest effect on TGF β-1 signalling, with SETDB1 knockdown resulting in a 
significant increase in SMAD3 transcriptional activity. Additionally, SETDB1 has previously 
been shown to be involved in TGF β-1 signalling and regulation of the ECM; suggesting 
SETDB1 as an attractive hit to further validate (Wakabayashi et al., 2011).  
Interestingly, the 3 methyltransferases SETDB1, SMYD2 and SETD3 that were identified as 
top hits in both screen 1 and 2 and validation screen 3 are all SET-domain lysine 
methyltransferases. Moreover, 15 of the 23 hits identified by Z-score anaylsis were lysine 
methyltransferases, 10 of which contain a SET-domain. This work has already identified 
SET9, another SET-domain lysine methyltransferase as playing a important role in TGF β-1 
signalling, additionally the hits identified from this work suggesting that other SET-domain 
lysine methyltransferases play a important role in TGF β-1 signalling. Their mechanism of 
action may include i) direct interaction with SMAD3 ii) direct methylation of SMAD3 or iii) 
methylation of histone proteins present at SMAD3 target genes. 
Silencing SYMD2, a lysine methyltransferase identified here, significantly reduced SMAD3 
luciferase activity. This suggests that SMYD2 can upregulate TGF β-1 signalling, perhaps by 
acting as a co-activator for SMAD3. SMYD2 was previously shown to be activate the BMP 
signalling pathway by methylation of the kinase domain of the BMP receptor II (Gao et al., 
2017). BMP is also a member of the TGF β superfamily, thereby raising the possiblity that 
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SMYD2 could also play a stimulatory role in TGF β-1/SMAD3 signalling. Further validation 
of SMYD2 as a potential co-factor in TGF β-1/SMAD3 signalling in renal fibrosis should also 
be determined.  
Here a direct interaction was identified between SMAD3 and SETDB1 by 
immunoprecipitation from nuclear fractions, but not whole cell lysates, suggesting the 
SMAD3-SETDB1 interaction might occur in the nucleus rather than the cytoplasm. 
Additionally, the interaction was only detectable in the presence of exogenous TGF β-1; this 
could either be a result of significantly higher levels of SMAD3 present in the nucleus after 
TGF β-1 stimulation or because SETDB1 has a preference to interact only with activated 
phosphorylated SMAD3 which could explain why there was no interaction detected in whole 
cell lysates even though SMAD3 and SETDB1 are expressed in the cytoplasm under basal 
conditions. SETDB1 might additionally have a cytoplasmic role which would explain its 
expression in the cytoplasm or it may be sequestered there until its function is required in the 
nucleus, upon TGF β-1 exposure. SETDB1 has been shown to be localised in the nucleus but 
is exported to the cytosol after undergoing proteosomal degradation (Tachibana et al., 2015). 
This could also explain why SETDB1 expression was observed in the cytosol in the work 
presented here. 
SETDB1 knock-down resulted in increased SMAD3 protein expression in HK C-8 and PRF 
cells. It would be interesting to further examine whether regulation of SMAD3 involves post-
translational modifications to SMAD3 such as lysine methylation, or whether SETDB1 could 
somehow regulate SMAD3 gene expression at a transcriptional level. Methylation assays and 
qPCR for SMAD3 upon SETDB1 knockdown could help answer these questions.  
Immuofluorescence data showed an increase in expression of pro-fibrotic markers  α-SMA, 
Collagen I and Collagen III upon SETDB1 siRNA knock-down compared to SCR control. 
Immunofluorescence images showed a 70% increase in SMAD3, 75% increase in α-SMA, 
46% increase in Collagen I and 28% increase in Collagen III expression, with comparable 
results obtained in TGF β-1 treated cells. Analysis of SETDB1 following siRNA transfection 
demonstrated approximately 50% loss of SETDB1 protein. Achieving a more efficient knock-
down would most likely further exaggerate the increased expression of these fibrotic markers.  
Additionally, the results should be confirmed using alternative siRNA sequences that target 
SETDB1. 
SETDB1 is a lysine methyltransferase that specifically catalyses trimethylation of H3K9. 
Trimethylation of H3K9 produces a specific tag for epigenetic transcriptional repression 
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through recruitment of HP1 (CBX1, CBX3 and/or CBX5) proteins to methylated histones 
(Bannister et al., 2001; Lomberk et al., 2006). It is therefore possible that increases in α-
SMA, Collagen I and Collagen III are due to loss of this trimethylation of H3K9 at their cis-
regulatory regions or it could be the direct result of increased SMAD3 protein levels. 
SET9 has been shown to promote migration of PRFs in the development of renal fibrosis 
(Shuttleworth et al., 2018) and protein arginine methyltransferase 1 (PRMT1) has been found 
to drive migration of human lung fibroblasts in the development of pulmonary fibrosis 
(Zakrzewicz et al., 2015). SETDB1 demonstrates a negative effect on PRF cell migration and 
collagen contractility. These recent findings indicate that methyltransferases play different 
roles in the regulation of migration and Collagen contractility in fibrotic diseases. 
Together, these data suggest that SETDB1 negatively regulates TGF β-1 signalling via its 
interaction SMAD3, although the mechanism is yet to be fully described. By acting as a brake 
on TGF β-1 signalling, SETDB1 may help avoid inappropriate or excessive TGF β-1 
signalling. 
SETDB1 promotes transcriptional repression by trimethylation of H3K9 and has previously 
been shown to be recruited to the IL-2 promoter by SMAD3 in T cells (Wakabayashi et al., 
2011). SETDB1 has also been shown to directly methylate non-histone protein p53, 
regulating its stability in cancer cells (Chuikov et al., 2004). These two findings support the 
hypothesis that SMAD3 might recruit SETDB1 to the α-SMA promoter to repress its 
transcription via trimethylation of H3K9. Or, SETDB1 might directly methylate SMAD3, 
leading to repression of transcriptional activity at the ACTA2 gene and the other pro-fibrotic 
genes. Additionally, it has been shown that in response to TGF β-1, SMAD3 recruits 
SETDB1 to the Snai1 gene leading to H3K9 methylation which subsequently inhibits H3K9 
acetylation resulting in Snai1 gene transcriptional repression. This raises a third possiblity in 
that SETDB1 methylation might repress acetylation at the ACTA2 gene, thereby resulting in 
transcriptional repression.  
SETDB1 has also been shown to associate with histone deacetylase 1 (HDAC1) and HDAC2 
as well as interact with co-repressors mSin3A and mSin3B; when recruited and bound to a 
promotor SETDB1 was shown to repress transcription independently of it’s histone 
methyltransferase activity but dependent on its interaction with co-repressors mSin3A/B 
(Yang et al., 2003). This raises yet another potential mechanism by which SETDB1 could 
inhibit the TGF β-1/SMAD3 signalling pathway.  
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As SETDB1 is upregulated in many cancers, causing aberrant silencing of tumour supressor 
genes, it is an attractive therapeutic target in cancer. However, the work presented here 
suggests that SETDB1 may act as as a brake on TGF β-1/SMAD3 signalling. SETDB1 
therefore does not lend itself to being a therapeutic target in CKD. Nevertheless, the research 
presented here offers an insight into how lysine methyltransferases may have different roles in 
the regulation of the TGF β-1/SMAD3 signalling pathway in renal fibrosis. Alternatively, if 
the mechanism of action of SETDB1 is determined to be methylation of SMAD3, its 
opposing demethylase enzyme could present a more suitable target for CKD.  
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Chapter 5. Aurora Kinase A Promotes Renal Fibrosis through TGF β-1 
Signalling in Myofibroblasts 
 
5.1 Introduction 
The Aurora Kinase (AURK) family are a group of three serine/threonine kinases that have a 
critical role in the regulation of the cell cycle, particularly mitosis and maintenance of genome 
stability (Vader and Lens, 2008). Disruption of AURK signalling can result in mitotic errors 
such as chromosomal aneuploidy. Overexpression of both AURKA and AURKB has been 
linked to human malignancies and also correlates with a poor prognosis in several tumour 
types (Naruganahalli et al., 2006).   
In order to carry out its function, AURKA interacts with several co-factors during cell 
division that determine its localisation, activation and substrate preference (Vader and Lens, 
2008). AURKA binds to and phosphorylates co-factor Ajuba, a protein that is required for 
AURKA initial centrosomal activation and autophosphorylation on threonine 288 within the 
AURKA activation loop (Hirota et al., 2003). Mitotic spindle assembly requires the co-factor 
of AURKA, microtubule-associated protein TPX2, which interacts with and tethers AURKA 
to the mitotic spindle and along with the  GTPase Ran; both are required for activation of 
AURKA (Kufer et al., 2002). AURKA has also been found to bind to co-factors Bora and 
Enhancer of Filament 1 (HEF1), both of which enhance its kinase activity (Pugacheva and 
Golemis, 2005; Hutterer et al., 2006). 
Overexpression of AURKA increases chromosome instability and has been shown to lead to 
oncogenic transformation and tetraploidy (Bischoff et al., 1998; Zhou et al., 1998; Meraldi et 
al., 2002). AURKA overexpression is therefore thought to promote tumourigenesis and so 
aneuploidy caused by chromosomal instability is now recognised as a marker of tumour 
progression as it is the most frequent form of genomic damage identified in cancer (Zhou et 
al., 1998).  
AURKA has also been shown to have non-mitotic roles such as regulation of Golgi apparatus 
architecture (Kimura et al., 2018), regulation of ciliary disassembly (Pugacheva et al., 2007) 
and cell migration and polarity (Wu et al., 2005). These findings highlight alternative roles 
and substrates for AURKA. 
The strong links with cancer make AURKA an attractive therapeutic target in the treatment of 
cancer. Many AUKA inhibitors have been developed and are being evaluated as anti-cancer 
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drugs, several of which are currently in clinical trials (Dar et al., 2010). One of the most 
promising AURKA inhibitors, MK-5108, is a potent adenosine triphosphate competitive 
inhibitor which is 200-fold more selective for AURKA than AURKB (Amin et al., 2016; 
Damodaran et al., 2017). MK-5108 has been trialled in Phase I studies, both as a 
monotherapy and in combination with cytotoxic chemotherapy in solid tumours (Amin et al., 
2016) and has been found to be the least toxic AURKA inhibitor to-date. MK-5108 has been 
shown to induce apoptosis in cancer cells resulting in cell death.  
Here, a novel role for AURKA is described, in the regulation of TGF β-1 signalling. AURKA 
phosphorylates SMAD3, an important downstream mediator of TGF β-1 signalling. 
Pharmacological inhibition of AURKA with MK-5108 leads to inhibition of myofibroblast 
activity in injured kidney and liver tissues.    
5.2 Results 
5.2.1 Aurora Kinase Inhibitors Selectively Reduce Proliferation, Induce Apoptosis and 
Prevent Myofibroblasts Differentiation of Human Primary Renal Fibroblasts 
In an attempt to identify compounds that might inhibit PRF cell proliferation, a library of 283 
small molecule inhibitors was screened in PRF cells stimulated with TGF β-1. Fourteen 
AURK inhibitors were screened, ten of which significantly reduced proliferation of PRFs by 
more than 50% at a concentration of 10μM, compared to control PRF treated with DMSO 
vehicle (Figure 5.1A). Seven out of the ten of these AURK inhibitors demonstrated highly 
potent activity in PRFs, reducing proliferation by more than 90% (Figure 5.1A). These seven 
AURK inhibitors demonstrated consistently potent activity in PRFs isolated from three 
different kidneys but exhibited very little effect on primary renal proximal tubular cells (PTC) 
which were isolated from the same three kidneys. Additionally, these 7 compounds were 
tested in the proximal renal tubular epithelial HK C-8 cell line, which demonstrated on 
average a 12-fold relative resistance compared to PRFs (Figure 5.1B). Other compounds 
targeting enzymes such as Janus Kinase 2 (JAK2) had little effect in PRFs but significantly 
reduced proliferation of tubular cells. This suggests that AURK inhibitors selectively reduced 
proliferation of PRFs in the presence of TGF β-1.  
Cell cycle arrest and apoptosis have been previously shown to occur upon AURK inhibition 
(Scharer et al., 2008; Shimomura et al., 2010), so were therefore examined in PRFs with three 
selected  AURK inhibitors. Upon treament with these three compounds, an enrichment of 
Annexin V was observed from approximately 5% in control cells, to between 49-80 % after 
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72 hours drug exposure (Figure 5.1). This apoptotic effect was not observed in HK C-8 cells, 
which showed resistance to these AURK inhibitors, but were sensitive to the Staurosporine 
positive control. Further to this, a more detailed time course was performed in which cells 
progressed from being Annexin V positive and Propidium Iodide negative to becoming 
Annexin V and Propidium Iodide positive, demonstrating they were going through apoptosis 
subsequently resulting in cell death (Figure 5.1E).  
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Figure 5.1. Aurora Kinase Inhibitors Cause Selective Apoptosis in Primary Renal Fibroblasts. (A) PRF 
cells were treated with 10μM of the indicated compounds, or DMSO vehicle control for 72 hours, in the 
presence of 5ng/ml TGF β-1, prior to WST-1 proliferation assay. Each condition was performed in quintuplet. 
Representative data from cells from one of three patients is shown. Error bars represent SD. * p <0.05, t-test. (B) 
PRF or PTC isolated from the same patient, or HK C-8 cells, were exposed to 10μM of selected AURKA 
inhibitors for 72 hours prior to WST-1 proliferation assay. Absorbance values were calculated as a percentage of 
each respective cell type treated with DMSO vehicle control. * p <0.05, t-test. (C) PRF or HK C-8 cells were 
exposed to 10μM of AURKA inhibitors indicated for 72 hours, or 1μM Staurosporine for 24 hours, then stained 
with Annexin V and Propidium Iodide prior to flow cytometry. Plots shown are representative PRF data with 
Annexin V staining on X axis. Graph indicates percentage positive Annexin V cells * p <0.05, t-test. (D) PRF or 
HK C-8 cells were treated with 10μM of the indicated compounds for 72 hours prior to Annexin V apoptosis 
assays as previously described. Plots shown are representative data, from the same PRF patient as in Figure (C), 
with Annexin V staining on X axis. * p <0.05, t-test. (E) PRF cells were treated with 10μM MK-5108 or 1μM 
Staurosporine for the indicated time periods prior to Annexin V apoptosis assays as previously described. Plots 
shown are representative PRF data with Annexin V staining on X axis.  
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Cell cycle analysis was performed at a lower, sub-apoptotic dose of 1μM so that sufficient 
cell numbers could be analysed. The three AURK inhibitors showed a more than 2-fold 
increase in PRF cells in the G2/M checkpoint (Figure 5.2A). AURK inhibitors demonstrate a 
selective potency in PRFs, reducing proliferation in these cells primarily by apoptosis and cell 
death.  
Transdifferentiation of PRFs was also examined in the presence of AURK inhibitor, MK-
5108. TGF β-1-induced transdifferentiation of PRFs to an activated myofibroblast state, as 
shown by significantly increased expression of α-SMA, a key marker of myofibroblast 
transdifferentiation (Figure 5.2B). TGF β-1 treatment also resulted in increased expression of 
Collagen I and III in PRF cells. Treatment with MK-5108 at a sub-lethal dose of 1μM caused 
a significant 75% reduction in α-SMA expression in PRF. Reductions in Collagen I and III 
expression were also observed (Figure 5.2C). These results suggest that the AURK inhibitor 
MK-5108 causes apoptosis in PRFs as seen in cancer cells, but also prevents TGF β-1-
mediated myofibroblast transdifferentiation of PRF.  
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Figure 5.2. Aurora Kinase Inhibitors Inhibit Proliferation and Transdifferentiation in Primary Renal 
Fibroblasts. (A) PRF cultured in the presence of 5ng/ml TGF β-1 were subject to 1μM of the indicated AURKA 
inhibitors for 48 hours, then stained with Propidium Iodide prior to flow cytometry. Histograms shown are 
representative PRF data. Graph indicates percentage of cells in G2/M checkpoint. * p <0.05, t-test. (B) PRF 
cultured in glass chamber slides were exposed to 5ng/ml TGF β-1 and 1μM MK-5108 or DMSO vehicle for 72 
hours prior to indirect immunofluorescence for α-SMA. Bar graph represents fold change in fluorescence over 
DMSO vehicle control-treated cells. * p <0.05, ANOVA. (C) PRF cultured in glass chamber slides were exposed 
to TGF β-1 and 1μM MK-5108 or DMSO vehicle for 72 hours prior to indirect immunofluorescence for the 
indicated markers. Control slides with secondary antibodies only did not exhibit fluorescence (Appendix). 
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5.2.2 AURKA Phosphorylates SMAD3 in Response to TGF β-1 
As MK-5108 had an impact on PRF transdifferentiation, in response to TGF β-1, a role for 
AURKA in the TGF β-1 signalling pathway was investigated. Firstly, SMAD3 protein 
turnover was examined to determine whether AURKA could regulate SMAD3 protein levels, 
a critical downstream mediator of TGF β-1 signalling in fibrosis. SMAD3 protein turnover is 
regulated by proteasomal destruction (Fukuchi et al., 2001) and can be measured by 
immunoblotting and densitometry after the addition of cycloheximide, to inhibit de novo 
protein synthesis. In control PRF cells, the SMAD3 half-life was approximately 4 hours. 
Upon AURKA siRNA transfection the half-life of SMAD3 remained unchanged, suggesting 
AURKA has no involvement in the SMAD3 protein turnover (Figure 5.3A). 
TGF β-1 stimulation leads to activation and autophosphorylation of TGF βRI and II which 
subsequently phosphorylate SMAD3 which is then translocated to the nucleus resulting in 
transcription of SMAD3 target genes. The effect of AURKA on the phosphorylation of 
SMAD3 was examined as an indication of its potential role in TGF β-1 signalling. 
Immunoprecipitation of SMAD3 was performed followed by immunoblotting for SMAD3 C-
terminal phosphorylation with C25A9 antibody. In the presence of TGF β-1, an enrichment of 
423/5 phosphorylation of SMAD3 was observed. As expected, phosphorylation of SMAD3 
was partially inhibited by inhibitor ALK5 inhibitor, a potent selective inhibitor of TGF βRI 
kinase. Addition of MK-5108 virtually abolished SMAD3 phosphorylation (Figure 5.3B), 
suggesting AURKA is involved in SMAD3 phosphorylation in TGF β-1 signalling. To 
confirm that this was not an off-target effect of MK-5108, immunoprecipitation of SMAD3 
was performed after transfection of AURKA or AURKB siRNA, in the presence of TGF β-1. 
AURKA siRNA transfection resulted in a significant reduction in SMAD3 423/5 
phosphorylation compared to AURKB siRNA which had no effect (Figure 5.3C). 
Immunoblotting with an alternative phospho-SMAD2/3 antibody produced the same effect 
suggesting that AURKA is required for SMAD3 phosphorylation in PRFs. These data 
confirm that AURKA but not AURKB is involved in TGF β-1 signalling, via SMAD3 
phosphorylation in PRFs.  
To determine whether AURKA directly phosphorylates SMAD3, in vitro kinase reactions 
were performed using purified recombinant SMAD3 and AURKA proteins. Immunoblotting 
with total SMAD3 antibody demonstrated a higher molecular weight, band-shifted SMAD3 
protein in the presence of AURKA suggestive of a phosphorylation event (Figure 5.3D). A 
time-course experiment with a fixed quantity of SMAD3 and AURKA demonstrated 
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accumulation of the band-shifted SMAD3 in a time-dependent manner (Figure 5.3E). These 
band-shifted SMAD3 species are likely to represent SMAD3 phosphorylation by AURKA 
given that they are present only in the presence of AURKA. Additional kinase reactions were 
performed and immunoblotted with a phospho-serine antibody which demonstrated a strong 
band at the correct molecular weight for SMAD3, only in the presence of AURKA, 
suggesting that AURKA phosphorylates SMAD3 on serine residues. This band was much 
weaker after the addition of calf intestinal phosphatase (CIP). Blotting with a phospho-
threonine antibody did not reveal any bands of the correct molecular weight for SMAD3, 
suggesting that AURKA may phosphorylate SMAD3 specifically on serine, but not threonine 
residues. Finally, the kinase reactions were blotted with a specific SMAD3 phospho-serine 
423/5 antibody. This demonstrated a strong band, of the correct molecular weight for SMAD3 
that was only detectable in the presence of AURKA. This band became undetectable after the 
addition of CIP (Figure 5.3F). In conclusion, AURKA directly phosphorylates SMAD3 
specifically on serine residues 423/5. This may account for the effects observed on TGF β-1-
induced α-SMA expression in PRFs by MK-5108.    
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Figure 5.3. AURKA Phosphorylates SMAD3. (A) PRF cells were reverse transfected with 20nM of the 
indicated siRNA overnight, in the presence of 5ng/ml TGF β-1. Cycloheximide was then applied in fresh 
complete medium at 50μg/ml for the indicated time periods prior to immunoblotting whole cell lysates as shown. 
SMAD3 protein turnover, calculated by densitometry (not shown), was approximately 4 hours. (B) PRF cells 
were treated overnight with DMSO vehicle, 1μM MK-5108 or 5μM SB505124 in the presence of 5ng/ml TGF β-
1 or vehicle prior to immunoprecipitation with SMAD3 antibody or control IgG then immunoblotting cell lysates 
(Inputs) and immunoprecipitated material (IPs) with the indicated antibodies including C25A9 to detect 
pSMAD3 423/5. * indicates non-specific immunoglobulin light chain. (C) PRF cells were reverse transfected 
overnight with siRNA targeting AURKA (AurA) or AURKB (AurB), both targets combined (AurA+B) or 
control siRNA (SCR), treated with 5ng/ml TGF β-1 for a further 24 hours, then subject to immunoprecipitation 
as in (A). Immunoblotting was then performed using the indicated antibodies including C25A9 and sc-11769, 
both of which detect phospho-SMAD3. (D) Increasing quantities of SMAD3 (1-3μg) and a fixed quantity of 
0.1μg AURKA proteins were incubated in kinase reactions for 4 hours, prior to gradient gel electrophoresis and 
immunoblotting for SMAD3. Upper arrow indicates band-shifted SMAD3. (E) Fixed quantities of 1ug SMAD3 
and 1μg AURKA proteins were incubated for increasing times between 0-8 hours in kinase reactions, prior to 
gradient gel electrophoresis and immunoblotting for SMAD3. Upper arrow indicates time-dependent appearance 
of band-shifted SMAD3. (F) Fixed quantities of 1μg SMAD3 and 0.1μg AURKA proteins, were incubated for 4 
hours in kinase reactions prior to standard electrophoresis and immunoblotting with the phospho-specific 
antibodies shown, including C25A9. Where shown, one reaction was treated with CIP at 37°C for the final 20 
minute period, resulting in disappearance of the phospho-specific bands. 
 
5.2.3 MK-5108 Inhibits Renal Fibrosis in Mice 
Aberrant TGF β-1 signalling is known play a critical role in fibrosis and SMAD3 is required 
for the development of renal fibrosis in mice (Flanders, 2004). The data presented here link 
AURKA to SMAD3 in TGF β-1 signalling in PRFs. The effect of MK-5108 in a UUO mouse 
model of renal fibrosis was therefore examined.  
UUO surgery was performed on the left kidneys of 15 female mice, causing them to develop 
renal fibrosis. MK-5108 was administered to 7 mice at 45mg/kg by daily oral gavage, leaving 
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8 mice in the control group which received methylcellulose by daily gavage. After 12 days, 
the mice were culled and both left and right kidneys harvested for histology. Paraffin-
embedded kidney tissues were cut and mounted onto slides for immunohistochemical 
staining. Staining with specific antibodies demonstrated a significant increase in α-SMA, 
Collagen I and III and Masson’s Trichrome staining (total Collagen) in obstructed left kidneys 
compared to uninjured control right kidneys (Figure 5.4). Mice treated with MK-5108 showed 
a significant reduction in expression of these pro-fibrotic markers, particularly α-SMA, 
suggesting that AURKA has a role in driving renal fibrosis in vivo. No toxicity from MK-
5108 was observed in the mice.  
Total SMAD3 and phospho-serine 423/5 expression were also examined using 
immunohistochemistry. Expression of phospho-serine 423/5 was increase in UUO kidneys 
compared to control kidneys but total SMAD3 expression remained unchanged (Figure 5.4). 
Upon MK-5108 treatment, phospho-serine 423/5 expression was significantly reduced, 
whereas total SMAD3 expression remained unchanged, suggesting  that AURKA reduces 
phosphorylation of SMAD3, in vivo. Finally, AURKA expression was examined but no 
significant difference between any groups was observed (Figure 5.4).   
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Figure 5.4. MK-5108 Attenuates Renal Fibrosis after Ureteric Obstruction. Mice that had undergone 
unilateral left ureteric ligation were treated with daily oral MK-5108 or methylcellulose vehicle then sacrificed 
after 12 days. Tissues from obstructed (injured) and control kidneys were stained with the antibodies indicated, 
or Trichrome, prior to automated analysis of staining with the exception of phospho-SMAD3 C25A9. Graphs 
show median percentage area positively stained for all kidneys, across 15 images per kidney, or mean visual 
score in the case of phospho-SMAD3. Error bars represent SD, * p <0.05, t-test. 
 
5.2.4 MK-5108 Reduces α-SMA Accumulation in Liver Injury in Mice 
After demonstrating MK-5108 has a significant effect in reducing α-SMA expression in the 
UUO model, the effect of MK-5108 in a carbon tetrachloride-induced model of acute liver 
injury was examined, to determine whether MK-5108 could reduce the number of α-SMA 
positive myofibroblasts in the early stages of wound healing, prior to the process of fibrotic 
Collagen deposition. Immunohistochemistry revealed a significant accumulation of α-SMA in 
the livers of mice 3 days after a single injection of carbon tetrachloride, compared to control 
mice that received the olive oil vehicle (Figure 5.5A). Mice treated with a daily dose of MK-
5108 at 45mg/kg demonstrated a significant 60% reduction in α-SMA expression compared to 
carbon tetrachloride treated mice given olive oil vehicle (Figure 5.5A). This result suggests 
that MK-5108 is involved in the early stages of the wound healing response by either 
inhibiting accumulation of myofibroblasts or inhibiting their differentiation.  
To examine this further, MK-5108 was tested in isolated mouse hepatic stellate cells (HSC), 
the myofibroblast precursor cells thought to be responsible for liver fibrosis. Culturing HSCs 
on plastic causes transdifferentiation, characterised by α-SMA expression. After 7 days in 
culture, treatment of HSC with 1μM MK-5108 resulted in a significant reduction in α-SMA 
expression compared to untreated cells (Figure 5.5B), similar to the data from PRFs. A 
reduction in Collagen I and III was also observed in HSCs treated with MK-5108 (Figure 
5.5C). Furthermore, MK-5108 treatment resulted in inhibition of TGF β-1-induced 
proliferation of HSCs (Figure 5.5D). These data indicate that the AURKA inhibitor, MK-
5108 is capable of inhibiting both transdifferentiation and proliferation of HSCs, which is 
likely to account for the reduction in α-SMA expression observed in the carbon-tetrachloride 
mice treated with MK-5108.  
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Figure 5.5. MK-5108 Prevents α-SMA Accumulation and HSC Proliferation in CCl4 Mice. (A) Mice 
received a single injection of carbon tetrachloride (CCl4) or olive oil vehicle, on day 1, in an acute model of liver 
injury to stimulate α-SMA expression. They then received daily oral doses of MK-5108 or methylcellulose 
vehicle, starting on day 1, and were sacrificed on day 3. Liver tissues were stained for α-SMA by IHC prior to 
automated analysis of staining as described previously. Graph represents percentage positive staining. (B) HSC 
isolated from 3 mouse livers were allowed to adhere to glass chamber slides prior to addition of 1μM MK-5108, 
5ng/ml TGF β-1, or DMSO vehicle for 72 hours then indirect immunofluorescence for α-SMA. Graph represents 
fold-change in fluorescence over DMSO vehicle treated cells. Representative data from one of three animals is 
shown. * p <0.05, ANOVA. (C) HSC cultured in glass chamber slides were exposed to TGF β-1 and 1μM MK-
5108 or DMSO vehicle for 72 hours prior to indirect immunofluorescence for Collagen I and Collagen III as 
shown. Representative data, from one mouse are shown. Values are represented as fluorescence as percentage of 
TGF β-1-treated cells. * p <0.05, ANOVA. (D) HSCs isolated from mouse livers were allowed to adhere to 96-
well plates prior to the addition of 10μM MK-5108, 5ng/ml TGF β-1, or DMSO vehicle for 72 hours then WST-
1 proliferation assays performed. Representative data from one of three animals is shown. * p <0.05, t-test. Error 
bars represent SD, throughout Figure 4. * p <0.05, t-test. 
 
5.3 Discussion 
AURKs are essential for the regulation of mitosis and are known to be overexpressed in 
several cancers (Vader and Lens, 2008). AURKA overexpression is a result of gene 
amplification, transcriptional induction or post-translational stabilisation (Farruggio et al., 
1999). AURK inhibitors have been developed as anti-cancer drugs and have been shown to 
disrupt the cell cycle, inhibit proliferation and induce apoptosis in rapidly dividing tumour 
cells but comparatively, AURK inhibitors have little effect on normal cells (Harrington et al., 
2004). Similarly, AURK inhibitors selectively reduce proliferation of activated PRF cells and 
induce apoptosis but have little effect on PTCs. AURKA has been shown to interact with and 
phosphorylate p53 regulating its functional activity by two mechanisms; phosphorylation of 
serine-315 of p53 facilitating its degradation in cancer cells (Katayama et al., 2004) and 
phosphorylation of serine-215 inactivating its transcriptional activity (Liu et al., 2004). 
AURKA over-expression results in increased phosphorylation of p53 leading to suppression 
of apoptosis in cancer cells. Additionally, AURKA enhances phosphorylation of AKT, a pro-
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proliferative kinase that promotes cell survival and inhibits apoptosis (Khwaja, 1999). 
Therefore, it seems that cells undergoing aberrant proliferation become dependent on the cell 
cycle regulator AURKA for survival and so over-expression of AURKA has made it an 
attractive focus for drug discovery. The anti-proliferative activity of AURK inhibitors make 
them an attractive therapeutic in the treatment of diseases that are characterised by aberrant 
cell proliferation such as cancer and fibrosis (Harrington et al., 2004; Tang et al., 2017). It 
remains to be seen whether AURKA targets p53 or AKT in renal fibroblasts. 
AURKA has been shown to induce EMT in vitro and in vivo in cancer cells (Wan et al., 2008; 
Beltran et al., 2011), promoting a mesenchymal phenotype, resulting in a reduction in E-
cadherin expression and an increase in Vimentin expression (D'Assoro et al., 2014). It is 
possible AURKA inhibitors might therefore inhibit EMT. Here, MK-5108 was shown to 
inhibit transdifferentiation of PRFs and HSCs. Inhibition of transdifferentiation of PRFs and 
HSCs by MK-5108 could be explained through the model in which AURKA phosphorylates 
SMAD3 resulting in transdifferentiation. Both the anti-proliferative activity and inhibition of 
transdifferentiation by AURKA inhibitors, particularly MK-5108, make AURKA a potential 
anti-fibrotic target for the treatment of CKD.  
SMAD3 is phosphorylated at the C-terminus at serine 423/425 by ALK in response to TGF β-
1, leading to direct interaction with SMAD4, and translocation of SMAD3 to the nucleus to 
promote gene transcription favouring transdifferentiation. Here, AURKA silencing by siRNA 
or MK-5108 also reduced SMAD3 phosphorylation in PRF cells. This is supported by the in 
vitro kinase assay which showed that AURKA is able to directly phosphorylate SMAD3 in 
response to TGF β-1. SMAD3 can be phosphorylated independently of TGF β-1 by kinases 
other than ALK5, suggesting that there is a role for other kinases such as AURKA in the 
phosphorylation of SMAD3 and regulation of TGF β-1 signalling (Li et al., 2004; Wang et 
al., 2009). For example, PAK4 is a kinase that has been shown to phosphorylate serine 423 of 
SMAD3 (Wang et al., 2014). The exact mechanism by which ALK5 and AURKA can both 
phosphorylate SMAD3 in response to TGF β-1 remains to be established. 
Whether AURKA is capable of phosphorylating additional residues of SMAD3 and whether 
AURKA can phosphorylate SMAD3 in other cell types remains to be established. The liver 
injury data indicates that AURKA could be involved in the early stages of wound healing, 
during myofibroblast activation and proliferation, preceding Collagen deposition. Due to time 
restraints, Collagen deposition in a longer-term liver fibrosis model was not examined but it is 
likely that treatment with MK-5108 would reduce Collagen deposition and inhibit fibrosis, as 
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shown in the UUO model. It remains unclear whether MK-5108 may affect normal wound 
healing, which should be tested.  
In renal fibrosis, the source of myofibroblasts has been widely debated with suggestions that 
they can be derived from a number of precursor cell types including resident renal fibroblasts, 
BMDC, pericytes and epithelial cells (Sun et al., 2016). It is therefore unknown whether 
AURKA inhibition has the same effects in these myofibroblast precursor cells. In all, the data 
presented indicates that AURKA is an attractive therapeutic target in the treatment of CKD. 
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Chapter 6. Final Discussion 
 
6.1 Overall Discussion 
CKD is a worldwide socioeconomic health problem with very limited therapeutic options. 
There is a vital need for greater understanding of the molecular mechanisms driving CKD in 
order to rectify this unmet clinical need. Renal fibrosis, characterised by the aberrant 
expression of ECM proteins, forming scar tissue is the histological endpoint of almost all 
forms of CKD. Anti-fibrotic drugs should therefore find clinical utility in the future treatment 
of CKD. 
TGF β-1/SMAD3 is the major signalling pathway in renal fibrosis. Much research has 
focussed on targeting TGF β-1, for example with the development of blocking antibodies. 
Several clinical studies using anti-TGF β-1 antibodies have been undertaken in patients with 
kidney disease. Although some early promising results were seen, a Phase II study was 
prematurely terminated due to lack of efficacy (Trachtman et al., 2011; Science, 2015). 
Another alternative approach to TGF β-1 inhibition using ALK5 inhibitors has shown to be 
effective in liver and kidney mouse models of fibrosis (de Gouville et al., 2005; Moon et al., 
2006). Clinical studies of these drugs are ongoing in patients with advanced cancer but they 
have not yet been tested in patients with kidney disease (Rodon et al., 2015). In summary, 
targeting TGF β-1 directly has not demonstrated any clinical patient benefit to-date 
(Klinkhammer et al., 2017). Because TGF β-1 is involved in so many essential biological 
processes such as immune regulation, cancer surveillance and glomerular defence against 
inflammation during injury (Kitamura and Fine, 1999) the development of clinically useful 
anti-TGF β-1 therapies that do not have detrimental effect on homeostasis is a major 
challenge.   
Several SMAD3 inhibitors have been developed and have demonstrated some success in 
mouse models; the SMAD3 inhibitor SIS3 was shown to reduce renal fibrosis in a diabetic 
nephropathy mouse model and an inhibitor of SMAD3 phosphorylation, GQ5, reduced 
fibrosis in a UUO mouse model (Li et al., 2010; Ai et al., 2015). SMAD3 deficiency is not 
lethal to mice, unlike TGF β-1 deficient mice that die within 3-4 weeks after birth from 
uncontrolled inflammation (Bommireddy et al., 2003). SMAD3 might therefore represent a 
more viable target to inhibit renal fibrosis in CKD without the undesirable side-effects of 
complete TGF β-1 inhibition (Goumans and Mummery, 2000). To-date however, no 
inhibitory SMAD3 compounds have been used clinically. One approach to inhibit the 
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function of SMAD3 has been to target SMAD3 indirectly, through SMAD3 co-factors which 
have a role in the regulation of TGF β-1 signalling. The research presented here has focussed 
on the identification and validation of such co-regulatory proteins in CKD.   
Previous studies have identified a role for lysine methyltransferase dysregulation in human 
disease. For example, the lysine methyltransferase, SET9, has been shown to be 
overexpressied in prostate cancer and is important in activating the androgen receptor (AR), a 
key transcription factor in prostate cancer development (Gaughan et al., 2011). SET9 has also 
been shown to have a role in renal fibrosis; silencing SET9 significantly attenuated renal 
fibrosis in UUO mice (Sasaki et al., 2016). Given these previous findings the role of SET9 
and other methyltransferases in the regulation of TGF β-1 signalling in renal fibrosis was 
examined.  
SET9 has been previously found to interact with transcription factors AR and ER at the N 
terminus and has been shown to directly methylate lysines within a conserved KKLKK motif 
(Subramanian et al., 2008; Gaughan et al., 2011). This work demonstrated an interaction with 
SMAD3 at the N terminus which harbours a KKLKK motif, suggesting that SET9 might also 
methylate SMAD3 at this conserved motif to regulate SMAD3.  Mass spectrometry and in 
vitro methylation assays performed during the course of this research, failed to show 
methylation of SMAD3 by SET9. Nevertheless, SET9 was found to directly regulate SMAD3 
protein stability and nuclear import, which required the methyltransferase activity of SET9. 
Cells transfected with a methyltransferase-deficient SET9 mutant showed increased SMAD3 
protein turnover, increased ubiquitylation and reduced nuclear translocation of SMAD3 
compared to the wild-type SET9. This suggests that a SET9 methylation event might 
indirectly regulate SMAD3 in order to regulate its activity. This work has shown SET9 is 
recruited to the ACTA2 gene promoter by SMAD3, in response to TGF β-1 which is likely to 
result in SET9 methylation at the ACTA2 gene promotor leading to upregulation of gene 
expression. Similar to previous studies showing SET9 recruitment to the pro-fibrotic gene 
promoters Col1α1, CTGF, and PAI-1, in response to TGF β-1, resulting in increased H3K4 
methylation at these gene promoters and increased transcriptional activity of these ECM-
associated genes (Sun et al., 2010).  
Lysine methyltransferases have been shown to exert different effects depending on the type of 
methylation and/or their substrate. SET9 has been shown to increase the transcriptional 
activity of transcription factors including AR, ER and p53. The work presented here has 
demonstrated that SET9 also interacts with SMAD3, to enhance its transcriptional activity, 
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enhancing the pro-fibrotic activity of TGF β-1. In contrast, SET9 can also interact with 
SMAD7, an inhibitory SMAD, at the C terminal domain, targeting it for ubiquitylation-
dependent degradation (Elkouris et al., 2016). This demonstrates that SET9 can both 
positively and negatively regulate the transcriptional activity of different SMAD substrates. In 
this case, the upregulation of SMAD3 and the downregulation of SMAD7 both result in 
increased TGF β-1 signalling in renal fibrosis, further supporting the important regulatory role 
of SET9 in TGF β-1 signalling.  
Another lysine methyltransferase SETDB1, is known to methylate H3K9 which is usually 
associated with transcriptional repression. SETDB1 is found to be upregulated in cancers such 
as hepatocellular carcinoma and breast cancer (Wong et al., 2016; Du et al., 2018) and 
therefore inhibition of SETDB1 could be useful in the treatment of these cancers. Conversely, 
the work shown here has demonstrated that SETDB1 acts as a co-repressor of SMAD3 in 
TGF β-1 signalling and its inhibition enhanced expression of pro-fibrotic markers in PRFs. 
These data showed suppression of SETDB1 enhanced migration and contractility of PRF 
cells, whereas, other research showed SETDB1 expression is upregulated in glioma cell lines 
and tissues and suppression of SETDB1 resulted in reduced migration of glioma cells 
(Spyropoulou et al., 2014). This suggests that SETDB1 might have opposing roles, depending 
upon cell type or disease context.  
This work has found migration and Collagen contractility of PRFs, both critical processes in 
fibrosis, are dependent upon SET9. In contrast, SETDB1 seems to act as a brake on these 
processes suggesting that lysine methyltransferases add an extra level of transcriptional 
regulation upon signalling pathways in fibrosis. More research needs to be undertaken to 
identify additional methyltransferases and their roles in signalling pathways and human 
disease.  
SET9 inhibition by R-PFI-2 was effective in reducing pro-fibrotic marker expression and 
significantly reducing migration and contractility of PRFs, suggesting that SET9 is a valid 
target for the treatment of CKD. The effect of R-PFI-2 inhibitor is yet to be explored in mouse 
models of disease and therefore its dosage, efficacy and tolerability remain unknown. The 
development of other SET9 inhibitors such as DC-S238 and DC-239 is ongoing but no 
compound to-date has been tested in mice (Meng et al., 2015a). SET9-deficient mice have a 
normal phenotype, which suggest that the specific SET9 inhibitor R-PFI-2 could have only 
negligible side-effects. However, studies of this inhibitor in mice will first enable us to 
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determine the effect of pharmacological inhibition of SET9 with respect to other TGF β-1 
driven processes such as normal wound healing.  
Targeting DNA and histone methylation in disease is a newly emerging field. Recently, 
compounds targeting histone methylation, such as an EZH2 inhibitor have entered clinical 
trials for cancer treatment (Morera et al., 2016). Interestingly, EZH2 is a lysine 
methyltransferase that was identified as a potential hit by Z-score analysis from the siRNA 
methyltransferase screens, further indicating the important role these enzymes play in disease 
identifying them as attractive targets for the treatment in human disease. The accumulative 
effect of inhibiting several methyltransferases that upregulate TGF β-1 signalling in PRFs 
may present the best approach to reduce renal fibrosis.  
It would be interesting to identify additional substrates for methylation in the TGF β-
1/SMAD3 signalling pathway, for example by mass spectrometry. Further identification of 
the role of lysine methylation in the TGF β-1 pathway might aid the identification of 
additional potential therapeutic targets for the treatment of CKD.  
By performing a HTS of 283 small molecule inhibitors in PRF cells, 10 AURK inhibitors 
were found to significantly reduce PRF proliferation. This work demonstrated that AURK 
inhibitors selectively inhibit proliferation and induce apoptosis in PRFs but have little effect 
on tubular cells. Rapidly dividing cells seem to become dependent on AURKA activity for 
survival making them an attractive target for AURKA inhibition (Dar et al., 2010). AURKA 
inhibitor, MK-5108 also demonstrated a reduction in transdifferentiation of PRFs and HSCs. 
This work demonstrated that AURKA directly phosphorylates the C-terminus of SMAD3 at 
Serine 423/5 in response to TGF β-1 in PRFs. Treatment with MK-5108 inhibited this 
phosphorylation and reduced transdifferentiation of PRFs and HSCs. A significant reduction 
in α-SMA, Collagen I and III, and total Collagen in UUO mice was observed upon MK-5108 
treatment and similarly a reduction in these markers was observed in the liver injury mouse 
model upon MK-5108 treatment. A longer-term liver fibrosis model was not pursued due to 
time restraints but it is likely that a reduction in liver fibrosis would occur upon MK-5108, 
given the effects upon α-SMA positive cells in the liver. Additionally, MK-5108 has been 
tested in clinical trials as an anti-cancer drug where it demonstrated effective anti-proliferative 
activity and has been found to be very well tolerated with minimal toxicity, further raising the 
prospect of AURKA as a therapeutic target in renal fibrosis (Amin et al., 2016).  
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This research has demonstrated that there are unidentified co-factors involved in the 
regulation of the TGF β-1/SMAD3 pathway. Novel roles for SET9, SETDB1 and AURKA in 
the regulation of TGF β-1 signalling in renal fibrosis have been identified, illustrated in 
Figure 6.1.  
 
Figure 6.1. Illustration of novel roles identified for SET9, SETDB1 and Aurora Kinase A in the TGF β-1 
/SMAD3 signalling pathway in renal fibrosis. SET9 interacts with SMAD3 to increase its stability and aid its 
nuclear translocation. SETDB1 interacts with SMAD3, acting as a brake on TGF β-1/SMAD3 signalling. Aurora 
Kinase A directly phosphorylates SMAD3 in response to TGF β-1. 
 
All three proteins have been previously linked with cancer, showing upregulated expression in 
several human cancers. Cancer and fibrosis have many characteristics in common such as 
aberrant signalling resulting in uncontrolled cell proliferation and therefore these proteins may 
share common roles between these two diseases.   
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Both R-PFI-2 and MK-5108 have shown to be effective in reducing TGF β-1/SMAD3 
signalling resulting in a significant reduction in pro-fibrotic markers and therefore could 
provide promising treatments for renal fibrosis. Although effective in reducing fibrosis 
whether these inhibitors have a detrimental effect to normal wound healing must be explored.  
Another question which must be answered is what is the wider effect of targeting TGF β-
1/SMAD3 signalling; such a central signalling pathway in many biological processes. Are the 
co-regulators we have identified in this pathway specific to PRFs or could the use of these 
inhibitors effect other cell types and biological processes? 
 
6.2 Future Directions  
 
Futher work should be undertaken to decipher the exact mechanism by which SET9 regulates 
SMAD3 in TGF β-1 signalling in renal fibrosis. Whether it is direct methylation of SMAD3 
or of H3K4 at the ACTA2 gene promoter or whether it is just the direct interaction of SET9 
with SMAD3 that enables it to regulate SMAD3 function. This could be determined by the 
use of further methylation assays and mass spectometry. ChIP could also be performed using 
an antibody against H3K4me to determine if this methylation is reduced upon SET9 
knockdown at the ACTA2 promoter. Additionally, it would be useful to perform mutagenesis 
on SMAD3, to introduce mutations in the lysine residues of the KKLKK motif to determine 
whether this would effect the interaction with SET9 and SMAD3 function.   
Similarly it should be determined whether SETDB1 is also acting through its 
methyltransferase activity with the use of similar experiments. It would also be interesting to 
identify whether there are any additional SETDB1 substrates to regulate TGF β-1 signalling, 
other than SMAD3 that could be exploited as additional novel targets.  
R-PFI-2 demonstrated a significant reduction in migration of PRFs, therefore it is critical to 
understand the effect of SET9 inhibition on normal wound healing. It would be useful to test 
R-PFI-2 in a UUO mouse model to determine its effect on the early developmental stages of 
renal fibrosis and any potential off-target effects. 
To further the work on MK-5108, testing it in a longer-term liver fibrosis model would be 
advantageous to determine whether it has the same significant effect in reducing fibrosis in 
the liver as we have observed in the kidney. The effect of MK-5108 on normal wound healing 
must also be explored.  
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Finally, further siRNA and compound screening utilising our newly established PRF cell 
model should be undertaken for the identification of additional novel targets in TGF β-1 
signalling to aid the discovery of much needed alternative therapeutics in renal fibrosis and 
CKD.      
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